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Summary 
     The neurochemical circuitry and molecular mechanisms underlying the regulation 
of sleep and waking remain an open and largely unanswered question in modern 
neuroscience. The ascending reticular arousal system located in the brain stem and 
basal ganglia, consists of a number of clearly defined cell groups with distinct 
neurotransmitters. These nuclei have been associated with sleep-wake regulation 
and predictably change their firing patterns across vigilance states. The striatum 
plays a central role in mediating arousal. It expresses distinct receptor heteromers, 
forming functional units of adenosine A2A receptors, dopamine D2 receptors, and 
metabotropic glutamate receptors of subtype 5 (mGluR5). The aim of the present 
thesis was to investigate contributions of the dopaminergic and glutamatergic 
neurotransmitter systems to the regulation of sleep and wakefulness. To do so, an 
integrative approach was applied, investigating functional genetic polymorphisms, 
molecular brain imaging, pharmacological interventions, polygraphic EEG recordings, 
actigraphy, and cognitive performance testing in healthy humans.  
 
     To investigate dopaminergic aspects of sleep-wake regulation, genotyping of two 
functional polymorphisms in the genes coding for the dopamine transporter (DAT) 
and the catechol-O-methyl-transferase (COMT) was performed in 110 healthy men 
and women. Both DAT and COMT regulate cerebral dopamine levels. They are 
primarily expressed in the striatum and prefrontal cortex, respectively. The variable-
number-tandem-repeat (VNTR) polymorphism in the 3’-untranslated region of the 
gene encoding DAT (DAT1, SLC6A3) has been associated with 15-20 % reduced 
striatal expression of DAT in 10-repeat allele homozygotes (10R/10R) when 
compared to hetero- and homozygous 9-repeat allele (9R) carriers. On the other 
hand, the Val158Met polymorphism of COMT causes a drastic reduction in COMT 
enzymatic activity. Daytime sleepiness ratings and continuous motor rest-activity 
recordings during a roughly 4-week period revealed that male DAT1 9R carriers have 
higher overall motor activity compared to 10R/10R homozygotes, and more often 
report elevated sleepiness. On the other hand, COMT genotype did not affect rest-
activity patterns, yet modulated body-mass-index (BMI) (Chapter 2).  
 
     To further investigate effects of the DAT1 polymorphism on sleep-wake 
regulation, 57 subjects underwent a controlled sleep deprivation protocol, and a 
subgroup of participates received either caffeine (n=16) or modafinil (n=22) in a 
placebo-controlled, double-blind manner. Sleep deprivation-induced increases in 
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established neurophysiological markers of sleep need, including slow wave sleep, 
EEG slow-wave activity (0.5 - 4.5 Hz), and number of individual low-frequency (0.5 - 
2.0 Hz) oscillations in non-rapid-eye-movement (NREM) sleep, was enhanced in 
10R/10R homozygotes when compared to 9R carriers. Moreover, caffeine and 
modafinil affected wakefulness-induced changes in functional bands (delta, sigma 
and beta) of rhythmic brain activity in wakefulness and sleep in a DAT1 genotype-
dependent manner. These findings suggest that striatal dopaminergic 
neurotransmission is involved in sleep-wake regulation and modulates the effects of 
the common stimulants modafinil and caffeine (Chapter 3).  
 
     To investigate glutamatergic aspects of sleep-wake regulation, positron emission 
tomography (PET) imaging with the highly selective, non-competitive mGluR5 
antagonist 11C-ABP688 was performed in 26 healthy men. All completed two distinct 
imaging session, following 9 and 33 hours of sustained wakefulness. Prolonged 
wakefulness increased the availability of mGluR5 in human brain by roughly 3.5%. 
Following correction for multiple comparison (p < 0.0038), a significant increase after 
prolonged wakefulness was observed in anterior cingulate cortex, insula, medial 
temporal lobe, parahippocampal gyrus, striatum, and amygdala. The increase in 
mGluR5 availability in all these regions correlated significantly with the sleep 
deprivation-induced increase in subjective sleepiness. These data suggest a role for 
mGluR5 in homeostatic sleep–wake regulation (Chapter 4).  
 
     The mGluR5 have been linked to the generation of slow oscillations (< 1 Hz), a 
hallmark of the NREM sleep EEG, which has been associated with neuronal plasticity 
and memory processing. Pharmacological inhibition of mGluR5 has been reported to 
rescue Fragile X syndrome in mice, a X-chromosome linked genetic disorder in 
humans, caused by a CGG repeat polymorphism in the Fragile X mental retardation 
1 (FMR1) gene underlying the complete loss of Fragile X mental retardation protein 
(FMRP). The loss of FMRP results in mental retardation and disturbed sleep in 
humans, and strongly increased sleep time in Drosophila. To examine the potential 
link between mGluR5 and FMRP in sleep-wake regulation, genetic analysis of the 
FMR1 gene was combined with nocturnal EEG recordings and in vivo measurements 
of the availability of mGluR5 in baseline and sleep-deprived conditions. A strong 
association between global mGluR5 availability and EEG markers of sleep need was 
observed. Especially EEG slow oscillations were highly correlated with global 
mGluR5 availability in rested and sleep-deprived states. Furthermore, genetic 
analysis revealed that healthy FMR1 odd CGG repeat number carriers have roughly 
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90% increased FMRP expression than even repeat number carriers. The odd 
number CGG repeat carriers exhibited a reduced response to sleep deprivation as 
observed by stagnant global mGluR5 availability, EEG slow oscillations and slow 
wave activity. Consequently, the data indicate that mGluR5 availability may provide a 
molecular marker of sleep need in humans. Additionally, mGluR5 availability may 
play a key role for the regulation of EEG slow oscillations in NREM sleep. Finally, the 
data suggest that FMR1 genotype modulates mGluR5 availability and affects EEG 
makers of sleep need in healthy adult men (Chapter 5). 
 
     In summary, this thesis examined effects of dopaminergic and glutamatergic 
neurotransmission on sleep-wake regulation in healthy humans. It provides first 
evidence that dopamine modulates markers of sleep homeostasis, and that a 
polymorphism of DAT1 differentially modulates distinct effects of the stimulants 
caffeine and modafinil. Furthermore, the work reveals that mGluR5 contribute to 
subjective and objective markers of sleep need. Finally, the availability of mGluR5 
and EEG markers of sleep need is modulated by a distinct polymorphism of the 
FMR1 gene. Overall, the findings support a significant role the DAT and mGluR5 in 
regulating human sleep and wakefulness.  
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Zusammenfassung 
     Die neurochemischen und molekularen Mechanismen, die der Regulation des 
Schlafs und des Wachzustands zugrunde liegen, sind bis heute offene und 
weitgehend unbeantwortete Fragen in der Neurowissenschaft. Das aufsteigende 
retikuläre Aktivierungssystem, welches sich im Gehirnstamm und in den 
Basalganglien befindet, beinhaltet eine Anzahl klar definierter Zellgruppen mit 
bestimmten Neurotransmittern. Diese Nuclei wurden mit der Schlaf-Wach-Regulation 
assoziiert und verändern ihre Feuerungsmuster in Abhängigkeit des Schlafs und 
Wachzustands. Das Striatum spielt eine zentrale Rolle bei der cerebralen 
Aktivierung. Es exprimiert verschiedene Rezeptor-Heteromere, die funktionelle 
Einheiten aus Adenosin A2A Rezeptoren, Dopamin D2 Rezeptoren und metabotropen 
Glutamatrezeptoren des Subtyps 5 (mGluR5) bilden. Das Ziel der vorliegenden 
Dissertation war zu untersuchen inwiefern das dopaminerge und das glutamaterge 
Neurotransmittersystem zur Regulation von Schlaf und Vigilanz beim Menschen 
beitragen. Dafür wurde eine integrative Vorgehensweise angewendet und folgende 
Untersuchungen kombiniert: Typisierung funktioneller, genetischer Polymorphismen; 
molekulare Bildgebund des Gehirns; pharmakologische Eingriffe; polygraphische 
EEG Aufnahmen; Aktigraphie und das Testen kognitiver Leistungen bei gesunden 
Versuchspersonen. 
 
     Um die dopaminergen Aspekte der Schlaf-Wachregulation zu untersuchen, 
wurden 110 gesunde Männer und Frauen bezüglich zweier funktioneller 
Polymorphismen in den Genen für den Dopamin Transporter (DAT) und die 
Catechol-O-Methyltransferase (COMT) genotypisiert. Beide, DAT und COMT 
regulieren gemeinsam die zerebralen Dopaminspiegel, wobei DAT primär im 
Striatum und COMT primär im präfrontalen Kortex zu finden sind. Der VNTR 
(variable-number-tandem-repeat) Polymorphismus in der 3’-untranslatierten Region 
des Gens, welches DAT (DAT1, SLC6A3) kodiert, bewirkt eine um 15-20 % 
verminderte DAT Verfügbarkeit im Striatum bei 10-Repeat-Allel-Homozygoten 
(10R/10R) im Vergleich zu hetero- und homozygoten Trägern des 9-Repeat-Allels 
(9R). Andererseits verursacht der Val158Met COMT-Polymorphismus eine 
drastische Abnahme der COMT Aktivität. Die Bestimmung der Tagesschläfrigkeit und 
die durchgehende Aufzeichnung der motorischen Aktivität während durchschnittlich 4 
Wochen zeigte auf, dass DAT1 9R Träger eine allgemein höhere Aktivität aufweisen 
und öfters über eine erhöhte Schläfrigkeit berichten. Andererseits waren zwischen 
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den COMT Genotypen die Ruhe-Aktivitätsrhythmen nicht underschiedlich, dagegen 
hatte dieser Polymorphismus einen Einfluss auf den Body-Mass-Index (Kapitel 2).  
 
     Um die Effekte des DAT1 Polymorphismus auf die Schlaf-Wachregulation 
genauer zu untersuchen, absolvierten 57 Versuchspersonen ein kontrolliertes 
Schlafentzugsprotokoll. Untergruppen der Teilnehmer nahmen gemäss einer 
placebo-kontrollierten, doppel-blinden Versuchsanordnung entweder Koffein (n=16) 
oder Modafinil (n=22) ein. Durch Schlafentzug induzierte Zunahmen bei etablierten 
neurophysiologischen Merkmalen des Schlafbedürfnisses, einschliesslich Tiefschlaf 
(slow wave sleep), langsam-wellige Hirnstromaktivität (0.5-4.5 Hz) und der Anzahl 
individueller niedrig-frequenter (0.5-2.0 Hz) Oszillationen im non-rapid-eye-
movement Schlaf (NREM) waren bei den DAT1 10R/10R im Vergleich zu den 9R 
Trägern erhöht. Des Weiteren führten Koffein und Modafinil durch die verlängerte 
Wachzeit zu induzierten Veränderungen in funktionalen Frequenzbändern (delta, 
sigma, beta) der rhythmischen Hirnaktivität im Wachzustand und im Schlaf gemäss 
dem DAT1 Genotyp. Diese Ergebnisse deuten darauf hin, dass sich Einflüsse der 
striatalen, dopaminergen Neurotransmission auf die Schlaf-Wachregulation und auf 
die Effekte der weit verbreiteten Stimulanzien Modafinil und Koffein auswirken 
(Kapitel 3). 
 
     Um glutamaterge Aspekte der Schlaf-Wach-Regulation zu untersuchen, wurde bei 
26 gesunden Männern die Methode der Positron Emissionstomographie (PET) mit 
dem hoch selektiven, nicht-kompetitiven mGluR5 Antagonisten 11C-ABP688 
angewendet. Alle Probanden nahmen an zwei individuellen Bildgebungssitzungen 
teil, einmal nach 9 und einmal nach 33 Stunden anhaltender Wachzeit. Die 
Verlängerung der Wachzeit bewirkte eine Erhöhung der mGluR5 Verfügbarkeit im 
Gehirn um circa 3.5%. Nach Bonferroni-Korrektur (p < 0.0038) zeigte sich nach 
anhaltendem Schlafentzug eine signifikante Zunahme im anterioren Cingulum, in der 
Inselrinde, im medialen Teil des vorderen Temporallappens, im Gyrus parahippo-
campalis, im Striatum und im Mandelkern (Amygdala). Die Zunahme in der mGluR5 
Verfügbarkeit in all diesen Regionen korrelierte signifikant mit der schlafentzugs-
induzierten Zunahme der subjektiven Schläfrigkeit. Diese Daten zeigen eine Rolle 
der mGluR5 beim homöostatischen Aspekt der Schlaf-Wachregulation (Kapitel 4). 
  
     Die mGluR5 werden mit der Generierung von langsamen Hirnwellen (< 1 Hz) in 
Verbindung gebracht, ein typisches Merkmal des NREM-Schlaf EEGs, welches mit 
neuronaler Plastizität und der Verarbeitung von Erinnerungen assoziiert wird. Durch 
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pharmakologische Blockierung der mGluR5 konnte das Fragiles-X-Sydrom (FXS) in 
Mäusen aufgehoben werden. Das FXS ist eine X-chromosomal assoziierte humane 
Erkrankung, die durch eine Mutation hervorgerufen wird, die zur Verfielfältigung 
eines CGG-Motivs im FMR1-Gen (fragile-X mental retardation 1 gene) und den 
kompletten Verlust des FMRP (fragile-X mental retardation protein) führt. Der Verlust 
des FMRP resultiert in mentaler Retardierung und gestörtem Schlafverhalten im 
Menschen und stark erhöhter Schlafdauer bei der Fruchtfliege Drosophila. Um die 
mögliche Verbindung zwischen mGluR5 und FMRP bezüglich Schlaf-Wach-
Regulation zu untersuchen, wurden genetische Analysen des FMR1-Gens mit 
nächtlichen EEG Aufnahmen und in vivo Messungen der mGluR5 Verfügbarkeit nach 
normalem Schlaf und nach Schlafentzug kombiniert. Es wurde ein starker 
Zusammenhang zwischen globaler mGluR5 Verfügbarkeit und EEG Merkmalen des 
Schlafbedürfnisses beobachtet. Insbesondere langsame Hirnwellen im EEG 
korrelieren mit der globalen mGluR5 Verfügbarkeit sowohl im ausgeruhten als auch 
im schlafentzogenen Zustand. Darüber hinaus haben genetische Analysen ergeben, 
dass gesunde FMR1 Träger mit ungerader Anzahl an CGG-Wiederholungen eine 90 
% erhöhte FMRP Expression aufweisen als Träger mit gerader Anzahl an CGG-
Wiederholungen. Die Träger mit ungerader Anzahl an CGG-Wiederholungen zeigten 
eine verminderte Antwort auf Schlafentzug, insbesondere bei der globalen mGluR5 
Verfügbarkeit, den langsamen Hirnwellen und dem Tiefschlaf. Folglich zeigen diese 
Daten, dass die mGluR5 Verfügbarkeit möglicherweise einen molekularen Marker für 
das Schlafbedürfnis darstellt. Zusätzlich spielt die mGluR5 Verfügbarkeit eine Rolle 
für die Regulierung von langsamen Hirnwellen im EEG während NREM-Schlaf. 
Schliesslich weisen die Daten darauf hin, dass der FMR1-Genotyp die mGluR5 
Verfügbarkeit moduliert und EEG Marker für Schlafbedürfnis in gesunden, 
erwachsenen Männern beeinflusst (Kapitel 5). 
 
     Diese Dissertation untersucht den Einfluss dopaminerger und glutamaterger 
Neurotransmission bei der Schlaf-Wach-Regulation in gesunden Menschen. Sie 
liefert Hinweise darauf, dass Dopamin die Schlafhomöostase moduliert und dass ein 
Polymorphismus im DAT1-Gen den Effekt der Stimulanzien Koffein und Modafinil auf 
unterschiedliche Weise beeinflusst. Zusätzlich zeigt die Studie, dass mGluR5 zu 
subjektiven und objektiven Merkmalen des Schlafbedürfnisses beitragen. Die 
Verfügbarkeit der mGluR5 und EEG Marker des Schlafbedürfnisses sind durch einen 
bestimmten Polymorphismus im FMR1-Gen moduliert. Insgesamt weisen die 
Ergebnisse dieser Dissertation auf eine signifikante Rolle von DAT und mGluR5 auf 
die Schlaf-Wachregulation im Menschen hin. 
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Chapter 1  
 
Introduction 
 
Sleep and the electroencephalogram  
     Sleep is a highly regulated and global state controlled by the brain. In its basic 
form, it is characterised by a reduced awareness to external stimuli, combined with 
an increased sleep intensity following deprivation. By this definition, sleep is 
observed throughout the animal kingdom and appears to have been conserved 
throughout evolution (Campbell and Tobler, 1984; Tobler, 2011). In the past, sleep 
was believed to be a passive state associated with memory impairments and loss of 
consciousness. However, following the discoveries of rapid eye movement (REM) 
sleep (Aserinsky and Kleitman, 1953) and later, the cyclic alternations between REM 
and non-REM (NREM) sleep (Dement and Kleitman, 1957), it was generally 
accepted that sleep is an active process.  
 
     Self-reported sleep duration among more than 1.1 million American adults 
revealed a median daily sleep duration of 8 hours, which accounts for approximately 
1/3 of our daily life (Kripke et al., 2002). Nevertheless, the importance and molecular 
mechanism(s) of sleep still remain poorly understood (Cirelli and Tononi, 2008). 
Indeed, as pioneering sleep researcher Prof. Allen Rechtschaffen commented: “If 
sleep doesn't serve an absolutely vital function, then it's the biggest mistake the 
evolutionary process ever made”.  
 
     Modern sleep research is to a large extent based on the development of the 
human electroencephalogram (EEG), which was first used by the German 
psychiatrist Hans Berger in the 1920s (Berger, 1929). Building on Berger’s 
pioneering work, the EEG today is an important tool for non-invasive investigation of 
the human brain. Standardized methods such as the 10-20 system ensures inter-
individual comparability for placing EEG electrodes, with a between electrode 
distance of 10% to 20% (Figure 1 left). The EEG is generated by rapid depolarization 
of neuronal membranes, mediated by sodium and potassium voltage-dependent ion 
conductance, and by neurotransmitter-dependent synaptic activation. As a result, 
action potentials propagate along axons and dendrites. Since there is no local 
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accumulation of charge, current flow in one direction, is compensated by opposite 
current flows elsewhere. As a result, excitatory or inhibitory postsynaptic potentials 
(EPSP and IPSP respectively) are generated. These alternating electric fields can be 
detected on the scalp surface (Figure 1 right) and are known as field potentials, 
which represent summated activity from a large number of neurons and can be 
recorded with at great temporal resolution. Field potentials measured by the EEG are 
primarily generated by synaptic activity in apical dendrites of cortical pyramidal 
neurons, oriented perpendicular to the cell surface (Westbrook, 2000). 
 
Figure 1: EEG generation and the typical 10-20 montage.  
 
Left: Example of an EEG montage using the 10-20 system. Electrodes are positioned 
according to well-defined criteria with an electrode distance of 10% to 20% of the total frontal-
occipital and left-right distance of the skull. Potential differences between electrodes are 
measured and EEG recordings therefore require at least two electrodes. Right: The EEG 
measures field potentials, the combined electrical activity of a large number of cortical 
pyramidal cells. The activity originates primarily from the apical dendrites orientated 
perpendicular to the cell surface. Figure from Purves, 2004. 
 
Quantification of the EEG during wakefulness and sleep 
     The human EEG, together with recordings of the electrooculogram (EOG), 
electromyogram (EMG) and electrocardiogram (ECG) can discriminate between the 
vigilance states of REM sleep, NREM sleep, and wakefulness. The EEG is typically 
divided into bands of waves including slow oscillations (< 1 Hz), delta (1 - 4 Hz), 
theta (4 – 7.5 Hz), alpha (8 – 13 Hz) and beta (14 - 30 Hz) waves, although these 
definitions vary considerably across literature. Slow oscillations are commonly used 
for the sleep EEG only. Similarly, beta activity during sleep is typically defined at a 
slightly higher frequency (15-30 Hz) to encompass spindles/sigma (12-15 Hz) 
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activity. Vigilance states, as illustrated on Figure 2, can systematically be defined 
according to the criteria developed by Rechtschaffen and Kales in the 1960s 
(Rechtschaffen and Kales, 1968). According to their criteria, rested wakefulness (with 
eyes closed) is typically associated with distinct low amplitude alpha activity. NREM 
sleep is divided into stages 1 – 4 of increasing intensity. Specifically, stage 1 sleep is 
considered a transitional state between wakefulness and sleep. It is short-lived and 
characterized by irregular low voltage, mixed frequency EEG activity, associated with 
a dissipation of alpha waves. Stage 2 sleep is recognized by the transient occurrence 
of K-complexes and 11 - 15 Hz waxing and waning sleep spindles. Stages 3 and 4 
contain moderate (20-50%) and high (>50%) amounts of slow waves respectively, 
with frequencies in the delta range and a peak-to-peak amplitude of >75 V. Stage 3 
and 4 are often combined into so-called slow wave sleep (SWS). Finally REM sleep, 
also known as paradoxical sleep, can be recognized by its mixed-frequency EEG 
activity that resembles active wakefulness. Nevertheless, REM sleep is associated 
with strong atonia, where only the eye muscles reveal rapid activity. 
 
Figure 2: Example of typical EEG oscillations during wakefulness and sleep 
 
EEG traces (20 s) recorded during a typical 8-hour sleep episode in a representative 
individual. Waking EEG with eyes closed can be recognized by strong alpha activity around 
10 Hz. Stage 1 sleep show irregular low voltage, mixed frequency EEG. Stage 2 sleep is 
recognized by the common spindles (~13.5 Hz) and large K-complexes. Slow wave sleep 
(stage 3 and 4) is illustrated by large slow waves (>75 V) in the delta frequency range. REM 
sleep is associated with mixed frequency, low amplitude waves. Furthermore, REM sleep is 
characterized by reduced muscle tone and rapid eye movements recognized in the EMG and 
EOG (not illustrated here). Dotted lines illustrates the amplitude criteria for slow waves; ± 37.5 
V.  
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     Despite the elegance of the sleep stage criteria defined by Rechtschaffen and 
Kales, scoring is based on visual inspection of the EEG in 20 – 30 s epochs, and can 
vary considerably even among experienced sleep scorers (Norman et al., 2000). A 
more objective way to quantify EEG activity is to apply fast-Fourier transformed 
(FFT) spectral analysis. This mathematical transformation converts the EEG signal 
from time to frequency domain (Cooley and Tukey, 1965). The FFT requires a 
stationary signal and is therefore performed in time windows of either 2 or 4 s for 
wakefulness and sleep, respectively. This allows for frequency resolutions of 0.25 Hz 
for sleep recordings and 0.5 Hz for wakefulness with a spectrum depicting spectral 
power (V2/Hz) for a specified time frame (e.g. across NREM sleep) (Figure 3).  
 
Figure 3: Illustration of an 8-hour sleep EEG recording  
 
Sleep recorded during a typical 8-hour sleep episode in a representative individual. At least 
four NREM-REM cycles can be identified, lasting 1.5 to 2 h, typically followed by short 
awakenings. Upper panel: A hypnogram illustrating 20 s of visually scored sleep epochs. 
Lower panel: Spectral power (0 - 20 Hz) colour coded on a logarithmic scale. Colour coding:  
0 dB = 1 µV2/ Hz. 
 
Conceptual framework of the regulation of sleep and waking  
     Sleep homeostasis is a founding principle of sleep-wake regulation. It was 
conceptualized in the 1980s by Alexander A. Borbély, when he first proposed the 
two-process model of sleep regulation, a concept widely accepted today (Borbély, 
1982; Achermann and Borbély, 2011). The two-process model describes the 
interaction between the homeostatic process S and the circadian process C. 
Together they generate the timing of sleep and wakefulness. Process S mediates the 
rise in sleep propensity, or sleep pressure, during wakefulness and the decline 
during sleep. If sleep is reduced or absent, sleep propensity is augmented, whereas 
excess sleep is followed by a reduction in sleep propensity. Based on human sleep 
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EEG recordings, process S has been linked to slow wave activity (SWA) in the delta 
range (specifically between 0.5-4.5 Hz). Pooled data across individuals revealed that 
SWA decline during nocturnal sleep in a way that can be described mathematically 
by an exponential function (Daan et al., 1984; Achermann et al., 1993; Achermann 
and Borbély, 2011) (Figure 4). Recently, the decline in SWA was also successfully 
simulated in single individuals (Rusterholz et al., 2010). During wakefulness, process 
S is modelled as a saturating exponential increase. 
 
Figure 4: The two-process model of sleep-regulation 
 
The two-process model of sleep regulation, conceptualized by A.A. Borbély in 1982. 
Schematic view of the interaction between the homeostatic process S and the circadian 
process C, during a normal night of sleep and following 40 hours of prolonged wakefulness. 
The interaction between process S and C is proposed to generate the timing of sleep and 
waking. The ultradian process depicted illustrates EEG SWA as it declines across 
consecutive NREM sleep episode. Figure from Landolt, 2008. 
 
     The circadian process C is regulated by the suprachiasmatic nucleus (SCN) in the 
hypothalamus, which consists of roughly 20.000 neurons (Moore and Eichler, 1972; 
Stephan and Zucker, 1972). The SCN functions as an endogenous zeitgeber and its 
outputs can be described by a sine-wave function with a period of roughly 24 hours, 
operating virtually independent of prior sleep or wakefulness. The SCN is mainly 
entrained by light, detected by retinal ganglion cells and transmitted via melanopsin-
releasing neurons of the retinohypothalamic tract (Gooley et al., 2001; Berson et al., 
2002). However, other zeitgebers such as temperature (Blake, 1967), and feeding 
behaviour (Richter, 1922), can also modulate the endogenous clock. The actual 
timekeeping is maintained by interconnected SCN neurons and clock gene 
transcription feedback loops (Albrecht and Eichele, 2003).   
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     The interaction between process S and process C regulates timing and duration 
of sleep, but also alertness and maintenance of wakefulness in the waking phase 
(Van Dongen and Dinges, 2003). Sleep deprivation is a demanding yet useful tool 
that allows for experimental disentanglement of the two processes, even in human 
subjects. Following a period of circadian entrainment to a specific bedtime, sleep at 
“baseline” levels can be compared with recovery sleep following 40 hours of 
prolonged wakefulness. This allows for comparison of sleep at different homeostatic 
levels, yet at the same circadian time point, thereby effectively eliminating the effects 
of process C. When the response to sleep deprivation is calculated intra-individually, 
it effectively reduces inter-individual differences in sleep intensity and architecture, 
which allows for more accurate between-subject comparisons. Furthermore, sleep is 
a highly controlled state characterized by the loss of consciousness. This again 
provides researchers with a long and “undisturbed” time window to examine the 
brain. As highlighted in the next section on genetics, this may reveal why the sleep 
EEG is one of the most hereditary features known in humans and can explain why 
sleep is an excellent tool for studying genetic influences. 
 
Genetic influences impacting sleep-wake regulation  
     Genetic studies investigating sleep and the sleep EEG can be traced back as far 
as the 1930s where Geyer investigated sleep, by comparing “sleep habits” among 
monozygotic (MZ) and dizygotic (DZ) twins. In his paper, Geyer reported higher 
concordance among MZ than among DZ twins (Geyer, 1937). More than half a 
century later, modern day analysis of the sleep EEG corroborates the initial findings 
of Geyer. Comparisons of the NREM sleep EEG between MZ and DZ twins revealed, 
that theta and alpha frequencies, but also to a lesser extent delta waves and 
spindles, are genetically modulated (Ambrosius et al., 2008). In a large study cohort 
of 80 twin pairs, de Gennaro and colleagues reported a heritability estimate of up to 
96% for 8 – 16 Hz EEG activity in NREM sleep (de Gennaro et al., 2008), a finding 
also supported by earlier studies (Buckelmüller et al., 2006). Not only the sleep EEG 
shows high heritability estimates. Also alpha activity during waking, investigated 
among 213 twin pairs, was reported to have a heritability estimate of up 89% (Van 
Beijsterveldt et al., 1996). Overall, this supports the trait-like nature of human sleep 
and the EEG. 
 
     Although genes have been conclusively established to play a role in regulating 
sleep and the EEG, the search for the specific genes involved has only recently been 
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the subject of investigation. One successful approach to shed light on this question, 
has been the so-called candidate gene approach, where a specific gene or single 
nucleotide polymorphism (SNP) is examined based on a priori knowledge of the 
functional effect, role and importance of that specific genetic factor. Hence, the 
candidate gene approach has high statistical power, but requires strong and valid 
hypotheses to be powerful. Otherwise, “noise” from other genetic factors may 
eliminate potential findings, or even lead to false discoveries (Zhu and Zhao, 2007; 
Wilkening et al., 2009; Amos et al., 2011). Within the sleep field, the candidate gene 
approach has so far been successfully used to establish the role of a handful of 
polymorphisms. One of which is the functional role of 3’ untranslated region (UTR) 
variable number tandem repeat (VNTR) polymorphism of the PER3 gene coding for 
the period circadian protein homolog 3. PER3 has so far been associated with 
diurnal preference, delayed sleep phase syndrome, differences in SWA, cognitive 
performance and modulations of body mass index (BMI) (Archer et al., 2003; Viola et 
al., 2007; Lázár et al., 2012). Similarly, SNPs in the genes coding for adenosine 
deaminase (ADA) and brain-derived neurotropic factor (BDNF) have been shown to 
affect markers of sleep homeostasis (Rétey et al., 2005; Bachmann et al., 2012a; 
2012b). Moreover, a polymorphism in the ADORA2A gene coding for the adenosine 
A2A receptor has been shown to modulate individual sensitivity to caffeine (Rétey et 
al., 2005; 2007); whereas the functional Val158Met polymorphism of the Catechol-O-
methyltransferase (COMT) gene (SNP-ID: rs4680), has been reported to modulate 
the effects of the stimulant modafinil (Bodenmann et al., 2009b; Bodenmann and 
Landolt, 2010).  
 
     Compared to the candidate gene approach, genome wide association studies 
(GWAs) use DNA chips to establish the effects of a large number of SNPs 
simultaneously. GWAs do not require a priori knowledge and are capable of 
discovering new genetic associations. However it suffers from low statistical power 
since it examines millions of SNPs, resulting in an alpha level of around 5 x 10-8 
(Amos et al., 2011). Therefore, unless the study sample is very large, GWAs may be 
best suited for detecting SNPs that pose greater effects. (Manolio et al., 2009; Amos 
et al., 2011). In that respect, the candidate gene approach remains a useful tool, 
along side GWAs, for disproving or confirming specific hypotheses. 
 
Current hypotheses for the “function(s) of sleep” 
     As previously mentioned, the functions and molecular mechanisms underlying 
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sleep-wake regulation are not yet fully understood. Although these functions remain 
a topic of debate and are beyond the scope of this thesis to systematically cover, the 
theories include: the detoxification of the brain from free radicals, glycogen 
replacement, immune system repair, as well as memory consolidation and the 
maintenance of synaptic homeostasis (Tononi and Cirelli, 2006; Rasch and Born, 
2013). Given that sleep is conserved across species and associated with reduced 
responsiveness to the surrounding environment, sleep is generally assumed to be of 
the brain, by the brain and for the brain (Hobson, 2005).  
     The synaptic homeostasis hypothesis (SHY), proposed by Tononi and Cirelli, can 
be considered an elaboration of the two-process model of sleep regulation. The 
hypothesis proposes that wakefulness is accompanied by long-term potentiation 
(LTP) in a large fraction of cortical circuits, and that sleep is necessary to renormalize 
the net synaptic weight (Tononi and Cirelli, 2003; 2006). The enhanced synaptic 
weight associated with wakefulness, is then directly linked to the amount of SWA 
(and generalized synaptic connectivity) observed in subsequent sleep. As a 
consequence, sleep is a state of downscaling, enhancing the signal-to-noise ratio of 
encoded information. Substantial evidence for this theory now exists. For instance, 
molecular markers of synaptic plasticity such as BDNF and Homer1a in rats, 
increase during waking and decline during sleep. Furthermore, the availability of 
BDNF following sleep deprivation, was associated with the rebound in SWA (Huber 
et al., 2007). Moreover, areas that have been “used” extensively during waking show 
higher SWA in subsequent sleep (Huber et al., 2004). Similarly, synapse number and 
size was increased during wakefulness and reduced during sleep in Drosophila kept 
in an enriched environment (Bushey et al., 2011). Finally, cortical metabolic rates in 
mice increase as a consequence of sleep deprivation and decrease with sleep 
(Vyazovskiy et al., 2008b). However, a major criticism of the SHY is how sleep is 
stringently assumed to be associated with downscaling - a state where LTP should 
not occur (Frank, 2012; Tononi and Cirelli, 2012). Indeed, some evidence rather 
suggest enhanced synaptic transmission during sleep (Ramm and Smith, 1990; 
Nakanishi et al., 1997; Cirelli et al., 2004). Furthermore, the upscaling or “learning”, 
assumed to happen during waking, may not solely rely on LTP. Instead, “learning” 
has been associated equally with long-term depression (LTD) and LTP-type synaptic 
plasticity (Kemp and Manahan-Vaughan, 2007; Frank, 2012). 
 
     The sleep and memory consolidation hypothesis assumes that sleep enhances 
the formation of memories by an active and highly selective process (Diekelmann 
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and Born, 2010; Rasch and Born, 2013). Memory consolidation is suggested to 
happen from a repeated reactivation of new memories during SWS, which leads to 
the strengthening and transfer of memory traces, from short-term storage in the 
hippocampus, to long-term storage in the cortex. Because memory consolidation is 
assumed to be an active process, unlike the SHY, it is not essential whether sleep is 
associated with LTP- or LTD-types of synaptic plasticity. Rather, a memory 
improvement is expected as a consequence of sleep. Methodologically however, this 
is hard to prove since time is almost always associated with memory deterioration, 
independent of sleep or wakefulness. Nevertheless, it has been elegantly shown that 
memory traces, and the hippocampal bold-response, can be enhanced during sleep 
using odor-cues, resulting in “less forgetting” (Rasch et al., 2007; Diekelmann et al., 
2011). Furthermore, the induction of slow oscillating potential fields to the human 
scalp, enhance memory recall of word-pairs following a night of sleep (Marshall et al., 
2006). Finally, the duration of SWS in a post learning nap session, could predict how 
well pictures were remembered in a recall session 3 months later (Takashima et al., 
2006). Combined, these data illustrate that sleep and SWS may be associated with 
memory consolidation. Nevertheless, the concept of “reduced forgetting” observed in 
these studies is somewhat problematic, since it makes it difficult to distinguish the 
specific effects of sleep from the effects of passing time.  
 
     To summarize, several hypotheses have been suggested which may partially 
explain the need for sleep, although they all still lack substantial evidence and are 
not yet generally accepted. Furthermore, it should be stressed that sleep is most 
unlikely to serve a single function, but rather, would be expected to play an important 
role for a number of homeostatic processes 
 
Neuronal pathways involved in sleep regulation 
     The principle of ‘sleep homeostasis’ is one of the most important principles of 
sleep regulation. Nevertheless, the biochemical and molecular mechanisms 
underlying sleep homeostasis are only poorly understood. However, scientific studies 
have begun to unravel some of the neuronal pathways that contribute to the 
regulation of vigilant states. These major neuronal systems influencing sleep and 
waking are congregated in the so-called ascending reticular activation system 
(ARAS) in which several distinct neurotransmitter dependent cell groups play a key 
role. These include nuclei of the brain stem, but also nuclei from the striatum, ventral 
thalamus, substantia nigra (SN), globus palidus (GP) and basal forebrain, commonly 
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denoted as the basal ganglia (BG). The activating role of the BG was initially 
advocated by the work of von Economo (1876 - 1931), who studied patients with viral 
Encephalitis lethargica (Economo, 1930). The infection resulted in lesions to the 
midbrain and limbic system. Specifically, von Economo could show that lesions to the 
midbrain ventral periaqueductal gray (vPAC) and posterior hypothalamus were 
followed by hypersomnolent symptoms. On the other hand, lesions to the anterior 
hypothalamus that extend into the BG were associated with symptoms of insomnia. 
The activating pathways of the central nervous system (CNS) was further 
investigated by Bremer and Magoun, whose work let to the first conceptual evidence 
for the ARAS (Bremer, 1935; Moruzzi and Magoun, 1949). Today, the ARAS 
incorporates arousal pathways originating from cell groups of the lateral 
hypothalamus (LH), BG and upper brain stem, thus including several distinct 
neurotransmitter systems (Saper et al., 2001; Hobson and Pace-Schott, 2002; Saper 
et al., 2005; Fort et al., 2009; Fuller et al., 2011; Edlow et al., 2012) (Figure 5). 
 
     Two major pathways are traditionally assigned to the ARAS. The thalamocortical 
projections (blue pathway, Figure 5) consist of neurons releasing acetylcholine (ACh) 
that project from the pedunculopontine (PPT) and laterodorsal tegmental nuclei 
(LDT) to the thalamus, thereby activating thalamic relay neurons and reticular 
thalamic cells, crucial for transmission of information via the thalamus to the cortex. 
The second pathway has prevailing cortical projections (red pathway, Figure 5) 
originating from the widely projecting neurotransmitter cell groups. They include 
norepinephrine (NE) releasing neurons from the locus coeruleus (LC), serotonin 
(5HT) releasing neurons from the raphe nucleus, dopamine (DA) releasing neurons 
from the ventral tegmental area (VTA), histamine (His) releasing neurons from the 
hypothalamic tuberomammillary nucleus (TMN), ACh releasing neurons from the 
basal forebrain (BF), as well as orexin (ORX) and melanin concentrating hormone 
(MCH) releasing neurons from the LH. All these projections show complex 
modulatory functions, but all promote waking behavior (Saper et al., 2005; Schwartz 
and Roth, 2008; Edlow et al., 2012). Nevertheless, the cortical pathway (red) also 
holds gamma-Aminobutyric acid (GABA) releasing neurons, which has strong 
projections from the ventrolateral preoptic nucleus (VLPO) inhibiting the ARAS and 
promoting sleep (Saper et al., 2005; Schwartz and Roth, 2008; Edlow et al., 2012). 
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Figure 5: The major neurotransmitter pathways of the ascending reticular arousal 
system (ARAS). 
 
The ascending arousal system (ARAS) has two main pathways for arousal projecting via the 
thalamus (dark blue) and directly to the cortex (red). Inhibitory projections from GABA’ergic 
neurons of the ventrolateral preoptic nucleus (VLPO) inhibit the ARAS and promote sleep. 
From Nestler et al., 2009a.  
 
     The ARAS neurotransmitter pathways demonstrate firing patterns that depend on 
vigilance states. Strong neuronal firing during waking, decreased firing during NREM 
sleep, and almost silent neuronal activity during REM sleep, is observed in the raphe 
nucleus (Portas et al., 1998), LC (Takahashi et al., 2010) and for ORX and TMN 
neurons from the LH (Lee et al., 2005; Takahashi et al., 2006). ACh releasing 
neurons of the PPT and LDT are active during waking and REM sleep, whereas they 
decrease firing during NREM sleep (Steriade et al., 1990a). The VLPO cluster, on 
the other hand, is mainly active during sleep allowing it to inhibit the ARAS (Sherin et 
al., 1996; Saper et al., 2005).  
 
     Although the ARAS provides a practical framework for the established pathways 
modulating sleep and waking, functional brain imaging studies, applying on different 
methodologies, have consistently suggested additional regions such as the ventro-
medial prefrontal cortex, the insula, anterior cingulate cortex and precuneus to be 
important for the regulation of slow waves and NREM sleep (Maquet et al., 1997; 
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Dang-Vu et al., 2008; Murphy et al., 2009). These brain structures appear to actively 
contribute to the physiological processes underlying sleep homeostasis (Dang-Vu et 
al., 2010), although they do not directly modulate vigilance states. This further 
highlights the complexity of the mamalian brain, and the regulation of sleep and 
waking.  
 
Dopamine and psychostimulants 
     The role for DA in sleep-wake regulation was initially believed to be of minor 
importance since the neurotransmitter DA showed only limited alterations across the 
sleep wake cycle, as observed in freely moving cats (Miller et al., 1983; Steinfels et 
al., 1983; Trulson and Preussler, 1984). However, recent evidence from rats 
revealed how extracellular DA levels in the medial prefrontal cortex (mPFC) and part 
of the ventral striatum known as the nucleus accumbens (NAc), are high during 
wakefulness and REM sleep, but significantly lower during NREM sleep (Léna et al., 
2005). Similarly, Dahan et al., could show that dopaminergic neurons originating from 
the VTA of the BG show increased burst-firing during REM sleep (Dahan et al., 
2007). The BG plays a crucial role for sleep-wake regulation by integrating signals 
from the cortex, thalamus, amygdala and the midbrain dopaminergic neurons, 
making it a central part of the ARAS (Monti and Monti, 2007; Lazarus et al., 2012; 
2013) (Figure 6). Dopaminergic neurons originating from the VTA innervate the 
striatum, where inhibitory G-protein coupled dopamine D2 receptors co-localize with 
adenosine A2A receptors (Fuxe et al., 2005). Such co-localization indicates interplay 
between the dopaminergic and adenosinergic systems, and may suggest a pathway 
for DA in modulating sleep and wakefulness. Although the exact origin of adenosine 
neurons projecting to the striatum is unknown, the sleep promoting effects following 
activation of A1 and A2A receptors, are well established (Porkka-Heiskanen et al., 
1997; Basheer et al., 2004). Adenosine levels in the brain are known to increase 
during waking and decline during sleep (Porkka-Heiskanen et al., 1997). Also, the 
stimulating effects of the methylxanthine caffeine, are mediated via the adenosine 
system, where caffeine acts as a antagonist on A1 and A2A receptors. Recent 
evidence suggest that the stimulatory effects of caffeine are primarily facilitated by 
adenosine A2A receptors (Huang et al., 2005; Rétey et al., 2007; Landolt, 2008; 
Bodenmann et al., 2012). Human studies have revealed that caffeine attenuates 
homeostatic EEG markers in NREM sleep, as observed in baseline sleep when 
compared to placebo, but also when the sleep homeostat is challenged by sleep 
deprivation (Landolt et al., 1995; 2004). Moreover and as previously mentioned, the 
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response to caffeine can be modulated by a distinct 1083T>C polymorphism of the 
ADORA2A gene (Rétey et al., 2007; Bodenmann et al., 2012).  
 
     Via the co-localization of A2A-D2 receptors, adenosine and DA are suggested to 
have reciprocal innervation of the NAc of the ventral striatum (Figure 6) (Lazarus et 
al., 2012). The NAc have distinct inhibitory GABAergic connections to some of the 
main nuclei of the ARAS. Specifically, the NAc can inhibit the ventral palidum (VP) 
(an area of the BG involved in addiction) and thereby parts of the thalamus and the 
mPFC, a pathway, which is important for cognition and emotional processes, 
sensitive to sleep need (Muzur et al., 2002; Chuah et al., 2006) (Figure 6a). A 
second pathway inhibits ORX neurons of the LH (Figure 6b). Indeed, ORX neurons 
play a key role in maintaining wakefulness, and selective loss of these neurons 
results in narcolepsy (Chemelli et al., 1999). Furthermore, the LH contains 
glutamatergic neurons and has major projections to the BF and cerebral cortex. The 
LH is also inhibited by the VLPO and shows reciprocal connections to the TMN and 
LC (Yoshida et al., 2006; Sano and Yokoi, 2007) (Figure 6b). A third pathway inhibits 
the parabrachial nucleus (PB), the BF and the cerebral cortex, a pathway also 
involved in maintaining wakefulness and cognitive performance (Usuda et al., 1998; 
Li et al., 2012) (Figure 6c). The fourth pathway illustrates the feedback loop between 
the NAc and the dopaminergic neurons of the VTA (Figure 6d). This feedback loop 
highlights a central role for dopaminergic neurons in regulating sleep and 
wakefulness (Lazarus et al., 2012; 2013). According to this model by Lazarus and 
colleagues, activation of dopaminergic neurons in the VTA activate inhibitory 
dopamine D2 receptors of the NAc, leading to a reduction of GABAergic inhibition of 
the four activating pathways (Figure 6 a-d). This in turn will enhance wakefulness 
and suppress sleep. On the other hand, activation of excitatory A2A receptors on the 
NAc promotes the inhibition of the four activating pathways and thus promotes sleep. 
 
     Evidence for the significance of the VTA projections in modulating sleep and 
wake, as proposed in the model of Lazarus, is slowly increasing. Dopamine 
transporter (DAT) knock-out mice show enhanced wakefulness and are 
hypersensitive to caffeine (Wisor et al., 2001). Indeed, the DAT is highly expressed in 
the striatum and VTA, and it can be speculated that the removal of DAT causes 
dramatic changes to the inputs of the NAc making the sleep-wake regulation more 
dependent on adenosine. On the other hand, the elimination of dopamine D2 
receptors in mice reduces wakefulness and enhances REM and NREM sleep (Qu et 
al., 2010). Furthermore, the activation of dopamine D2-type receptors in the NAc 
Dopamine and psychostimulants 
14 
enhances wakefulness, while the blockage of these same NAc D2 receptors 
enhances sleep (Barik and de Beaurepaire, 2005). 
 
Figure 6: Incorporation of the NAc of the ventral striatum into the ARAS. 
 
The figure illustrates four activating pathways (a-d) promoting wakefulness. The NAc is a 
central cluster with inhibitory innervations (magenta round-headed lines) to all four pathways. 
The model proposes a central role for the VTA given its capability to feedback onto the NAc. 
As result, wakefulness is promoted upon activation of the VTA. Adapted from Lazarus et al. 
2012. 
Plus sign (+) represents excitatory receptors; minus sign (-) represents inhibitory receptors. 
Arrows represent excitatory synapses; round-headed lines represent inhibitory synapses; 
bars with both symbols represent reciprocal excitatory (arrows) and inhibitory (round-headed) 
connections. A2AR: Adenosine A2A receptors, BF: Basal forebrain, D2R: Dopamine D2 
receptors, LC: Locus coeruleus, LH: Lateral hypothalamus, mPFC: Medial prefrontal cortex, 
NAc: Nucleus accumbens, PB: Parabrachial nucleus, TMN: Hypothalamic tuberomammillary 
nucleus, VLPO: Ventrolateral preoptic nucleus, VP: Ventral palidum, VTA: Ventral tegmental 
area. 
 
  Human brain imaging data corroborate these preclinical findings in mice. Dopamine 
D2 receptors have been reported to be down-regulated in the NAc and ventral 
striatum following sleep deprivation, a decrease that is correlated with reduced 
cognitive performance (Volkow et al., 2008; 2009b; 2012). Nevertheless, it is very 
likely that other dopaminergic projections also play a role in sleep-wake regulation. 
Indeed, selective lesions to the dopaminergic neurons of the ventral periaqueductal 
gray (vPAG) reduce wakefulness and enhance sleep (Lu et al., 2006; Ueno et al., 
2012).  
 
     Other region-unspecific evidence for an involvement of DA in sleep-wake 
regulation arises from studies investigating the potent psychostimulant modafinil 
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(also known as 2-[(Diphenylmethyl) sulfinyl]acetamide). Modafinil is used as the first-
line of treatment for excessive daytime sleepiness in narcoleptic patients, but it is 
also administered to relieve symptoms of sleepiness in shift workers and apnea 
patients. Off label use is reported among patients suffering from multiple sclerosis, 
attention deficit/hyperactive disorder (ADHD), Parkinson’s disease and schizophrenia 
(reviewed in (Minzenberg and Carter, 2008)). Similar to caffeine, modafinil is 
reported to be used among healthy people to enhance cognition and reduce sleep 
need (Wesensten, 2006; Maher, 2008). Although modafinil clearly enhances 
wakefulness, the actual molecular mechanisms are still debated. In vivo animal 
studies revealed that modafinil interferes with both the DAT and the norepinephrine 
transporter (NET) (Madras et al., 2006; Mitchell et al., 2008). On the other hand, the 
wake promoting effects of modafinil, as well as other DA dependent stimulants, are 
abolished in DAT knock-out mice (Giros et al., 1996; Wisor et al., 2001). Data from 
human positron emission tomography (PET) imaging revealed that modafinil appears 
to inhibit the DAT and increase the levels of DA in the striatum and NAc. Overall, this 
suggests a mode of action for modafinil similar to that of amphetamine (Volkow et al., 
2009a), although it is likely that modafinil interferes with both dopaminergic and 
noradrenergic neurotransmission. It is therefore not surprising that the wake 
promoting actions of modafinil differ in key areas from those of caffeine. Whereas 
caffeine is known to interfere with homeostatic markers of sleep need such as SWA 
and SWS, the administration of modafinil shows no such effects, not even when 
challenging sleep-wake regulation by sleep deprivation (Saletu et al., 1989; 
Bodenmann et al., 2009b; Bodenmann and Landolt, 2010). Nevertheless, modafinil 
modulate the sleep EEG, but in a COMT genotype dependent manner (Bodenmann 
and Landolt, 2010). Indeed, the Val158Met polymorphism of COMT is known to 
affect enzymatic activity (Akil et al., 2003; Chen et al., 2004). The COMT is 
responsible for degradation of catecholamines and may play a key role in regulating 
dopaminergic neurotransmission in the prefrontal cortex, where the DAT show only 
very limited expression (Sesack et al., 1998; Morón et al., 2002).  
 
     In summary, DA may have an important and central role to play in regulating 
sleep and wakefulness. Also, the psychostimulant effects of caffeine and modafinil 
may be facilitated directly or indirectly by dopaminergic neurotransmission. 
Nevertheless, the exact molecular mechanisms of how DA promotes wakefulness 
and facilitates the effects of psychostimulants are not yet fully understood. 
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Synaptic dopaminergic neurotransmission 
     Dopaminegic neurotransmission relies on several key steps including: DA 
synthesis, DA receptor activation, DA reuptake and DA degradation. DA is 
synthesized from tyrosine in two steps. Initially tyrosine is converted into L-dopa by 
L-tyrosine hydroxylase (TH), which is then converted into DA by L-aromatic amino 
acid decarboxylase (Figure 7). Following presynaptic vesicular storage, DA can be 
released into the synaptic cleft following an action potential and the corresponding 
membrane depolarization. Once DA is released into the synaptic cleft, it will bind to 
dopamine D1 and D2 type G-protein coupled receptors resulting in downstream 
signaling. A key protein in regulation DA neurotransmission is the DAT which is 
responsible the reuptake of DA into the presynaptic neuron (Giros and Caron, 1993) 
(Figure 7). It is well established that the reuptake of DA by the DAT involves 
sequential binding and co-transport of two Na+ ions and one Cl– ion per DA molecule. 
As a result, the actual driving force for DAT-mediated DA reuptake is the ion 
concentration gradient generated by the Na+/K+-ATPase on the presynaptic 
membrane (Sonders et al., 1997; Torres et al., 2003). This highlights how the activity 
of the DAT also depends on the presynaptic membrane potential.  
 
     DAT expression in the brain is region-specific. While the DAT show only limited 
expression in the prefrontal cortex, it is highly expressed in the striatum. Specifically, 
the DAT is expressed in the VTA and SN of the striatum, areas associated with the 
nigrostriatal, mesolimbic, and mesocortical dopaminergic pathways (Scatton et al., 
1985; Ciliax et al., 1999; Lewis et al., 2001; Torres et al., 2003). Additionally, the DAT 
is believed to be the rate limiting protein for synaptic removal of DA in the striatum 
(Jones et al., 1998; Benoit-Marand et al., 2000). The human gene encoding DAT 
(DAT1) is located on chromosome 5 and contains a 3’-UTR VNTR polymorphism 
(SNP-ID: rs28363170). This 40-bp sequence may occur in forms from 3 to 11 
repeats, yet the presence of 9 or 10 repeats is most common (Vandenbergh et al., 
1992).  Although the functional significance of DAT1 is still debated, accumulating 
evidence in young healthy adults indicates that 10-repeat allele homozygotes 
(10R/10R) have 15-20 % reduced DAT availability in the striatum when compared to 
hetero- and homozygous 9-repeat allele (9R) carriers (Jacobsen et al., 2000; van 
Dyck et al., 2005; van de Giessen et al., 2009; Costa et al., 2011; Spencer et al., 
2013).  
 
     Other key proteins involved in the regulation of dopaminergic neurotransmission 
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include the enzymes COMT, alongside with monoamine oxidase (MAO) A and B - 
enzymes which degrade DA via several steps into homovanilic acid (HVA) (Figure 7). 
MAO is typically bound to the outer membrane of mitochondria where they can 
catalyze monoamines by removing an amine group via oxidative deamination 
(Youdim et al., 2006) (Figure 7). As previously discussed, COMT is responsible for 
degradation of catecholamines by catalyzing the transfer of a methyl group onto the 
catecholamine. Two distinct isoforms of COMT exists: Membrane-bound COMT (MB-
COMT); and soluble COMT (S-COMT); where the MB-COMT is the most abundant 
isoform in the human brain (Tunbridge et al., 2006) (Figure 7). Given the low 
expression of DAT in the prefrontal cortex, COMT has been suggested to play a key 
role in regulating dopaminergic neurotransmission in this brain-region (Sesack et al., 
1998; Morón et al., 2002).  
 
Figure 7: Simplified illustration of a striatal dopaminergic synapse. 
 
The figure illustrates the synthesis of DA from tyrosine by L-tyrosine hydroxylase (TH). 
Following an action potential, vesicular stored DA is released into the synaptic cleft where it is 
rapidly taken up by DAT for recycling, or degraded by COMT and MAO into homovanilic acid 
(HVA). Adapted from Tunbridge et al., 2006; Blackstone, 2009.  
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     The COMT gene, unlike DAT1, contains a well-established functional 
polymorphism (Val158Met, SNP-ID: rs4680) of MB-COMT, which leads to a Val-to-
Met amino acid substitution in the COMT protein. The polymorphism reduces the 
thermo-stability of the enzyme, which leads to a 3-4 fold decrease in enzymatic 
activity in homozygous Met-allele carriers when compared to Val (Akil et al., 2003; 
Chen et al., 2004). The COMT gene is located on chromosome 22. 
 
     DA does not only play a critical role in the striatum and BG. As a widely projecting 
neurotransmitter, DA is also involved in the regulation of frontal network dependent 
cognitive processes, specifically in the mPFC and frontal lobe. Frontal processing 
has been suggested to be dependent on dopaminergic levels according to an 
inverted-U-shape relationship, which may be modulated by COMT (Tunbridge et al., 
2006). According to this paradigm, any “homeostatic” challenge (e.g. sleep 
restriction, cognitive load etc.) will cause a shift in cortical DA levels and thus also, 
cortical function. Under this paradigm, a number of studies have associated the 
highly active Val allele of COMT with poorer working memory (Malhotra et al., 2002; 
Blasi et al., 2005; Bodenmann et al., 2009a) and a number of psychiatric disorders 
including schizophrenia and bipolar disorder (see Tunbridge et al., 2006 for review). 
Furthermore, Dauvilliers and colleagues demonstrated that the COMT Val158Met 
polymorphism affects daytime symptoms of narcolepsy in a gender dependent 
manner (Dauvilliers et al., 2001). 
  
    Based on the proposed role for DA, and in particular for DAT and COMT, we 
studied the two polymorphisms (DAT1, rs28363170 and COMT, rs4680) to 
investigate the role of DAT and COMT on the daily and habitual regulation of sleep 
and wakefulness, in a large-scale, 4 week, actigraphy-derived rest-activity study, 
including 65 men and 45 women (Chapter 2). Based on the findings in the actigraphy 
study, we further investigated 57 subjects for the specific effects of DAT on sleep-
wake regulation, in a controlled sleep deprivation study, which included the 
administration of caffeine (2 x 200 mg) and modafinil (2 x 100 mg) to a subgroup of 
participants (Chapter 3). 
 
Corticothalamic regulation of brain oscillations  
     The three main oscillations observed in the human sleep EEG - slow oscillations, 
delta waves and spindles, - are hallmarks of neuronal interactions between the 
thalamus and cortex. The thalamus can be divided into thalamocortical and reticular 
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cells. The thalamocortical cells are relay neurons exhibiting excitatory glutamatergic 
projections to the cortex and to the reticular thalamic cells (Figure 8). On the other 
hand, the reticular cells only have inhibitory connections to the thalamocortical cells 
releasing GABA. Finally, cortical pyramidal cells are capable of innervating both 
reticular and thalamocortical cells, via glutamatergic excitatory connections. 
Combined, the thalamus and cortex form a loop capable of generating the major 
EEG oscillations observed in the human EEG (Amzica and da Silva, 2012) (Figure 8). 
 
     The neuronal firing patterns of the thalamus depend on the vigilance state. At the 
transition from wakefulness to NREM sleep, inputs from the ARAS are reduced and 
the thalamocortical cells enter a burst-pause firing mode with long periods of 
hyperpolarization, which inhibits the transmission of signals through the thalamus to 
the cortex (Moruzzi and Magoun, 1949; Steriade, 1970). In the beginning of NREM 
sleep when the homeostatic drive for sleep is high, the thalamocortical cells are 
hyperpolarized and exhibit resting membrane potentials (Vm) of around -65 mV to -70 
mV (Figure 8). This triggers delta oscillations, an intrinsic firing mode of the 
thalamocortical network characterized by two hyperpolarization-activated inward 
currents (McCormick and Pape, 1990; Steriade et al., 1991). Indeed, these NREM 
delta waves are the main source of SWA, the classic EEG marker of sleep 
homeostasis (Figure 4). Spindles, on the other hand, are generated at more 
depolarized membrane potentials in the thalamus at around -60 mV (Figure 4). 
Spindles themselves arise from the reticular thalamic neurons transmitting IPSPs to 
the thalamocortical relay neurons. This in turn triggers rhythmic burst-pause spindle 
oscillations in the thalamocortical cells, which is transmitted to the cortex (Steriade et 
al., 1990b). Meanwhile, the slow oscillations which were discovered by Steriade and 
colleagues (Steriade et al., 1993a), are primarily cortically generated and can occur 
at different thalamic resting membrane potentials. They consist of prolonged 
depolarized up-states associated with neuronal firing. The slow oscillation can group 
together periods of sleep spindles and delta waves during their up- (depolarization) 
and down- (hyperpolarization) states. They are also observed in the human EEG and 
show peak frequency between 0.7 - 0.8 Hz (Achermann and Borbély, 1997; Crunelli 
and Hughes, 2010). Slow oscillations are seen during all stages of NREM sleep, 
although their actual generation is still debated.	 Slow oscillations have a strong 
cortical component and are observed in the cortex even without thalamic inputs 
(Sanchez-Vives and McCormick, 2000; Crunelli and Hughes, 2010), yet vanish when 
the thalamus is isolated from the cortex (Riedner et al., 2011). 
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Figure 8: The cortico-thalamo-cortical system and the generation of EEG oscillations  
 
The thalamus is divided into reticular and thalamocortical neurons. Excitatory cortical 
pyramidal cells innervate both reticular and thalamocortical neurons. Similarly, 
thalamocortical neurons have excitatory innervation of both cortex and reticular thalamic 
neurons, whereas the reticular cells have inhibitory interneuronal connections (GABAergic) to 
the thalamocortical cells. These cells make up the so-called thalamocortical loop, + and − 
indicate excitatory and inhibitory synapses, respectively. The thalamus plays an important 
role in generating some of the major EEG hallmarks of sleep, namely delta waves and 
spindles. Furthermore the thalamus facilitates the slow oscillations. The resting membrane 
potential of the thalamus during NREM sleep leads to the generation of either delta waves 
(Vm ~ -70 mV) or spindles (Vm ~ -60 mV). Adapted from Crunelli and Hughes 2010 and 
Steriade et al., 2003. 
 
     Slow oscillations have been characterised as travelling waves (Massimini et al., 
2004) and EEG-based source modelling has located their main origin in the cingulate 
gyrus and left insula (Murphy et al., 2009; Riedner et al., 2011). MRI and PET 
imaging further linked the origin to areas around the medial and inferior frontal 
cortex, precuneus and posterior cingulate (Dang-Vu et al., 2005; 2008). Finally the 
large slow waves (> 140 V) were associated with activity in the parahippocampal 
gyrus cerebellum and brain stem (Mascetti et al., 2011). Group I metabotropic 
glutamate receptors (mGluR), which will be extensively covered in following sections, 
have also been linked to the regulation of slow oscillations in NREM sleep (Hughes 
et al., 2002; Blethyn et al., 2006) as well as theta activity during waking (Cobb et al., 
2000).  
 
     Interestingly, slow oscillations have been linked to neuronal plasticity and memory 
processing (Steriade and Timofeev, 2003). Specifically, Marshall and colleagues 
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could show that the induction of oscillating potential fields to the humans scalp in the 
slow oscillating range (0.75 Hz), could enhance memory recall of word-pairs 
following a night of sleep (Marshall et al., 2006), while stimulation at 5 Hz reduced 
word-pair memory performance (Marshall et al., 2011). Collectively, these findings 
may show an interesting aspect of slow oscillations that are in need of further 
investigation. 
 
Glutamatergic signalling in the CNS 
     Synaptic plasticity associated with learning and memory is related to 
glutamatergic neurotransmission in general, and to the availability and activation of 
ionotropic glutamate receptors, such as a-amino-3-hydroxy-5- methyl-4-isoxazole 
propionic acid receptors (AMPARs) and N-methyl-d-aspartate receptors (NMDARs) 
in particular (Malenka and Bear, 2004; Kauer and Malenka, 2007). Indeed, glutamate 
plays a key role in the human CNS, where it is expressed in high concentration and 
considered the major excitatory neurotransmitter. Glutamate is synthesised from 
glutamine and stored in vesicles by the vesicular glutamate transporter (VGluT), a 
subtype of excitatory amino acid reuptake transporters (EAAT) (Figure 9). Following 
electrical stimulation, glutamate is released into the synaptic cleft in a Ca2+ 
dependent manner, where it can act via ionotropic and metabotropic glutamate 
receptors, post- or pre-synaptically. The synaptic actions of glutamate are mainly 
concluded by uptake into glial cells by different classes of EAATs, such as GLT-1 
and GLAST. In glia, glutamate is converted into glutamine for recycling (Nestler et 
al., 2009b). Group I mGluRs (mGluR1 & mGluR5) activate phosporlipase C, which 
catalyses the second messenger’s inositol triphosphate (IP3) and diacyl glycerol 
(DAG). This enhances downstream signal amplification and protein synthesis 
(Nelson and Cox, 2008) thereby indirectly controlling NMDAR and AMPAR 
expression (Oliet et al., 1997; Collingridge et al., 2004). Group I mGluRs are found 
on astrocytes and neurons, and are mainly post- and extra-synaptic (van den Pol et 
al., 1995; Lujan et al., 1996; Fellin et al., 2004) (Figure 9). Other mGluR types 
include group II (mGluR2 and mGluR3) and group III (mGluR4, mGluR6, mGluR7 
and mGluR8) mGluRs, which are typically presynaptic and modulate 
neurotransmitter release (Figure 9). Group II and III mGluRs inhibit adenyl cyclase 
and reduce neuronal transmission. An important function of Group I mGLuRs is their 
involvement in neuronal plasticity, LTD, and to some extent LTP (Lu et al., 1997; 
Ayala et al., 2009; Izumi and Zorumski, 2012). Although other receptors may also be 
involved along side the mGluRs, they have specifically been linked to plastic 
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processes in the neocortex, striatum, nucleus accumbens and hippocampus 
(reviewed by Anwyl, 2009). Indeed, several studies have linked sleep-wake 
regulation to alterations in glutamate and LTP-processes. 
 
Figure 9: Simplified illustration of a glutamatergic synapse. 
 
Following the synthesis of glutamate from glutamine, glutamate is stored in vesicles and can 
be released in response to an action potential. Following release, glutamate may interact with 
ionotropic or metabotropic glutamate receptors, pre-, post-, or extra-synaptically. Following 
the uptake of glutamate into glial cells, glutamate is converted into glutamine and is 
transported back into the presynpase for recycling. From (Nestler et al., 2009b). 
 
     Glutamate levels in the frontal cortex, measured in freely moving rats, were 
shown to increase progressively during waking and REM sleep, but decreased 
during NREM sleep (Dash et al., 2009). Microarray analysis comparing mRNA levels 
in sleeping and awake rats revealed that: the synthesis of glutamate; the clustering of 
glutamate receptors (Homer/Vesl & NARP transcription levels); and markers of LTP 
(Arc, BDNF & NGFI-A transcription levels); were higher during wakefulness than 
sleep (Cirelli et al., 2004). The study also revealed that mRNA transcripts related to 
the protein translational machinery (EEF2 & eIF4 transcription levels), and several 
other elements related to myelin maintenance and membrane trafficking, were 
increased during sleep (Cirelli et al., 2004). This supports an active role for sleep in 
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protein synthesis and neural plasticity. Additionally, Vyazovskiy and colleagues could 
show a reduction of AMPARs during sleep in rats (Vyazovskiy et al., 2008a). 
Furthermore, wakefulness was associated with an enhanced phosphorylation of 
AMPARs and CAMKII, suggesting a form of progressive potentiation (Vyazovskiy et 
al., 2008a). Combined with an enhancement of evoked cortical potentials during 
waking, these findings can be interpreted as synaptic potentiation or LTP, occurring 
during wakefulness and counterbalanced during sleep (Vyazovskiy et al., 2008a; 
Huber et al., 2012). 
 
     The mGluR5 are especially interesting as they have been associated with a 
number of CNS functions including anxiety, memory, autism, learning, pain 
perception, depression and addiction (Swanson et al., 2005; Barker et al., 2006; 
Dölen et al., 2007; Xu et al., 2009; Deschwanden et al., 2011; Jung et al., 2011; 
Hulka et al., 2013). Although these effects may seem disassociated, they are all 
likely to be linked to plastic neuronal processes. Evidence also suggests that the 
mGluR5 receptors may be specifically associated with sleep-wake regulation. 
Several brain regions associated with the ARAS (e.g. the ventromedial prefrontal 
cortex, BF, insula, anterior cingulate cortex, striatum, parahippocampal gyrus, 
precuneus, etc.) are brain regions where mGluR5 are preferentially expressed 
(Ametamey et al., 2007; Gasparini et al., 2008). Furthermore, and as previously 
explained, the mGluR5 are known to play an important role in shaping NREM EEG 
slow oscillation (Hughes et al., 2002; Blethyn et al., 2006). Additionally, a distinct 
interaction between DA D2, adenosine A2A and mGluR5 receptors have been 
described specifically in the striatum (Ferré et al., 2007). Finally, given how G-protein 
coupled metabotropic receptors are tightly regulated and provide a powerful 
mechanism of signal amplification (Nelson and Cox, 2008), even minor changes may 
be linked to relevant physiological consequences. Taken together, convening 
evidence supports a role for the mGluR5 in modulating sleep-wake regulation.  
 
     Today, it is possible to accurately quantify the mGluR5 in vivo by molecular PET 
imaging with the highly selective non-competitive mGluR5 antagonist 11C-ABP688 
(Ametamey et al., 2006). In line with pre-clinical knowledge (Romano et al., 1995), 
the availability of mGluR5 was found to be high in the anterior cingulate, medial 
temporal lobe, amygdala and striatum; whereas white matter and the cerebellum 
revealed only low levels of mGluR5 (Ametamey et al., 2007). Based on the 
associations between neuronal plasticity, sleep-wake regulation and mGluR5 
receptor expression; in chapter 4 and 5, we investigated if mGluR5 may be linked to 
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sleep-wake regulation in healthy adult men. We used the PET ligand 11C-ABP688 to 
quantify mGluR5 availability after 9 and 33 hours of wakefulness.  
 
Sleep regulation and the mGluR5 – FMR1 interaction 
     The most widespread single-gene cause of autism is the fragile X syndrome 
(FXS), triggered by a 5’ UTR (CGG)n repeat expansion in the Fragile X mental 
retardation 1 (FMR1) gene, located on the X chromosome. Following a CGG triplet 
expansion above 200 repeats, the DNA is hypermethylated and the FMR1 gene 
completely silenced (Cummings and Zoghbi, 2000). Although such triplet repeats 
(often denoted as microsatellites) are actually common in the human genome and 
are observed approximately every 2 kb of DNA (Barker, 2002), they are rarely 
associated with any disease. However, because of the large (> 200) repeat 
sequence, it is likely (although not yet conclusively shown) that slipped-strand 
mispairing interferes with normal DNA replication and causes the observed 
polymorphic transmission of CGG repeats across generations (Pearson et al., 2005). 
The silencing of the FMR1 gene results in the complete loss of the fragile X mental 
retardation protein (FMRP) (Robertson, 2005).  
 
     The FMRP is a RNA binding protein expressed in the brain, which is associated 
with polyribosomes and regulates neuronal mRNA trafficking, translation and 
synthesis at synapses (Bagni and Greenough, 2005; Ben A Oostra and Willemsen, 
2009). The FMRP is important for synaptic plasticity, LTP and LTD in neuronal cell 
bodies and dendritic spines. Specifically, the FMRP is believed to inhibit downstream 
signaling from group I mGluRs thereby maintaining translation at an optimal level. 
The loss of FMRP leads to an uncontrollable activation of mGLuR1 and mGLuR5, 
thereby causing of FXS. This concept is known as the “mGluR theory of FXS” (Bear 
et al., 2004; Dölen and Bear, 2008) (Figure 10). In the absence of FMRP, the 
initiation of protein synthesis from mGluRs is no longer sufficiently regulated, and 
excessive AMPAR internalization and enhanced LTD is observed (Bassell and 
Warren, 2008). As such, the loss of FMRP is associated with long, thin and immature 
dendritic spines (Irwin et al., 2001; Nimchinsky et al., 2001). Strong support of the 
mGluR theory of FXS came from the treatment of FMR1 knock-out mice with 
selective mGluR5 inhibitors, which were reported to rescue the FXS phenotype 
(Dölen et al., 2007; Michalon et al., 2012) (Figure 10). Taken together, these findings 
suggest a strong interaction between mGluR5 and FMRP.  
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Figure 10: The mGluR theory of fragile X syndrome 
 
A simplified scheme of how mGluR5 and FMRP regulates protein translation. In normal 
healthy individuals, mGluR5 and FMRP together maintain protein translation at an optimal 
level. Among fragile X patients, the loss of FMRP leads to an up-regulation of protein 
translation, causing FXS. The application of a mGluR5 antagonist to FXS patients reduce 
protein translation initiation and thereby conceptually counterbalance the FXS phenotype. 
From Dölen and Bear, 2008. 
 
     The neuronal changes associated with FXS causes severe cognitive deficits in 
human FXS patients, a condition associated with severely reduced intelligence (low 
IQ ~ 40). Specifically, FXS in humans has been associated with reduced working and 
short-term memory, reduced executive function, disturbed sleep, anxiety and 
obsessive-compulsive disorder (Penagarikano et al., 2007). Furthermore, spatial 
features, such as an elongated face and large ears, are commonly observed. The 
loss of FMRP and its impact on sleep, has been extensively studied in animal 
models. Brain FMRP levels in drosophila have been shown to increase with time 
awake, and to be inversely linked to sleep duration (Bushey et al., 2009). 
Furthermore, overexpression of FMRP in the fly model revealed reduced neuronal 
plasticity in response to sleep deprivation and an overall reduced sleep duration 
(Bushey et al., 2011). Additionally, the mGluR5 has been linked to synaptic 
processes and to the regulation of sleep and wakefulness in other studies. For 
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instance, an associations between mGluR5 and the immediate early gene Homer1a 
(Ronesi et al., 2012); a well defined marker of sleep need (Maret et al., 2007) has 
been reported.  
 
     A mild form of FXS is observed in so-called “premutation carriers”. As defined by 
The American College of Medical Genetics, the premutation is diagnosed when the 
number of CGG repeats in the FMR1 gene is are between 54 – 199 (Maddalena et 
al., 2001). This mild form of FXS has been associated with fragile X tremor ataxia 
syndrome (FXTAS) and premature ovarian failure (Bourgeois et al., 2009). The 
premutation range is associated with increased FMR1 mRNA levels, yet decreased 
FMRP expression (Tassone et al., 2000; Allen et al., 2004; Peprah et al., 2009). 
Furthermore, specific AGG interruptions in the (CGG)n sequence exists, which 
increase repeat stability and reduce the risk of maternal premutation carriers 
transmitting a full mutation to their offspring (Yrigollen et al., 2012). Nevertheless, the 
AGG interruptions have not been shown to affect FMRP expression levels in 
premutation carriers (Yrigollen et al., 2011). Among healthy individuals, very little is 
known about how FMRP expression is regulated, or whether the number of FMR1 
CGG repeats plays a significant role. Studies examining both premutation and 
healthy carriers have shown an increase in FMR1 transcription levels and a reduction 
in FMRP levels with increasing CGG repeat number. However, within the healthy 
CGG repeat range alone, no association was found (Allen et al., 2004; Peprah et al., 
2009).  
 
     Based on the association between the FMR1 CGG expansion, mGluR5, and 
sleep-wake regulation observed in animal models, we hypothesized that these 
proteins would also affect healthy human sleep and wakefulness. This potential 
association is investigated in chapter 5. 
 
Main research aims of the thesis 
     As mentioned in the previous sections, the main research goals of this thesis are 
to investigate the roles of the dopaminergic and glutamatergic neurotransmitter 
systems in regulating wakefulness and sleep.  
 
     In Chapter 2 and 3, two polymorphisms of the genes coding for the DAT and 
COMT (DAT1 - rs28363170 and COMT - rs4680, respectively) will be investigated to 
elaborate on the effects of DA, in modulating sleep and waking. Specifically, Chapter 
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2 will investigate the role of DAT and COMT on daily actigraphy-derived rest-activity 
patters across a 4-week period among 65 men and 45 women. In Chapter 3, the 
specific role of DAT will be further examined in a subgroup of 57 participants who 
underwent a controlled sleep deprivation protocol, which included the administration 
of caffeine (2 x 200 mg, n=16) and modafinil (2 x 100 mg, n=22). Nocturnal EEG 
recordings was analysed in baseline and recovery sleep and the effects of the DAT1 
genotype, caffeine, and modafinil investigated.  
 
     In Chapter 4 and 5, the role of glutamate in sleep-wake regulation is examined. 26 
healthy men underwent two PET imaging sessions following 9 and 33 hours of 
sustained wakefulness. The quantification of mGluR5 availability was achieved by 
using the highly selective non-competitive radio-ligand 11C-ABP688. Chapter 4 will 
examine how sleep deprivation affects the availability of mGluR5 and its association 
to subjective sleepiness. In Chapter 5, the interactions between NREM EEG 
oscillations and mGluR5 will be investigated and combined with genetic estimates of 
FMRP levels and their role in modulating the mGluR5 availability. 
 
     Finally, the “Concluding remarks” in Chapter 6, will discuss and elaborate, on 
some of the most important findings of this thesis.  
 
 
 
 
 
 
 
  
  
 
 
 29 
Chapter 2  
 
Genetic polymorphisms of DAT1 and COMT differently 
affect actigraphy-derived sleep-wake cycles in 
humans 
 
 
Amandine Valomon1,2, Sebastian C. Holst1,2, Valérie Bachmann1,2, Antoine U. 
Viola1,3, Christina Schmidt3, Jurian Zürcher4, Wolfgang Berger2,4,5, Christian 
Cajochen3, and Hans-Peter Landolt1,2,5 
 
 
1 Institute of Pharmacology and Toxicology, University of Zürich, Switzerland 
2 Zürich Centre for Integrative Human Physiology, University of Zürich, Switzerland 
3 Centre for Chronobiology, Psychiatric Hospital of the University of Basel, 
Switzerland 
4 Institute of Medical Molecular Genetics, University of Zürich, Switzerland 
5 Neuroscience Center Zürich (ZNZ), University and ETH Zürich, Switzerland 
 
 
 
 
 
 
 
 
 
 
In revision: Chronobiology International 
 
Abstract 
30 
Abstract  
     Accumulating evidence suggests that dopamine plays a role in sleep-wake 
regulation. Cerebral dopamine levels are regulated primarily by the dopamine 
transporter (DAT) in the striatum and by catechol-O-methyl-transferase (COMT) in 
the prefrontal cortex. We hypothesized that the variable-number-tandem-repeat 
(VNTR) polymorphism in the 3’-untranslated region of the gene encoding DAT 
(DAT1, SLC6A3; SNP-ID: rs28363170) and the Val158Met polymorphism of COMT 
(SNP-ID: rs4680) differently affect actigraphy-derived rest-activity cycles and sleep 
estimates in healthy adults (65 men; 45 women; age range: 19-35 years). Daytime 
sleepiness, continuous motor rest-activity and sleep diary data during roughly 4-
weeks were analysed. Nine-repeat (9R) allele carriers of DAT1 more often reported 
elevated sleepiness (Epworth sleepiness score ≥ 10) than 10-repeat allele 
homozygotes (10R/10R) (p < 0.02). Moreover, male 9R allele carriers showed higher 
overall activity, whereas this difference was not present in women (‘DAT1 genotype’ 
x ‘gender’ interaction: p < 0.005). Rest-activity patterns did neither differ among 
COMT genotypes. Nevertheless, a significant ‘COMT genotype’ x ‘type of day’ 
(workdays vs. rest days) interaction for sleep duration was observed (p = 0.03). The 
Val/Val and Met/Met homozygotes habitually prolonged sleep on rest days compared 
to workdays by more than 30 min, while Val/Met heterozygotes did not significantly 
extend their sleep (mean difference: 7 min). Moreover, whereas the proportion of 
women among the genotype groups did not differ, COMT genotype affected body-
mass-index (BMI), such that Val/Met individuals had lower BMI than the homozygous 
genotypes (p < 0.04). In conclusion, our data support a contribution of genetically-
determined differences in cerebral dopaminergic neurotransmission in modulating 
daytime sleepiness and individual rest-activity profiles, as well as other sleep-
associated health characteristics such as the regulation of BMI. The differential 
effects of DAT1 and COMT polymorphisms may reflect the distinct local expression 
of the encoded proteins in the brain. 
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Introduction 
     The brain levels of dopamine are regulated in the striatum primarily by dopamine 
transporter (DAT), which removes dopamine from the synaptic cleft, and in the 
prefrontal cortex primarily by catechol-O-methyl-transferase (COMT), which 
degrades dopamine to 3-methoxy-tyramine. Accumulating evidence suggests that 
dopamine is a prominent regulator of wakefulness and sleep (Monti and Monti, 
2007), which are controlled by the intricate interplay of the endogenous circadian 
clock and a sleep-wake dependent, homeostatic process (Borbély, 1982). 
Pronounced diurnal fluctuations of extracellular brain dopamine levels across 24 h 
rest-activity and sleep-wake cycles are well established (Rye and Freeman, 2011). 
Furthermore, disease states with altered dopaminergic neurotransmission, such as 
Parkinson’s disease (PD) and attention deficit hyperactivity disorder (ADHD), are 
often associated with disturbed rest-activity profiles and sleep problems (Whitehead 
et al., 2008; Van Veen et al., 2010). Apart from influencing the circadian clock, 
dopamine may also play a role in regulating the homeostatic facet of the sleep-wake 
cycle. Studies in animal models identified wake-active dopaminergic neurons 
innervating sleep-promoting regions such as the ventro-lateral pre-optic area (Lu et 
al., 2006; Ueno et al., 2012), and also pharmacologic and clinical observations 
suggest an important contribution of dopamine to sleep-wake regulation. For 
example, stimulants like metamphetamine and agonists of dopamine receptors 
promote wakefulness and motor activity in mice and humans (Wise and Bozarth, 
1987; Wisor et al., 2001). Dopamine D2 receptor knock-out mice exhibit prolonged 
sleep time when compared to wild-type animals (Qu et al., 2010), while genetically 
modified mice and flies without functional dopamine transporter (DAT) have 
increased wakefulness (Giros et al., 1996; Kume et al., 2005). Finally, patients with 
PD often suffer from rapid-eye-movement (REM) sleep behavior disorder and 
excessive daytime sleepiness (Rye and Jankovic, 2002; Comella, 2008). Increased 
motor activity to counteract elevated sleepiness due to reduced prefrontal 
dopaminergic ‘tone’ may also be present in patients with ADHD (Cohen-Zion and 
Ancoli-Israel, 2004; Cortese et al., 2009). Such a pathophysiology may explain why 
hyperactivity in ADHD can be improved with medications that increase dopamine 
release (Minzenberg, 2012).  
 
     The gene encoding DAT (DAT1, SLC6A3) exists in different variants in the 
healthy population. More specifically, it contains a 40-base pair (bp) variable-number-
tandem-repeat (VNTR) polymorphism in its 3’-untranslated region (rs28363170), 
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expressing 3 to 11 repeats, with the presence of 9 and 10 repeats as the most 
common isoforms (Vandenbergh et al., 1992; Kang et al., 1999). Although VNTRs in 
general (Nakamura et al., 1998) and the VNTR domain of DAT1 in particular 
(Michelhaugh et al., 2001) can influence transcriptional and translational processes, 
the consequences of this polymorphism on DAT availability in the human striatum 
are slightly controversial (Heinz et al., 2000; Jacobsen et al., 2000; van Dyck et al., 
2005). Nevertheless, more recent brain imaging studies in young adults consistently 
suggest that the presence of the 9-repeat (9R) allele of DAT1 increases striatal DAT 
availability compared to 10-repeat allele homozygotes (10R/10R) (van de Giessen et 
al., 2009; Costa et al., 2011; Spencer et al., 2013). This polymorphism affects the 
rebound in deep slow wave sleep after prolonged waking in healthy volunteers (Holst 
et al., 2012) (see Chapter 3), and the 9R allele has been associated with ADHD in 
adult patients (Barkley et al., 2006; Franke et al., 2010; Spencer et al., 2013) who 
typically exhibit increased DAT expression when compared to matched controls 
(Dougherty et al., 1999; Dresel et al., 2000; Spencer et al., 2005; Krause et al., 2006; 
Spencer et al., 2013). We, thus, predicted that 9R carriers of DAT1 may differ from 
10R/10R homozygotes and show elevated sleepiness and increased motor activity 
across wakefulness and sleep, similar to patients with ADHD in comparison to 
healthy controls (Boonstra et al., 2007; Surman et al., 2009).   
 
     In contrast to the effect of the DAT1 VNTR, the functional impact of the 
Val158Met polymorphism (rs4680) in the gene encoding COMT is well established. It 
leads to a Val-to-Met amino acid substitution in the COMT protein, which reduces 
thermo-stability of the enzyme and drastically decreases enzymatic activity in Met-
allele carriers (Akil et al., 2003; Chen et al., 2004). This polymorphism has been 
associated with various psychiatric disorders (Hosák, 2007), and it modulates 
individual responses to modafinil in healthy adults after sleep deprivation 
(Bodenmann et al., 2009b; Bodenmann and Landolt, 2010) and to methylphenidate 
in children with ADHD (Kereszturi et al., 2008). Here, we aimed at investigating its 
effect on long-term actigraphy-derived habitual rest-activity profiles in young men and 
women. Additionally, because several studies reported an association between 
COMT genotype and food intake (Tworoger et al., 2004; Galvão et al., 2012), we 
investigated whether this polymorphism had an impact on body-mass-index (BMI), 
which provides another important sleep-associated health outcome measure that 
differs widely even among healthy individuals. 
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Materials and Methods 
Study participants  
     One-hundred twenty-nine young healthy males and females were recruited with 
flyers and on the Internet for participation in sleep studies at the Universities of 
Zürich and Basel. The study protocols, screening questionnaires, and consent forms 
were approved by the local ethics committees and conformed to the Declaration of 
Helsinki. 
 
     A general entrance questionnaire was used to gather demographic information 
including age, gender, BMI, level of education, and to screen for medical diseases. 
The inclusion criteria consisted of young age (19-35 years), normal BMI (17-29), 
good subjective sleep quality, absence of neurological or psychiatric disorders, no 
history of drug abuse, no current medication intake, no excessive consumption of 
alcohol, no shift work or crossing of >2 time zones within the last 3 months, and no 
extreme chronotype as assessed with the Münich ChronoType Questionnaire 
(Roenneberg et al., 2003). Subjective sleepiness was assessed with the Epworth 
Sleepiness Scale (Johns, 2000). All subjects received monetary compensation for 
their participation.  
 
Actimetry 
     All participants completed 3- to 4-week rest-activity recordings at home, including 
at least 2 weekends, without any behavioral restrictions. During the recording period, 
they continuously wore an Actiwatch® (Cambridge Neurotechnology, Cambridge, 
UK) on their non-dominant arm, and filled-in a sleep-wake diary twice per day. A total 
of 3001 days and nights worth of actigraphic data were recorded, consisting of 19.5 ± 
4.4 workdays and 7.7 ± 2.1 rest days (i.e., weekend days) per study participants. The 
validity of actigraphic recordings for sleep-wake estimation in healthy volunteers and 
patients is widely accepted (Sadeh, 2011).  
 
     The non-parametric circadian rhythm analysis (NPCRA) developed by Van 
Someren et al. (1999) was used to determine circadian rhythm characteristics (Van 
Someren et al., 1999). The analysed outcome variables included the inter-daily 
stability (IS) (i.e., degree of resemblance between activity patterns of each 
individual), the intra-daily variability (IV) (i.e., fragmentation of periods of activity and 
rest), the 5-least-active-hours (L5), the 10-most-active-hours (M10) and the relative 
amplitude (RA) (ratio between M10 and L5). L5 and M10 were determined from the 
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24-h average curve indicating the mean activity counts of nadir and peak of the day, 
as well as their time of onset.  
 
     For the activity analysis, raw activity counts were exported from the ‘Sleep and 
Activity Analysis 7.23V software’ (Cambridge Neurotechnology Ltd, version 5.42). 
The data of consecutive 30-min bins were averaged over 24 hours in each individual. 
For the nighttime sleep analysis, the ‘Sleep Scoring Algorithm’ module of the same 
software allowed the investigation of several objective, sleep-related variables, 
including time in bed (i.e., difference between bed time and rise time), sleep and 
wake times, estimated sleep duration (i.e., difference between sleep time and wake 
time), sleep latency (i.e., time between bedtime and sleep onset), sleep efficiency 
(i.e., estimated sleep duration divided by the time in bed), and wakefulness after 
sleep onset (WASO). The bed and rise times (i.e., times of lights-off and lights-on) 
were identified and manually set by the same experienced person (Amandine 
Valomon) in all nights and subjects. The wake/sensitivity threshold was set to “low”, 
showing optimal agreement between actigraphy and polysmonography (PSG) in this 
study population (Tonetti et al., 2008). The actimetric recordings were combined with 
the information contained in the sleep-wake diaries, including bed times, get-up 
times, caffeine consumption, occurrence of naps, use of alarm clock, etc.  
 
Genotyping  
     Genomic DNA was isolated from 3 ml fresh EDTA-blood (n = 83) (Wizard® 
Genomic DNA Purification Kit, Promega, Madison, WI) or from saliva (n = 46) 
(NucleoSpin® Blood Kit, Macherey-Nagel AG, Oensingen, Switzerland). The 
genotypes of both DAT1 and COMT could be reliably established in 115 study 
participants.  
 
     The DAT1 genotypes were determined by PCR on an MJ Research PTC-225 
thermal cycler (MJ Research/Bio-Rad, Reno, NV). The following primers were used: 
forward primer, 5’-tgtggtgtagggaacggcctga-3’ and reverse primer 5’-
cttcctggaggtcacggctcaa-3’ (annealing temperature of 67 °C with HOT FIREPol® DNA 
Polymerase). The 430-480 bp PCR products were then analysed by agarose gel 
electrophoresis. COMT genotypes were determined using a Taqman® SNP 
Genotyping Assay (Life Technologies Europe B.V.) and allelic discrimination analysis 
was performed using the software SDS v2.2.2 (Applied Biosystems, Foster City, CA, 
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USA). All analyses were replicated at least once for independent confirmation of 
results. 
 
     Five volunteers had rare DAT1 genotypes (one 10R/7R, two 9R/8R, two 
10R/11R) and were excluded from the analyses. Seven subjects were homozygous 
for the 9-repeat allele. They were combined with the 9R/10R genotypes and referred 
to as 9R carriers. The allelic distributions of DAT1 (p = 0.25) and COMT (p = 0.27) 
genotypes were in Hardy–Weinberg equilibrium (Genepop version 4.0.10) (Rousset, 
2008).  
 
Statistical analyses  
     All statistical analyses were performed with SAS 9.1.3 software (SAS® Institute, 
Cary, NC). Fisher’s exact tests were used to evaluate differences in frequencies and 
distributions. Demographic data and sleep-wake variables were analyzed with mixed-
model analyses of variance (ANOVA) with the between-subject factors ‘gender’ 
(male, female), ‘DAT1 genotype’ (9R, 10R/10R), ‘COMT genotype’ (Val/Val, Val/Met, 
Met/Met), and the covariate ‘age’, such as indicated in text and legends to Tables 
and Figures. For the circadian rest-activity profiles, the within-subject factors time (48 
30-min bins across 24 h) was added. Differences in sleep duration between 
workdays and rest days were analyzed with an ANOVA with the between-subject 
factor ‘COMT genotype’ (Val/Val, Val/Met, Met/Met), the within-subject factor ‘type of 
day’ (workdays, rest days) and the covariate ‘age’. In text and tables, mean values ± 
standard deviations of outcome variables are reported. Contrasts were assessed 
with the LSMEANS statement of PROC MIXED. Only significant effects of factors 
and interactions are mentioned (α < 0.05). 
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Results 
Demographics of study sample  
     The data of 110 young healthy individuals were analyzed (Table 1). The study 
sample consisted of 65 men (59 %) and 45 women (41 %), with a mean age of 25.2 
± 3.8 years, 13.3 ± 2 years of education and a normal BMI (22.2 ± 2.3 kg/m2). 
Chronotype (Munich Chronotype Questionnaire: 4.4 ± 1 [corrected midpoint of 
sleep]) and subjective sleepiness (Epworth Sleepiness Scale: 5.8 ± 2.8) ratings were 
also in the normal range. No significant differences among DAT1 and COMT 
genotype groups with respect to sex ratio, age, years of education, chronotype, and 
daytime sleepiness were noted (pall > 0.05; Fisher’s exact tests). When split by either 
DAT1 or COMT genotype, the distributions of genotype groups of the other gene did 
not differ (pall > 0.05; Fisher’s exact tests). 
 
Study participants show robust circadian rest-activity profiles 
     Typical for our study sample consisting primarily of University students (77 %), 
NPCRA revealed high-amplitude, yet relatively irregular circadian rest-activity 
rhythms (Table 2). The latter was reflected in low IS scores due to large differences 
between workdays and rest days. The periods of lowest (L5) and highest (M10) 
activity began roughly 1 hour after actimetry-derived sleep onset and 2.7 hours after 
actimetry-derived sleep offset, respectively. The L5 initiated significantly earlier and 
revealed lower activity counts in women than in men (Table 2). 
 
     Time spent in bed (TIB) derived from the actimetry recordings correlated with self-
reported TIB in the sleep-wake diaries (R2 = 0.51, p < 0.001, n = 109; Pearson’s 
product moment correlation). On average, the study participants slept 7.5 hours ± 36 
min, with actigraphy-derived sleep onset at 00:36 ± 66 min and sleep offset at 08:06 
± 60 min (Table 3). Sleep onset and offset were affected by ‘gender’ and ‘type of 
day’, such that these values were earlier in women than in men (Figure 1A) and 
earlier on workdays than on rest days (Figure 1 B). Sleep duration was not affected 
by ‘gender’. By contrast, sleep was shorter on workdays than on rest days. The 
average difference was 22 ± 51 min, yet highly variable among individuals (range: -
89 to 173 min). 
 
  
Table 1. Demographic characteristics of study participants. 
Variable 
10R/10R 9R carriers 
Val/Val Val/Val Val/Met Met/Met Val/Met Met/Met 
N 21 27 27 15 23 10 
Sex ratio (% Female) 43 44 21 40 48 40 
Education (years) 13.0 ± 2.0 13.4 ± 1.8 13.2 ± 1.7 13.1 ± 2.8 13.3 ± 2.0 14.0 ± 2.4 
Age (years) 25.2 ± 3.9 24.9 ± 3.9 26.5 ± 4.0 25.3 ± 3.7 25.0 ± 3.7 24.3 ± 3.8 
Chronotype (MCTQ) 4.5 ± 1.0 4.2 ± 1.2 4.4±1.0 4.5 ± 1.1 4.4 ± 1.0 4.1 ± 1.1 
Daytime sleepiness (ESS) 5.2 ± 2.5 5.3 ± 2.4 5.7 ± 3.2 6.5 ± 2.8 6.4 ± 3.4 6.5 ± 2.7 
Body Mass Index (kg/m2) 23.3 ± 2.4 21.4 ± 2.2 23.4 ± 2.3 22.2 ± 2.2 21.6 ± 2.4 22.0 ± 1.4 
 
 
Variable 'gender' 'DAT1 genotype' 'COMT genotype' 'DAT1’ x ‘COMT’ 'age' 
F p F p F p F p F p 
Education (years) F1,96=0.23 0.63 F1,96=1.41 0.24 F2,96=0.49 0.62 F2,96=1.40 0.25 F1,96=17.6 < 0.0001 
Age (years) F1,100=0.00 0.98 F1,100=0.29 0.59 F2,100=0.15 0.86 F2,100=0.56 0.57   
Chronotype (MCTQ) F1,99=0.43 0.52 F1,99=0.00 0.96 F2,99=0.31 0.31 F2,99=0.12 0.88 F1,99=0.98 0.33 
Daytime sleepiness (ESS) F1,97=0.01 0.93 F1,97=1.86 0.18 F2,97=0.15 0.86 F2,97=0.13 0.67 F1,97=0.18 0.67 
Body Mass Index (kg/m2) F1,99=0.31 0.58 F1,99=2.17 0.14 F2,99=3.36 0.04 F2,99=1.10 0.34 F1,99=5.57 0.02 
Values represent means ± STD. Information about education and daytime sleepiness was missing in 3 and 2 individuals, respectively. MCTQ values 
indicate the mid-sleep time on leisure days, corrected for sleep debt accumulated during the week, age and gender.  
F- and p-values refer to mixed-model ANOVA with the factors ‘gender’, ‘DAT1 genotype’, ‘COMT genotype’ and the covariate ‘age’.  
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Table 2. Non-parametric circadian rhythm analysis (NPCRA) reveals robust circadian 
rest-activity profiles. 
Variable Women Men ‘gender’ ‘age’ n=45 n=65 F1,107 p F1,107 p 
IS 0.40 ± 0.10 0.38 ± 0.12 1.08 0.30 0.77 0.38 
IV 0.85 ±01.6 0.84 ± 0.17 0.06 0.81 2.14 0.15 
Relative Amplitude 0.85 ± 0.08 0.81 ± 0.09 4.33 0.04 5.33 0.02 
L5 onset 1.31 ± 0.92 1.77 ± 1.11 5.23 0.02 3.37 0.07 
M10 onset 10.52 ± 1.52 10.93 ± 1.70 0.05 0.82 4.87 0.02 
Amplitude 19428 ± 7393 18627 ± 6934 0.36 0.55 3.72 0.06 
L5 1664 ± 1110 2161 ± 1427 4.07 0.05 10.1 < 0.01 
M10 21092 ± 7686 20788 ± 7424 0.05 0.82 5.67 0.02 
Values represent means ± STD in all participants split by gender. IS = inter-daily stability; IV = 
intra-daily variability; L5 = activity during the least 5 active hours; M10 = activity during the 10 
most active hours. 
F- and p-values refer to mixed-model ANOVA with the factor ‘gender’ and the covariate ‘age’.  
 
Figure 1. Rest-activity rhythms and sleep are affected by gender and type of day. 
 
(A) 24-hour rest-activity profiles in men (n = 65) and women (n = 45). Means ± SEM are 
represented. Mixed-model ANOVA with the between-subject factor ‘gender’, the between-
subject factor ‘time’ (30-min bins), and the covariate ‘age’ (covariance structure: 
autoregressive type 1) revealed significant effects of ‘time’ (F48,5113 = 20.18, p < 0.0001) and 
‘age’ (F1,228 = 10.43, p < 0.002). The actigraphy-derived sleep episode occurred roughly 30 
minutes earlier in women than in men (horizontal bars; see Table 3 for mean values and 
statistics). (B) 24-hour rest-activity profiles on workdays (n = 19.5 ± 4.4 days per person) and 
rest days (n = 7.7 ± 2.1 days per person). Means ± SEM are represented. Mixed-model 
ANOVA with the within-subject factor ‘type of day’ and the between-subject factor ‘time’ (30-
min bins) revealed significant effects of ‘type of day’ (F1,461 = 6.59, p = 0.01), ‘time’ (F48,4988 = 
23.52, p < 0.0001), and ‘time’ x ‘type of day’ (F48,5185 = 4.8, p < 0.0001). Crosses at the bottom 
of the panel indicate significant differences between workdays and rest days (p < 0.05; paired 
t-tests). The actigraphy-derived sleep episode occurred later and lasted longer on rest days 
than on workdays (horizontal bars; see Table 3 for mean values and statistics). 
  
Table 3. Overview of actimetry-derived sleep variables. 
Variable 
Women Men ‘gender’ ‘age’ Workdays Restdays ‘type of day’
n=45 n=65 F1,107 p F1,107 p n=110 n=110 F1,109 p 
N (days/person) 28.0 ± 5.3 26.8 ± 6.4 1.03 0.31 0.21 0.65 19.5 ± 4.4 7.7 ± 2.1 1257 <0.0001 
Time in bed (h) 7.9 ± 0.6 7.7 ± 0.7 1.81 0.18 0.30 0.59 7.7 ± 0.7 8.0 ± 0.9 17.52 <0.0001 
Bedtime 24.1 ± 0.8 24.6 ± 1.3 7.58 < 0.01 6.64 0.01 24.1 ± 1.1 25.2 ± 1.4 116.5 <0.0001 
Risetime 8.0 ± 0.8 8.4 ± 1.1 5.01 0.03 6.71 0.01 7.8 ± 1.0 9.2 ± 1.3 142.0 <0.0001
Sleep duration (h) 7.6 ± 0.6 7.4 ± 0.7 2.21 0.14 0.26 0.62 7.4 ± 0.7 7.8 ± 0.9 19.60 <0.0001 
Sleep onset 24.3 ± 0.8 24.9 ± 1.3 8.29 < 0.01 6.33 0.01 24.3 ± 1.1 25.4 ± 1.4 110.3 <0.0001 
Wake onset (sleep offset) 7.9 ± 0.8 8.3 ± 1.1 5.44 0.02 6.65 0.01 7.7 ± 1.0 9.1 ± 1.2 142.0 <0.0001 
Midsleep 3.9 ± 0.6 4.6 ± 1.1 6.83 0.01 7.07 0.01 4.1 ± 1.0 5.1 ± 1.2 41.4 <0.0001
WASO (min) 37 ± 22 35 ± 15 0.14 0.18 1.82 0.71 35 ± 18 38 ± 19 7.14 <0.01 
Sleep efficiency (%) 88.5 ± 4.4 88.3 ± 3.9 0.07 0.80 1.80 0.18 88.4 ± 4.2 88.5 ± 4.4 0.40 0.53 
Sleep latency (min) 12 ± 4 14 ± 7 3.06 0.08 0.11 0.74 13 ± 6 12 ± 6 8.49 < 0.01 
Mean activity 27 ± 14 26 ± 12 0.12 0.73 1.43 0.23 26 ± 13 27 ± 14 3.32 0.07 
Total activity 7220 ± 3838 7010 ± 2599 0.13 0.72 2.21 0.14 6945 ± 3177 7471 ± 3504 7.55 <0.01 
∆ sleep duration (min) 28 ± 55 18 ± 50 0.93 0.34 1.02 0.31 n.a. n.a. 
∆ sleep time (min) 57 ± 50 64 ± 68 0.43 0.51 3.09 0.08 n.a. n.a. 
∆ wake time (min) 85 ± 70 83 ± 76 0.02 0.89 0.53 0.47 n.a. n.a. 
Values represent means ± STD, split by gender and type of day. 
WASO: Wake after sleep onset. F- and p-values refer to mixed-model ANOVAs with the within-subject factor ‘type of day’, the between-subject factor 
‘gender’ and the covariate ‘age’.  
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The VNTR polymorphism of DAT1 affects subjective sleepiness, and overall 
motor activity in men  
     Although mixed-model ANOVA revealed no significant main effect of DAT1 
genotype on subjective sleepiness (Table 1), visual inspection of the individual data 
suggested that 9R carriers might be slightly sleepier than the 10R/10R homozygotes. 
Indeed, focusing on those individuals with clinically-defined elevated daytime 
sleepiness (Epworth sleepiness score over 10) (Johns, 2000) demonstrated that 
DAT1 9R (8/47 = 17.0%) carriers were more often present in this subgroup than 
10R/10R homozygotes (2/61 = 3.3%) (Figure 2).  
  
    Whereas 24-hour motor activity profiles in the entire study sample did not differ 
significantly between men and women (Figure 1A), mixed-model ANOVA disclosed a 
sig-nificant ‘DAT1 genotype’ x ‘gender’ interaction (F1,200 = 8.3, p < 0.005). Thus, 
male 9R carriers showed generally higher motor activity than 10R/10R homozygotes 
(Figure 3A), while this difference was absent in women (Figure 3B). The interaction 
between ‘DAT1 genotype’ and ‘gender’ was further corroborated when workdays 
(F1,247 = 8.44, p = 0.004) and rest days (F1,254 = 10.68, p < 0.002) were separately 
considered, and when the NPCRA outcome variable L5 (F1,99 = 6.05, p < 0.02) was 
analyzed (insets in Figure 3A & 3B). In summary, the DAT1 VNTR modulates 
circadian sleep-wake cycles in a gender-specific manner.  
 
Figure 2. DAT1 genotype affects subjective daytime sleepiness. 
 
Data reflect individual scores on the Epworth Sleepiness Scale (n = 108). Black (ESS score ≥ 
10) and white (ESS score < 10) circles represent individual data points. DAT1 9R carriers are 
more often present in the subgroup with elevated daytime sleepiness than 10R/10R 
homozygotes (p < 0.02; Fisher’s exact test). Coloured horizontal bars represent the mean 
values in 9R (n = 47) and 10R/10R (n = 61) carriers. 
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Figure 3. DAT1 polymorphism modulates circadian rest-activity profiles in a gender-
dependent manner 
 
24-hour rest-activity profiles 9R and 10R/10R genotypes of DAT1 in male (A) and female (B). 
Mixed-model ANOVA with the between-subject factors ‘gender’, ‘DAT1 genotype’ and ‘COMT 
genotype’, the within-subject factor ‘time’, and the covariate ‘age’ yielded significant effects of 
‘time’ (F48,4732 = 17.37, p < 0.0001) and ‘age’ (F1,213 = 11.23, p = 0.001), and a significant 
‘DAT1’ x ‘gender’ interaction (F 1,200 = 8.3, p < 0.005). Male 9R carriers had higher activity 
levels throughout the day when compared to 10R/10R homozygotes (p = 0.002; 2-tailed, 
unpaired t-test). Female study participants did not show this difference (p = 0.28). Activity 
during the least active five hours (L5; indicated by the horizontal dotted arrow), yielded a 
similar ‘DAT1’ x ‘gender’ interaction (F1,99 = 6.05, p < 0.02). Orange (9R) and red (10R/10R) 
bars represent mean activity counts during L5 derived from the NPCRA analysis. The asterisk 
indicates the significant difference between the genotypes in men (p = 0.03; unpaired, 2-tailed 
t-test). 
 
The Val158Met polymorphism of COMT affects the difference in actigraphy-
derived sleep duration between workdays and rest days and BMI  
     The Val158Met polymorphism of COMT had no effect on subjective sleepiness 
and circadian rhythm variables. Nevertheless, mixed-model ANOVA with the 
between-subjects factors DAT1 genotype, COMT genotype and gender, and the 
covariate age revealed that COMT genotype affected the increase in time in bed 
(F2,99 = 3.24, p = 0.04) and in sleep duration (F2,99 = 3.34, p < 0.04) between 
workdays and rest days. The Val/Val and Met/Met homozygotes prolonged their 
sleep on rest days relative to workdays by 37 ± 58 and 31 ± 54 min. By contrast, this 
difference equalled only 7 ± 41 min in Val/Met individuals (Val/Met vs. Val/Val: p < 
0.03; Val/Met vs. Met/Met: p < 0.08; 2-tailed, unpaired t-tests). A statistical analysis 
of sleep duration with type of day as within-subject factor confirmed the significant 
COMT genotype x type of day interaction (F2,107 = 3.78, p = 0.03) (Figure 4A). 
Importantly, overall sleep duration was similar in the three genotypes, and did not 
significantly differ between genotypes, neither on workdays nor on rest days (pall > 
0.1; unpaired, 2-tailed t-tests).  
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     A genotype-dependent association between sleep-wake timing across workdays 
and rest days and BMI was recently suggested for a PER3 polymorphism (Lazar et 
al., 2012). We, therefore, examined whether the Val158Met polymorphism of COMT 
affects BMI in our healthy sample. Indeed, ANOVA confirmed a significant main 
effect of COMT genotype (Table 1). Specifically, BMI was lower in Val/Met 
heterozygotes when compared to Val/Val homozygotes (p < 0.02; unpaired, 2-tailed 
t-test) and tended to be lower in Val/Met heterozygotes when compared to Met/Met 
homozygotes (p = 0.09) (Figure 4B). 
 
Figure 4. COMT genotype modulates sleep rebound from workdays to rest days and 
affects body-mass-index (BMI). 
 
(A) Sleep duration on workdays and rest days in the three COMT genotypes. Mixed-model 
ANOVA with the between-subject factor ‘COMT genotype’, the within subject factor ‘type of 
day’ and the covariate ‘age’ yielded a significant main effect of ‘type of day’ (F 1,107 = 24.88, p 
< 0.001) and ‘type of day’ x ‘COMT genotype’ interaction (F 2,107 = 3.78, p = 0.03). Thus, in 
contrast to Val/Val (dark green) and Met/Met (light green) homozygotes, Val/Met allele 
carriers (black) did not increase their sleep duration on rest days when compared to 
workdays. *** p = 0.0001, ** p = 0.001 (unpaired, 2-tailed t-tests). (B) Mixed-model ANOVA 
with the between-subject factors ‘DAT1 genotype’, ‘COMT genotype’  and ‘gender’, and the 
covariate ‘age’, yielded a significant effect of ‘COMT genotype’ (F2,99 = 3.36, p < 0.04) and 
‘age’ (F2,99 = 5.57, p = 0.02). Val/Met allele carriers had lower BMI than Val/Val (p = 0.02) and 
Met/Met (p < 0.10) homozygotes (unpaired, 2-tailed t-tests). 
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Discussion 
     In an attempt to further specify the roles for dopamine in physiological sleep-wake 
regulation, we examined the effects of two functional polymorphisms in genes 
regulating cerebral dopamine levels on circadian rest-activity profiles and objective 
sleep estimates derived from actimetry. Consistent with our hypotheses, we found 
that a VNTR polymorphism of DAT1 affects subjective sleepiness and modulates 
overall motor activity throughout activity and rest in men. Moreover, heterozygous 
Val/Met allele carriers of the Val158Met polymorphism of COMT showed consistently 
lower values than Val/Val and Met/Met homozygotes in their sleep rebound on rest 
days compared to workdays, as well as in their BMI. 
 
The rs28363170 polymorphism of DAT1, individual subjective sleepiness and 
motor activity 
     We found that elevated daytime sleepiness was more prevalent in DAT1 9R allele 
carriers than in 10R/10R allele homozygotes. Excessive daytime sleepiness is a 
common symptom in patients with PD, a disease which is characterized by 
pathologically reduced dopamine levels in the striatum (Arnulf and Leu-Semenescu, 
2009). Interestingly, a Taiwanese case-control study suggested that the homozygous 
10R/10R genotype of DAT1 confers protection against PD in men (Lin et al., 2003). 
Accumulating evidence in healthy adults demonstrates that the 9R allele is 
associated with higher DAT expression and lower dopamine availability than the 10R 
allele (Jacobsen et al., 2000; van Dyck et al., 2005; van de Giessen et al., 2009; 
Costa et al., 2011; Spencer et al., 2013). Our genetic data in healthy volunteers may, 
thus, suggest a possible pathophysiological link between the disabling sleepiness 
and the pronounced dopamine deficiency in PD patients.  
 
     This notion is further strengthened by the finding that male 9R carriers exhibited 
higher motor activity throughout days and nights compared to 10R/10R individuals. 
Elevated sleepiness and increased motor activity may be reminiscent of patients 
suffering from adult ADHD. This disorder more often afflicts males than females, and 
patients typically present with excessive daytime sleepiness, superficial sleep, 
elevated daytime and nighttime motor activity, and increased DAT expression when 
compared to controls (Dougherty et al., 1999; Dresel et al., 2000; Cheon et al., 2003; 
Spencer et al., 2005; Krause et al., 2006; Boonstra et al., 2007; Surman et al., 2009; 
Spencer et al., 2013). Thus, our finding of a behavioral ‘ADHD-like’ phenotype in 
healthy male 9R allele carriers who are presumably in a decreased dopaminergic 
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state when compared to 10R/10R homozygotes is in agreement with the hypo-
arousal theory of ADHD (Swanson et al., 2007). This hypothesis posits that 
exaggerated physical activity and increased movements reflect a countermeasure to 
remain vigilant and alert in a condition of low dopaminergic tone.  
 
     The observed sexual dimorphism of the effects of DAT1 polymorphism on motor 
activity may reflect the known impact of sex hormones and the menstrual cycle on 
the dopaminergic system (Dreher et al., 2007). Because the recording period in our 
study covered roughly an entire menstrual cycle, it is unlikely that cycle-related 
changes in DAT expression account for the different impact of DAT1 genotype in 
men and women.  
 
The rs4680 polymorphism of COMT, sleep-wake patterns and body weight 
regulation 
     With respect to the Val158Met polymorphism of COMT, we observed that Val/Met 
heterozygotes showed an attenuated increase in sleep duration on rest days when 
compared to workdays, and also presented with a lower BMI than homozygous 
genotypes. While no such association was present due to allelic variation in DAT1, 
Lazar et al. (2012) investigated the impact of a PER3 polymorphism on sleep and 
health outcomes in 675 study participants. Similar to our results, they found that the 
group showing the highest BMI (PER35/5 genotype) also reported the largest 
difference in time in bed between workdays and rest days (Lázár et al., 2012). These 
observations are in accordance with a large-scale (n = 20’731) epidemiological study 
relying on a questionnaire, in which a positive association was found between BMI in 
overweight individuals (BMI ≥ 25) and the difference in midsleep time between free 
days and workdays (Roenneberg et al., 2012). While the number of participants in 
the present study is smaller than the previous samples, our work not only relied on 
questionnaires but also quantified sleep-wake patterns objectively over several 
weeks. It adds to the accumulating evidence that circadian rhythm irregularities and 
sleep-wake cycle disruptions contribute to individual differences in body-weight 
regulation, even in a population with normal weight and in the absence of shortened 
sleep duration.  
 
     Increasing evidence supports a role for dopamine in regulating food intake and 
modulating food reward via a meso-limbic circuitry (Schwartz et al., 2000; Wang et 
al., 2001). COMT metabolizes catechol-estrogens in peripheral tissue to 2-
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methoxyestradiol, which influences fat regulation (Picó et al., 1998; Tworoger et al., 
2004). Based on this background, a growing area of research has begun to explore 
potential associations between dopaminergic genes and obesity (Wang et al., 2001; 
Need et al., 2006). Indeed, an association between the Val158Met polymorphism of 
COMT and individual differences in food intake or BMI has been previously 
suggested (Tworoger et al., 2004; Galvão et al., 2012). Nevertheless, while the 
available studies revealed an inconsistent picture, comparison to our work is difficult 
because different research questions were addressed and in different populations 
with respect to age, gender, and health for example.  
 
Distinct impact of DAT1 and COMT polymorphisms on rest-activity cycles 
     Our analyses disclosed no epistatic interactions between DAT1 and COMT 
polymorphisms on rest-activity cycles in humans. The lack of such interactions may 
reflect the different regional distributions of DAT and COMT proteins in the brain. 
DAT is solely found in striatum (Ciliax et al., 1995), whereas COMT is mostly 
expressed in prefrontal cortex and to a lower extent in striatum (Meyer-Lindenberg et 
al., 2005; Tunbridge et al., 2006). Although the basal ganglia, including striatum, may 
be actively involved in regulating sleep-wake behavior (Lazarus et al., 2013), the 
main role of the dopaminergic neurons in the striatum is the regulation of motor 
activity. Indeed, Dat -/- mice display clear hyperactivity (Giros et al., 1996), and a DAT 
loss of function mutation in humans causes Infantile Parkinsonism-Dystonia with 
slow movements, rigidity and rest tremor (Kurian et al., 2009). Although our data 
were obtained in a rather small number of healthy individuals and await independent 
replication, they may be in line with the clinical manifestation of this fatal mutation.  
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Abstract  
     The roles for dopamine in regulating wakefulness and sleep are incompletely 
understood. Genetically modified mice lacking functional dopamine transporters 
(DAT) show prolonged wakefulness, shortened sleep, hypersensitivity to caffeine, 
and reduced-responsiveness to modafinil. Here we combined epidemiologic, 
pharmaco-genetic, and neurophysiologic methods to analyze the effects of the 3’-
UTR variable-number-tandem-repeat polymorphism (SNP-ID: rs28363170) of the 
gene encoding DAT (DAT1, SLC6A3) on sleep-wake regulation in humans. 
Homozygous 10-repeat (10R/10R) allele carriers of this genetic variant presumably 
have reduced DAT protein expression than 9-repeat (9R) allele carriers. Consistent 
with the findings in mice, higher subjective caffeine sensitivity was associated with 
the 10R allele (n = 360) when compared to the 9R allele (n = 125). Moreover, 
caffeine and modafinil affected wakefulness-induced changes in functional bands 
(delta, sigma, beta) of rhythmic brain activity in wakefulness and sleep in DAT1 
genotype-dependent manner. Finally, the sleep deprivation-induced increase in 
established neurophysiological markers of sleep homeostasis, including slow wave 
sleep, EEG slow-wave activity (0.5-4.5 Hz), and number of individual low-frequency 
(0.5-2.0 Hz) oscillations in non-rapid-eye-movement sleep, was significantly larger in 
the 10R/10R genotype (n = 30) than in the 9R carrier genotype (n = 27). In 
conclusion, the data suggest that dopamine transporters contribute to sleep-wake 
regulation in humans. 
 
 
 
 
 
 
 
 
 
 
 
Keywords: 
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Introduction 
     The dopamine transporter (DAT) is responsible for presynaptic re-uptake of 
dopamine from the synapse (Giros and Caron, 1993). Accumulating evidence 
suggests that dopamine and DAT contribute to the physiological regulation of 
wakefulness and sleep. Drosophila and mouse mutants lacking functional DAT 
exhibit prolonged wakefulness and shortened rest bouts or sleep (Giros et al., 1996; 
Wisor et al., 2001; Kume et al., 2005; Wu et al., 2008). Moreover, dopamine D1 and 
D2 receptor stimulation increases wakefulness in mice (Isaac and Berridge, 2003). In 
humans, the current evidence is less clear. While the dopamine precursor, L-dopa, 
and dopamine D2/D3 receptor agonists such as pramipexole may induce sleepiness 
and reduce wakefulness in healthy volunteers (Andreu et al., 1999; Micallef et al., 
2009), loss of dopaminergic neurons in patients suffering from Parkinson’s disease 
can cause different  sleep-related symptoms, ranging from insomnia to increased 
daytime sleepiness (Park and Stacy, 2011).  
 
     The DAT protein is highly expressed in the striatum (Scatton et al., 1985; Lewis et 
al., 2001), where it constitutes the rate limiting mechanism of synaptic removal of 
dopamine (Jones et al., 1998; Benoit-Marand et al., 2000). Although behavioral and 
pharmacological findings in Dat knock-out mice need to be interpreted with caution, 
these animals appear to be hypersensitive to the stimulant effects of caffeine (Wisor 
et al., 2001). Although caffeine has no documented affinity for DAT, moderate doses 
of the stimulant may increase dopaminergic neurotransmission in the brain 
(Kaasinen et al., 2004). Thus, apart from blocking adenosine receptors (Fredholm et 
al., 1999), dopaminergic mechanisms may contribute importantly to wake-promotion 
by caffeine (Boutrel and Koob, 2004; Fisone et al., 2004; Andretic et al., 2008).  
 
     The concept of sleep homeostasis predicts that increased sleep need associated 
with prolonged wakefulness results in compensatory changes in sleep duration and 
intensity in recovery sleep (Borbély, 1982). The proportion of deep non-rapid-eye-
movement (NREM) sleep, referred to as slow wave sleep (SWS), as well as EEG 
slow-wave activity (power within ~ 0.5-4.5 Hz) and number, amplitude and slope of 
individual slow (0.5-2.0 Hz) waves in NREM sleep after sleep deprivation are robust 
physiological markers of sleep homeostasis (Massimini et al., 2007; Bersagliere and 
Achermann, 2010; Achermann and Borbély, 2011). The neurochemical and 
molecular bases underlying this important regulatory mechanism of wakefulness and 
sleep are still poorly understood. In humans, pharmaco-genetic studies suggest that 
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caffeine interferes with sleep homeostasis by blocking adenosine A2A receptors 
(Landolt et al., 2004; Rétey et al., 2006; 2007; Landolt, 2008; Bodenmann et al., 
2012). These receptors are highly expressed in striatum and functionally interact with 
dopamine D1 and D2 receptors (Lovinger, 2010).  
 
     Wake-promoting agents such as cocaine, amphetamine, and also modafinil, 
increase dopaminergic neurotransmission by inducing the release of dopamine and 
inhibiting DAT (Kilty et al., 1991; Kahlig et al., 2004; Volkow et al., 2009a). 
Newertheless modafinil does not affect neurophysiological markers of sleep need in 
humans (Bodenmann et al., 2009b; Bodenmann and Landolt, 2010) nor does 
modafinil impact Dat knock-out mice (Wisor et al., 2001). From these studies, 
however, it cannot be concluded that dopamine plays no role in sleep homeostasis. 
Indeed, a recent study of our laboratory suggested that functional polymorphisms of 
the genes encoding COMT and DAT distinctly affect actigraphy-derived activity-rest 
patterns and sleep estimates in humans (Valomon et al., unpublished observations) 
(see Chapter 2).  
 
     Here we analyzed epidemiologic, pharmaco-genetic, and neurophysiologic data to 
examine the effects of the 3’-UTR variable-number-tandem-repeat polymorphism 
(SNP-ID: rs28363170) of the gene encoding DAT (DAT1, SLC6A3) on sleep-wake 
regulation in humans. This 40-bp sequence may occur in forms from 3 to 11 repeats, 
yet the presence of 9 or 10 repeats is most common (Vandenbergh et al., 1992). 
Accumulating evidence in young healthy adults indicates that 10-repeat (10R) allele 
homozygotes have 15-20 % reduced DAT availability in the striatum when compared 
to hetero- and homozygous 9-repeat (9R) allele carriers (Jacobsen et al., 2000; van 
Dyck et al., 2005; van de Giessen et al., 2009; Costa et al., 2011; Spencer et al., 
2013). Based on the observations in Dat knock-out mice, we hypothesized that 
caffeine, modafinil, and sleep deprivation affect neurophysiologic markers of sleep 
homeostasis to a different extent in 10R/10R and 9R allele carriers of DAT1. 
Specifically, we expected that caffeine and sleep loss modify SWS, SWA, and 
individual EEG slow waves in recovery sleep stronger in 10R/10R homozygotes than 
in 9R allele carriers. 
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Materials and Methods 
Study participants and genotyping 
     The study protocol was approved by the ethics committee of the Canton of Zürich 
for research on human subjects. Written informed consent was obtained from all 
participants prior to the experiments, as required according to the principles in the 
Declaration of Helsinki. All subjects received financial compensation for their 
participation.  
 
     A total of 504 healthy volunteers (374 males, 104 females) between 18 and 35 
years of age were investigated. They were interested in participating in sleep studies 
and provided 3 ml fresh EDTA-blood (n = 472) (Wizard® Genomic DNA Purification 
Kit, Promega, Madison, WI) or saliva (n = 32) (NucleoSpin®Blood Kit, Marchery-
Nagel AG, Oensingen, Switzerland) for isolation of genomic DNA. Their genotype of 
the rs28363170 polymorphism of DAT1 was determined by allele-specific PCR on an 
MJ Research PTC-225 thermal cycler (MJ Research/Bio-Rad, Reno, NV) at an 
annealing temperature of 67°C. Forward primer, 5’-tgtggtgtagggaacggcctga-3’ and 
reverse primer 5’-cttcctggaggtcacggctcaa-3’ with HOT FIREPol® DNA Polymerase 
was used. The 430-480 bp PCR products were analysed by agarose gel 
electrophoresis. All analyses were replicated at least once for independent 
confirmation of results. In total, 258 individuals (69 females) were 10R/10R allele 
carriers, 204 (56 females) were heterozygous 9R/10R allele carriers, and 23 (4 
females) were homozygous 9R/9R allele carriers. Nineteen carriers of rare DAT1 
alleles were excluded from the analyses. The answer to the question “Do you 
consider yourself as caffeine sensitive?” (yes / no) was compared among the DAT1 
genotypes.  
 
     To examine a possible impact of the DAT1 polymorphism on sleep-wake 
regulation, sleep and sleep EEG recordings before and after sleep deprivation were 
analysed in a subset of 57 genotyped, right-handed subjects (46 men and 11 
women) who previously completed sleep studies in our laboratory. Given the low 
number of 9R/9R homozygotes (n=3), homozygous (10R/10R) and heterozygous 
(9R/10R) 9R allele carriers (n = 27) were grouped together and compared to 
10R/10R homozygotes (n = 30). These two genetic groups were previously found to 
differ in DAT expression (Jacobsen et al., 2000; van Dyck et al., 2005; van de 
Giessen et al., 2009). They were very similar in age, body-mass-index, habitual sleep 
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duration, daily caffeine and alcohol consumption, as well as in the distribution of 
distinct COMT and adenosine A2A receptor (ADORA2A) genotypes (Table 1).  
 
Table 1: Demographics 
Variable 10R/10R 9R allele carriers p-value 
COMT genotype (rs4680; G/A)   
 G/G (Val/Val) 13 11 
 G/A (Val/Met) 8 7 
 A/A (Met/Met) 9 9 
ADORA2A genotype (rs575876; T/C)   
 T/T 8 4 
 C/T 16 11 
 C/C 6 12 
Sex ratio (% females) 25.0 22.7 
Age (years) 24.6 ± 0.6 24.7 ± 0.6 0.89 
Body-mass-index (kg/m2) 22.8 ± 0.4 22.0 ± 0.3 0.09 
Habitual sleep duration (hours) 7.3 ± 0.2 7.4 ± 0.2 0.79 
Caffeine consumption (mg/day) 139.0 ± 26.0 103.6 ± 22.5 0.31 
Alcohol consumption (drinks/week) 3.2 ± 0.6 2.8 ± 0.4 0.60 
Trait Anxiety (STAI) 39.3 ± 1.5 36.9 ± 1.5 0.26 
Daytime Sleepiness (ESS) 7.2 ± 0.5 7.0 ± 0.5 0.81 
NCBI symbols indicate genes encoding dopamine transporter (DAT1), catechol-O-
methyltransferase (COMT), and adenosine A2A receptor (ADORA2A). The distributions of 
COMT (p = 1.0) and ADORA2A (p = 0.15) genotypes, and the sex ratio in 10R/10R and 9R 
allele carriers of DAT1 did not differ between the two groups (Fisher’s Exact Tests). Values 
represent means ± SEM. P-values refer to 2-tailed Student’s t-tests. All subjective estimates 
were based on validated self-report questionnaires. STAI: State-trait anxiety inventory 
(Spielberger et al., 1970) ESS: Epworth Sleepiness Scale (Johns, 1991).  
 
     All volunteers reported to be good sleepers, adhering to regular bedtimes, to be in 
good physical health, and to have a medical history free of neurological and 
psychiatric disorders. Two months prior to enrollment, subjects stated not to have 
consumed any medication or illicit drugs, not to have passed through time zones and 
to consume moderate amounts of caffeine and alcohol. To check for potential 
undiagnosed sleep disorders or low sleep efficiency (< 85%), they underwent a 
screening night in the sleep laboratory prior to study inclusion. Two weeks prior to 
study initiation, participants were instructed to wear a wrist activity monitor on their 
non-dominant arm, to fill out a sleep-wake diary, and to completely refrain from 
intake of caffeine. The final 3 days before the start of the experiment, they were 
required to strictly maintain regular bedtimes (8-hours sleep) and to abstain from 
alcohol.  
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Sleep deprivation protocol  
     The sleep deprivation study involved either one (n = 19 [12 females, 7 male]) or 
two (n = 38, all males) experimental blocks. Three participants completing only one 
block were moderate smokers (< 10 cigarettes per day). Each experimental block 
consisted of three nocturnal sleep recordings, all starting either at 23:00 or 00:00, 
divided into 8-hour adaptation and baseline nights, 40 hours of constantly supervised 
prolonged wakefulness, and concluded by a 10-hour recovery night.  
 
     Subjects completing two experimental blocks were administered after 11 (at 
19:00) and 23 hours (at 07:00) of prolonged wakefulness two times 200 mg of 
caffeine and placebo (n = 16), or two times 100 mg modafinil and placebo (n = 22), in 
randomized, double blind, cross-over fashion.  
 
All-night polysomnography 
     Sleep was polysomnographically quantified during all experimental nights. The 
EEG, electrooculogram (EOG), submental electromyogram (EMG), and 
electrocardiogram (ECG) were recorded using polygraphic amplifiers (PSA24, 
Braintronics Inc., Almere, The Netherlands (Bachmann et al., 2012a); or Artisan, 
Micromed, Mogliano Veneto, Italy (Rétey et al., 2006)) as follows: For 16 subjects 
recorded via PSA24 amplifiers, analog EEG data were band-pass filtered (-3 dB at 
0.16 Hz; -3 dB at 102Hz) and sampled at 512 Hz, then digitally low pass filtered (-3 
dB at 49 Hz) and stored with a resolution of 128 Hz. For 41 subjects recorded via 
Artisan amplifiers, analog EEG data were band-pass filtered (-3 dB at 0.15 Hz; -3 dB 
at 67.2 Hz), sampled and stored with a resolution of 256 Hz. EEG data of derivation 
C3A2 were analyzed.  
 
     Sleep stages were visually scored in 20-s epochs according to standard criteria 
(Rechtschaffen and Kales, 1968). Four-s EEG spectra (fast Fourier transform 
routine, Hanning window, 0.25-Hz resolution) were calculated using MATLAB 
(MathWorks Inc., Natick, MA), averaged over 5 consecutive 4-s epochs, and 
matched with scored sleep stages. Arousal- and movement-related artifacts were 
semi-automatically identified and excluded. All-night power spectra between 0-20 Hz 
represent the average of all artifact-free 20-s values in NREM sleep (stages 1-4) and 
REM sleep. In the recovery nights, data analysis was restricted to the first 8 hours of 
the 10-h sleep recordings. All-night and episodic EEG power values in NREM sleep 
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were standardized in each individual to the corresponding all-night power of the 
baseline night.  
 
     To analyse the effects of caffeine, modafinil, DAT1 genotype, and sleep 
deprivation on individual EEG slow waves, an algorithm previously described by 
(Bersagliere and Achermann, 2010) was applied. Data sampled with 256 Hz were 
down sampled to 128 Hz using the MATLAB function decimate (MathWorks Inc., 
Natick, MA). To ensure reliable wave detection, the EEG (0.5-2.0 Hz) was band-pass 
filtered (third-order Chebyshev type II high-pass filter; –3 dB at 0.4 Hz; sixth-order 
Chebyshev type II low-pass filter, –3 dB at 2.3 Hz). Filters were applied both in 
forward and reverse directions, to prevent phase distortion. Individual positive and 
negative half-waves with an amplitude of ≥ 37.5 µV (75 V peak-to-peak) 
(Rechtschaffen and Kales, 1968) were defined as positive or negative deflections 
between consecutive zero-line crossings. Waves were analysed in steps of 0.1 Hz. 
The amplitude was defined as the local maximum or minimum between two 
consecutive zero line crossings, whereas the slope was defined as the amplitude of 
the peak or the trough, divided by the time from the previous zero-line crossing (initial 
mean slope). The number of waves included all detected waves that fulfilled the ≥ 
37.5 µV-amplitude criterion.  
 
Waking EEG recordings  
     At 3-hour intervals during the 40 hours prolonged wakefulness, standardized 
waking EEG recordings were performed. At least 1 hour before each recording, 
subjects had to stay in the laboratory (constant temperature: 19-21 oC; light intensity: 
< 150 lux). Fifteen minutes before each recording, they calmly stayed on their own in 
their bedrooms. The study participants were instructed to comfortably relax in a chair, 
and to place their chin on an individually adjusted chinrest. An initial 3-min recording 
period with eyes closed was followed by a 5-min period with eyes open, while 
subjects fixated a black dot attached to the wall. Artifacts in all derivations were 
visually identified and excluded. Power spectra (C3A2 derivation) of artifact-free, 2-s 
epochs (50 % overlap, Hanning window, frequency resolution 0.5 Hz) were 
computed and analyzed between 0-25 Hz. To minimize inter-individual differences in 
absolute power and to compensate for circadian effects, spectra were standardized 
in each individual to the mean of the first four sessions during extended waking.  
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Statistical analyses  
     All statistical analyses were performed with SAS 9.1.3 software (SAS Institute, 
Cary, NC). In 10R/10R and 9R allele carriers of DAT1, self-rated caffeine sensitivity, 
the effects of caffeine and modafinil on waking EEG, sleep architecture, EEG 
spectra, and individual EEG slow half-waves, as well as the sleep deprivation-
induced rebound in these variables were analyzed. Two- and 3-way mixed-model 
analyses of variance (ANOVA) for repeated measure (PROC MIXED) with the 
between-subjects factor ‘genotype’ (10R/10R vs. 9R allele carriers) and the within-
subjects factors ‘treatment’ (caffeine / modafinil vs. placebo), ‘NREM sleep episode’ 
(1-4), ‘condition’ (baseline vs. sleep deprivation / recovery), and ‘frequency bin’ (0.5-, 
0.25-, or 0.1-Hz resolution) were performed. The significance level was set at α < 
0.05. Only significant effects and interactions are mentioned, unless otherwise 
specified. Post-hoc analyses were only performed when the respective main effect 
and/or interaction of the ANOVA were significant.  
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Results 
Highest self-rated caffeine sensitivity in 10R/10R allele carriers of DAT1 
     To test the hypothesis that genetically determined differences in DAT availability 
could affect sensitivity to caffeine, self-rated caffeine sensitivity was compared 
10R/10R, 9R/10R, and 9R/9R allele carriers of DAT1. The proportion of sensitive 
individuals differed among the genotypes (p < 0.008, Fisher’s exact test). It equaled 
38.8 % in 10R/10R allele carriers, 33.3 % in 9R/10R allele carriers, and 8.7 % in 
9R/9R allele carriers (Figure 1). The difference was most pronounced when 
homozygous 10R and 9R carriers were compared.  
 
Figure 1. DAT1 genotype affects self-rated caffeine sensitivity. 
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Five-hundred and four healthy adults rated themselves as either being caffeine sensitive or 
caffeine insensitive. Numerators and denominators at the bottom of the bar represent the 
numbers of caffeine sensitive individuals and the total numbers of subjects in each genotype.  
 
DAT1 genotype modulates effects of caffeine on low-frequency brain 
oscillations in wakefulness and sleep 
     To investigate a possible role for DAT in sleep-wake regulation, the combined 
effects of sleep deprivation and caffeine and modafinil were examined in a data set 
of 57 healthy adult 10R/10R and 9R allele carriers (Table 1). Sleep architecture in 
baseline, and the behavioral effects of prolonged wakefulness (i.e., increased 
sleepiness and impaired performance on the psychomotor vigilance task; data not 
shown) were highly similar in the two genotypes.  
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Figure 2. DAT1 genotype dependent modulation of caffeine and modafinil. 
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The DAT1 genotype modulates the effects of caffeine (10R/10R: n = 7 [green symbols]; 9R 
allele carriers: n = 9 [olive symbols]) and modafinil (10R/10R: n = 11 [blue symbols]; 9R allele 
carriers: n = 11 [dark cyan symbols]) intake during sleep deprivation on EEG activity in 
wakefulness (eyes open) and NREM sleep. (A & B) Effects of caffeine. (C & D) Effects of 
modafinil. Left panels: Relative power values in the waking EEG recording sessions at 08:00, 
11:00, 14:00, and 17:00 on day 2 of prolonged wakefulness after caffeine (2 x 200 mg) and 
modafinil (2 x 100 mg) were expressed as a percentage of the corresponding values after 
placebo (horizontal dashed lines at 100 %). Caffeine reduced power in many bins below 14.5 
Hz, and increased power in high-beta (21-24 Hz) frequencies (in 10R/10R carriers only). 
Modafinil reduced theta (5.5-7 Hz) activity and increased alpha (11-12 Hz) activity. Right 
panels: Standardized all-night power values in NREM sleep (stages 1-4) after caffeine (2 x 
200 mg) and modafinil (2 x 100 mg) intake were expressed as a percentage of the 
corresponding values after placebo (horizontal dashed lines at 100 %). Caffeine reduced 1.5-
2 Hz activity. Modfinil increased power in many bins in the alpha/beta range (11.25-20 Hz), 
primarily in 9R carriers of DAT1. Means ± SEM of consecutive 0.5-Hz (wakefulness) or 0.25-
Hz (NREM sleep) frequency bins are plotted. Grey diamonds (caffeine: F1,14 ≥ 4.25; modafinil: 
F1,20 ≥ 4.49; pall < 0.05) indicate a significant ‘genotype’ x ‘treatment’ interaction of a 2-way 
mixed-model ANOVA with the between subjects factor ‘genotype’ and the within-subjects 
factor ‘treatment’ (caffeine or modafinil). Up- and downward black triangles (caffeine: F1,14 ≥ 
4.61; modafinil: F1,20  ≥ 5.13; pall < 0.05) indicate a significant main effect of ‘treatment’. Note 
the different scales of y- and x-axes in wakefulness and NREM sleep.  
 
     Caffeine intake during sleep deprivation affected EEG low-frequency activity in 
wakefulness and sleep. The stimulant reduced waking EEG activity in delta (< 2 Hz), 
theta (4 - 7 Hz), alpha (8 - 9.5 Hz) and low-beta (13 - 14.5 Hz) frequencies (Figure 
2A). Moreover, consistent with increased subjective sensitivity to its stimulant 
actions, the xanthine enhanced beta (21 - 24 Hz) activity in 10R/10R carriers 
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(caffeine: 151.6 ± 9.5 %, placebo: 109.3 ± 9.7 %, t = -2.40, p < 0.05; paired, 2-tailed 
t-test), yet not in 9R carriers (caffeine: 103.9 ± 11.4 %, placebo: 127.2 ± 4.5 %, t = 
1.51, p > 0.18). During recovery sleep, caffeine consistently reduced EEG low-delta 
(1.5 - 2.0 Hz) activity in NREM sleep (Figure 2B). Close inspection of the data 
indicated that this effect of caffeine may differ between 10R/10R and 9R allele 
carriers of DAT1. To further examine this notion, individual sleep slow waves were 
analyzed.  
 
DAT1 genotype modulates the effects of caffeine on individual slow waves in 
NREM sleep 
     Sleep deprivation markedly increased number, amplitude, and slope of individual, 
positive and negative slow half-waves in recovery sleep when compared to baseline 
sleep (three-way mixed model ANOVA, ‘condition’: F1,55 > 93.7, pall < 0.0001). Intake 
of caffeine during prolonged wakefulness reduced all these features of negative half-
waves, as well as number and amplitude of positive half-waves in 10R/10R carriers 
of DAT1 (Figure 3). By contrast, the stimulant did not affect the characteristics of 
positive and negative slow half-waves in 9R allele carriers.  
 
Modafinil does not affect low-frequency brain oscillations in wakefulness and 
sleep 
     Intake of modafinil during prolonged wakefulness reduced waking EEG activity in 
the 5.5 - 7 Hz range and elevated activity in the 11 - 12 Hz band when compared to 
placebo (Figure 2C). In the recovery night, modafinil did not affect low-frequency 
EEG activity in NREM sleep (Figure 2D), or the number, amplitude and slope of EEG 
slow half-waves (data not shown). Nevertheless, the stimulant increased power in 
alpha (11.25 - 12.5 Hz) and beta (13.5 - 20 Hz) frequencies in NREM sleep, primarily 
in 9R carriers of DAT1 (Figure 2D).  
 
DAT1 genotype modulates the rebound in slow wave sleep and EEG slow-wave 
activity after sleep deprivation 
     Because the effects of caffeine in NREM sleep reflected DAT1 genotype-
dependent changes in EEG slow oscillations, the repercussions of prolonged 
wakefulness on these neurophysiologic markers of sleep homeostasis were 
examined in 10R/10R and 9R allele carriers of DAT1. In both genotypes, sleep 
deprivation increased sleep efficiency and the duration of NREM sleep, and 
shortened sleep latency, sleep stages 1 and 2, REM sleep, and wakefulness after 
sleep onset in the recovery night when compared to the baseline night (data not 
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shown). Nevertheless, the rebound in deep SWS was roughly 15 min longer in 
10R/10R than in 9R allele carriers (Figure 4, inset). This difference was accompanied 
by a slightly more pronounced reduction in the 10R/10R genotype in stage 2 sleep 
(DAT 9R: -9.8 min, DAT 10R/10R: -21.6 min, two-way mixed model ANOVA, 
‘genotype x condition’: F1,55 = 3.0, p = 0.09).  
 
Figure 3. DAT1 genotype modulates individual slow half-waves in a caffeine dependent 
manner. 
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DAT1 genotype modulates the effects of caffeine intake during sleep deprivation on positive 
(left) and negative (right) EEG slow half-waves in NREM sleep. Number (A & B), amplitude 
(C & D), and slope (E & F) in 10R/10R (green lines, n = 9) and 9R allele carriers (olive lines, 
n = 7) genotypes of DAT1 are illustrated. Absolute data were normalized to the corresponding 
recovery night after intake of placebo (horizontal dashed line at 100 %) and used for 
analyses. P-values refer to the factor ‘genotype’ of a 2-way, mixed-model ANOVA with the 
between-subject factor ‘genotype’ and the within-subject factor ‘frequency bin’. Error bars 
denote ± SEM. 
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Figure 4. SWS and EEG-SWA is affected by the DAT1 genotype. 
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DAT1 genotype modulates the rebound in slow wave sleep (SWS) and EEG slow-wave 
activity (SWA, 0.5-4.5 Hz) in the recovery night after sleep deprivation. Inset: Data reflect the 
mean absolute all-night increase in SWS after sleep deprivation when compared to baseline, 
in 10R/10R (black bar, n = 30) and 9R allele carriers (grey bar, n = 27) genotypes of DAT1. 
Two-way mixed-model ANOVA: ‘condition’: F1,55 = 644.1, p < 0.0001; ‘genotype’: ns; 
‘condition’ × ‘genotype’: F1,55 = 10.8, p < 0.002. Asterisk: p < 0.002 (2-tailed t-test). Main 
figure: Mean relative SWA, expressed as a percentage of the all-night value in baseline 
(horizontal dashed line at 100 %). Values in 10R/10R (black dots, n = 30) and 9R allele 
carriers (grey dots, n = 27) across the first 4 NREM sleep episodes were plotted at the mean 
episode midpoints relative to sleep onset. Two-way mixed-model ANOVA on relative values: 
‘genotype’: F1,55 = 4.8, p = 0.03; ‘NREM sleep episode’: F3,165 = 372.7, p < 0.0001; ‘genotype’ 
× ‘NREM episode’: ns). Error bars indicate ± SEM.  
 
     In baseline and recovery nights, EEG SWA (0.5-4.5 Hz range) decayed 
exponentially across consecutive NREM sleep episodes, reflecting the dissipation of 
homeostatically regulated NREM sleep pressure. The time constants of the decay 
(τd) quantified by the method proposed by (Borbély, 1982; Rusterholz et al., 2010) 
were similar in both nights and genotypes (data not shown). Interestingly, however, 
the rebound in SWA in the recovery night compared to the baseline night was larger 
in 10R/10R than in 9R allele carriers of DAT1 (Figure 4).  
 
     The analyses of individual EEG slow waves revealed that this difference reflected 
a more pronounced increase in 10R/10R than in 9R allele genotypes in the number 
of positive and negative half-waves after sleep deprivation (Figure 5). By contrast, 
the changes in amplitudes and slopes of individual slow-waves in NREM sleep did 
not differ between the genotypes. 
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Figure 5. The DAT1 genotype modulate effects of sleep deprivation on individual slow 
half-waves. 
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DAT1 genotype modulates the effects of sleep deprivation on positive (left) and negative 
(right) EEG slow half-waves in NREM sleep. Number (A & B), amplitude (C & D), and slope 
(E & F) in 10R/10R (black lines, n = 30) and 9R allele carriers (grey lines, n = 27) genotypes 
of DAT1 are illustrated. Normalized data relative to the corresponding all-night baseline 
values (= 100 %) were analyzed. P-values refer to the factor ‘genotype’ of a 2-way, mixed-
model ANOVA with the between-subject factor ‘genotype’ and the within-subject factor 
‘frequency bin’. Error bars indicate ± SEM. 
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Discussion 
     The dopamine transporter (DAT) is responsible for re-uptake of dopamine into 
presynaptic neurons (Giros and Caron, 1993) and regulates synaptic dopamine 
availability primarily in the striatum (Jones et al., 1998; Benoit-Marand et al., 2000; 
Jaber et al., 2004). The 3’-VNTR polymorphism of the DAT1 gene examined here 
has been linked to reduced DAT protein expression in homozygous 10R/10R allele 
carriers when compared to 9R allele carriers (Heinz et al., 2000; Jacobsen et al., 
2000; Fuke et al., 2001; van Dyck et al., 2005; VanNess et al., 2005; van de Giessen 
et al., 2009). We investigated the impact of this polymorphism as an “experiment of 
nature”, to examine the effects of genetically altered striatal dopaminergic 
neurotransmission on wake-sleep regulation in healthy humans. Based on preclinical 
studies in DAT mutant animals (Giros et al., 1996; Wisor et al., 2001; Kume et al., 
2005; Wu et al., 2008), as well as molecular brain imaging data in humans (Volkow 
et al., 2012), we hypothesized that genetically-determined differences in striatal 
dopaminergic neurotransmission have an impact on sleep-wake regulation. Our data 
revealed not only pharmaco-genetic evidence for this hypothesis, but also 
demonstrated that healthy carriers of the 10R/10R genotype show increased 
rebound in SWS, SWA, and number of slow EEG waves after sleep deprivation when 
compared to 9R allele carriers. These findings suggest an increased homeostatic 
response to sleep deprivation in 10R/10R carriers compared to 9R carriers of DAT1. 
 
     The mode of action of the stimulants caffeine and modafinil has been suggested 
to rely directly or indirectly on the dopaminergic system, and to depend on DAT 
expression (Wisor et al., 2001; Boutrel and Koob, 2004; Fisone et al., 2004; Andretic 
et al., 2008). In view of caffeine, our study revealed that DAT1 genotype modulates 
subjective caffeine sensitivity, such that 10R/10R homozygotes reported higher 
sensitivity than 9R allele carriers. A more pronounced response to caffeine in the 
10R/10R genotype was confirmed objectively in the elevation of 21 - 24 Hz activity in 
wakefulness (Figure 2A). These data are consistent with findings in genetically 
modified mice (Wisor et al., 2001). They suggest enhanced caffeine sensitivity with 
reduced expression of DAT, such as in 10R/10R allele carriers of DAT1 and in Dat 
knock-out mice. This observation indicates that adenosine-dopaminergic interactions 
are important in determining the stimulant actions of the adenosine receptor 
antagonist, caffeine. 
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     Our study showed for the first time in humans that this conclusion may also apply 
to the effects of caffeine on neurophysiologic markers of sleep homeostasis. Intake 
of the stimulant during prolonged wakefulness reduced EEG low-frequency activity in 
the delta (wakefulness: 0 - 2 Hz; NREM sleep: 1.5 - 2 Hz) and theta (wakefulness: 4 - 
9.5 Hz) ranges in vigilance state-specific manner (Figure 2A & 2B). By contrast, 
administration of modafinil, which reduces DAT-mediated re-uptake of dopamine in 
animals (Mignot et al., 1994) and humans (Volkow et al., 2009a), decreased theta 
power in a narrow band (5.5 - 7 Hz) in waking, yet had no effect on delta activity in 
NREM sleep (Figure 2C & 2D). It was previously concluded that pharmacological 
blockade of adenosine receptors (by caffeine) and enhancement of dopaminergic 
neurotransmission (by modafinil) during sleep deprivation differentially affect distinct 
markers of sleep homeostasis (Bodenmann et al., 2009b; Bodenmann and Landolt, 
2010). The present refined EEG analyses revealed that caffeine reduced number, 
amplitude, and slope of individual slow waves in a DAT1 genotype-dependent 
manner. This finding suggests that the interference of caffeine with neurophysiologic 
markers of sleep homeostasis not only relies on adenosinergic mechanisms but also 
involves dopaminergic processes. 
 
     The rebound after prolonged wakefulness in SWS, SWA, and the number of 
individual slow half-waves in NREM sleep was significantly larger in 10R/10R allele 
homozygotes than in 9R allele carriers. A recent study based on a lower number of 
participants (n = 27 men) and lacking quantitative EEG analyses and sleep 
deprivation, reported no effect of the DAT1 VNTR on sleep architecture (Guindalini et 
al., 2010). By contrast, our findings derived from fine-grained EEG analyses 
demonstrate that DAT contributes to sleep-wake regulation. Individual low-frequency 
EEG oscillations in the 0.5 - 2 Hz range in NREM sleep are homeostatically 
regulated (Bersagliere and Achermann, 2010) and thought to reflect at the cellular 
level the degree of synchrony in the occurrence of up- and down-states in the 
membrane potential of cortical neurons (Mukovski et al., 2007; Murphy et al., 2009; 
Vyazovskiy et al., 2009; Bersagliere and Achermann, 2010). Sleep loss increased in 
genotype-dependent manner the number of slow waves, but not their amplitude and 
slope (Figure 5). Together with the data presented in Figure 4, this observation 
suggests the conclusion that DAT1 modulates the duration of the sleep deprivation-
induced rebound in SWS, rather than the absolute level of SWA that reflects the 
synchrony of up- and down-states in cortical networks. 
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     When relating our data to clinical and preclinical findings, a complex role for 
striatal dopamine in sleep-wake regulation emerges. More specifically, many patients 
with Parkinson’s disease suffer from severely disturbed sleep and disabling daytime 
sleepiness (Park and Stacy, 2011). These patients have pathologically impaired 
dopaminergic neurotransmission in the striatum. We recently observed that elevated 
daytime sleepiness and increased motor activity are more prevalent in healthy 9R 
allele carriers of DAT1 when compared to 10R/10R homozygotes (Valomon et al., 
unpublished observations) (see Chapter 2). Together with the stronger response to 
caffeine and the larger rebound in neurophysiologic markers of sleep homeostasis 
after sleep deprivation presented in this study, the findings are consistent with 
reduced DAT expression and increased dopaminergic signaling in 10R/10R allele 
carriers. Furthermore, pronounced hyperactivity, caffeine hypersensitivity, and 
reduced sleep duration are typically observed in Dat knock-out animals (Giros et al., 
1996; Wisor et al., 2001; Kume et al., 2005; Wu et al., 2008). Nevertheless, because 
constitutive knock-out of Dat produces drastically increased dopaminergic tone and 
may cause pronounced behavioral changes, the relevance of this genetic 
intervention for the interpretation of the subtle effects of genetic variation of DAT1 in 
healthy volunteers needs to be judged with caution.  
 
     In conclusion, our study provides novel physiological evidence for a functional 
effect of the common VNTR polymorphism of DAT1. Moreover, because the DAT 
protein is primarily expressed in the striatum, it suggests a specific role for striatal 
dopaminergic neurotransmission in sleep-wake regulation.  
 
Notes 
     Supplemental material for this article is available in Appendix 1. The supporting 
supplemental material (one table and two figures) includes more detailed information 
on DAT1 genotype dependent sleep architecture, analysis of the individual positive 
and negative slow half-waves for absolute data and for the estimates of SWA decay 
time constants (τd). This material has not been peer reviewed 
. 
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Abstract 
Background: Sleep deprivation (wake therapy) provides rapid clinical relief in many 
patients with major depressive disorder (MDD). Changes in glutamatergic 
neurotransmission may contribute to the antidepressant response, yet the exact 
underlying mechanisms are unknown. Metabotropic glutamate receptors of subtype 5 
(mGluR5) are importantly involved in modulating glutamatergic neurotransmission 
and neuronal plasticity. The density of these receptors is reduced in the brain of 
patients with MDD, particularly in brain structures involved in regulating wakefulness 
and sleep. We hypothesized that prolonged wakefulness would increase mGluR5 
availability in human brain.  
 
Methods: mGluR5 binding was quantified with positron emission tomography (PET) 
in 22 young healthy men who completed 2 experimental blocks separated by one 
week. Two PET examinations were conducted in randomized, cross-over fashion 
with the highly selective radioligand, 11C-ABP688, once after 9 hours (sleep control) 
and once after 33 hours (sleep deprivation) of controlled wakefulness. 11C-ABP688 
uptake was quantified in 13 volumes of interest with high mGluR5 expression and 
presumed involvement in sleep-wake regulation.  
 
Results: Sleep deprivation induced a global increase in mGluR5 binding when 
compared to sleep control (p < 0.006). In anterior cingulate cortex, insula, medial 
temporal lobe, parahippocampal gyrus, striatum, and amygdala, this increase 
correlated significantly with the sleep deprivation-induced increase in subjective 
sleepiness.  
 
Conclusions: This molecular imaging study demonstrates that cerebral mGluR5 
availability is increased after a single night without sleep. Given that modulators of 
mGluR5 have antidepressant properties, further research is warranted to examine 
whether this mechanism is involved in the potent antidepressant effect of ‘wake 
therapy’.  
 
Keywords:  
Antidepressant; 11C-ABP688; major depression, molecular brain imaging, sleepiness, 
wake therapy. 
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Introduction 
     Sleep and mood regulation are tightly associated. Disrupted sleep is an important 
diagnostic criterion and risk factor for major depressive disorder (MDD) (Baglioni et 
al., 2010). Insomnia symptoms often precede the onset of depression by several 
months, are resistant to treatment, and increase the risk of relapse in remitted 
patients. Intriguingly, whereas sleep-wake disturbances are highly prevalent in MDD, 
sleep deprivation (wake therapy) provides rapid clinical relief in many patients 
(Bunney and Bunney, 2012). Changes in glutamatergic neurotransmission have 
been proposed to contribute to the antidepressant response (Bunney and Bunney, 
2012), but the exact underlying mechanisms are unknown.  
 
     Metabotropic glutamate receptors, including metabotropic glutamate receptors of 
subtype 5 (mGluR5), play an important role in regulating glutamatergic 
neurotransmission (Sanacora et al., 2008). The density of mGluR5 is reduced in 
various cortical and subcortical brain regions in patients with MDD when compared 
with healthy control subjects (Deschwanden et al., 2011). These receptors are 
present on postsynaptic neurons and glia cells and contribute to long-term 
depression (LTD), as well as long-term potentiation (Ayala et al., 2009; Izumi and 
Zorumski, 2012). Moreover, they are involved in sleep-wake related postsynaptic 
plasticity in rats (Tadavarty et al., 2011) and interact directly or indirectly with 
different molecular markers of sleep-wake regulation in animals and humans. These 
markers include Homer 1a (Franken et al., 2001; Maret et al., 2007), fragile X mental 
retardation protein (FMRP) (Bushey et al., 2009; 2011; Hays et al., 2011), brain-
derived neurotrophic factor (BDNF) (Faraguna et al., 2008; Bachmann et al., 2012b), 
adenosine deaminase (Okada et al., 2003; Bachmann et al., 2012a), and the 
adenosine A2A receptor (Gallopin et al., 2005; Bodenmann et al., 2012).  
 
     Prolonged wakefulness not only affects mood and other day- time functions, 
including sleepiness, but also elevates sleep need in a recovery night when 
compared with a baseline night. The most reliable markers of sleep need are the 
amount of slow wave sleep and electroencephalographic (EEG) slow-wave activity 
(SWA) in non-rapid-eye-movement (NREM) sleep (Achermann and Borbély, 2011). 
Functional brain imaging studies consistently suggest that ventromedial prefrontal 
cortex, basal forebrain, insula, anterior cingulate cortex, striatum, parahippocampal 
gyrus, precuneus, and other regions are importantly involved in the regulation of slow 
waves and NREM sleep (Maquet et al., 1997; Dang-Vu et al., 2008; Murphy et al., 
Introduction 
70 
2009). Interestingly, mGluR5 are preferentially expressed in most of these brain 
regions (Gasparini et al., 2008). In addition, they are important for shaping the EEG 
slow oscillation in NREM sleep (Blethyn et al., 2006) and synchronized theta mode 
network activity in wakefulness (Cobb et al., 2000). Based on this convergent 
evidence for a possible involvement of mGluR5 in sleep-wake regulation, we aimed 
to quantify mGluR5 availability in rested and sleep-deprived state in humans.  
 
     We used the recently developed, selective mGluR5 radioligand, 11C-ABP688, to 
directly visualize mGluR5 availability in the living human brain (Ametamey et al., 
2006; 2007). We quantified in healthy adults 11C-ABP688 uptake in sleep control and 
sleep deprivation conditions in 13 brain regions with high mGluR5 expression and 
presumed involvement in sleep-wake regulation. Given the recent observation that 
mGluR5 density is reduced in depressed patients (Deschwanden et al., 2011) and 
the suggested role of mGluR5 in sleep-wake related postsynaptic plasticity 
(Tadavarty et al., 2011), we predicted that prolonged wakefulness may increase 
mGluR5 availability in the brain.  
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Methods and Materials 
Study participants 
     The study protocol and all experimental procedures were approved by the 
cantonal and federal authorities for research on human subjects and carried out in 
accordance with the Declaration of Helsinki (1964).  
 
Table 1. Demographic characteristics of study participants 
 Twenty-two male participants completed the study; one participant had to be excluded from 
positron emission tomography analyses because of strong head movement. German versions 
and validated German translations of 
questionnaires were used to assess 
lifestyle and personality traits. 
Caffeine consumption was estimated 
based on the following average 
caffeine contents per serving: coffee: 
100 mg; ceylon or green tea: 30 mg; 
cola drink: 40 mg (2 dL); energy 
drink: 80 mg (2 dL); chocolate: 50 
mg (100 g). Diurnal preference: 
Horne-Östberg Morningness-
Eveningness Questionnaire (Horne 
and Ostberg, 1976); daytime 
sleepiness: Epworth Sleepiness 
Scale (Bloch et al., 1999); trait 
anxiety: State-Trait Anxiety Inventory 
(Spielberger et al., 1970); 
depression score: Beck Depression 
Inventory (Beck et al., 1961); 
personality traits: Eysenck 
Personality Questionnaire (Francis 
et al., 2006) and Cloninger’s 
Tridimensional Personality 
Questionnaire (Weyers et al., 1995).  
 
     Twenty-two healthy young men completed the 2-week study after giving written 
informed consent and being extensively screened for medical history and 
psychological state. Individuals with a significant medical history (e.g., loss of 
consciousness) or past psychiatric illness were excluded. A prestudy screening night 
was performed in the sleep laboratory to exclude subjects with unknown sleep 
disturbances and low sleep efficiency (< 85%). All participants were nonsmokers, 
right-handed, and abstinent from any medication; denied previous and current illicit 
drug use; and had not crossed time zones or done shift work during the last 3 
months before the experiment. Validated questionnaires to assess lifestyle and 
demographic characteristics demonstrated the presence of a healthy study sample 
(Table 1).  
 
 Mean ± SD 
Age (years) 23.4 ± 2.1
Body-mass index (kg/m2) 22.1 ± 1.9
Alcohol consumption (drinks/week) 3.5 ± 3.3
Caffeine consumption (mg/day) 153.5 ± 160.9
Diurnal preference 49.7 ± 8.4
Daytime sleepiness 7.1 ± 3.3
Trait anxiety 34.5 ± 7.0
Depression score 3.2 ± 3.8
 
Eysenck Personality Traits 
 Extraversion 
 Neuroticism 
 Lie scale 
 Psychoticism 
8.6 ± 2.8
3.7 ± 2.8
2.5 ± 1.9
3.1 ± 1.4
 
Cloninger Personality Traits 
 Novelty seeking 
 Harm avoidance 
 Reward dependence 
14.7 ± 5.6
11.8 ± 4.7
16.0 ± 5.2
  
Methods and Materials 
72 
Prestudy procedures and experimental protocol 
     Three days before each study block, participants abstained from caffeine and 
alcohol and adhered to a 16-hour wake/8-hour sleep schedule. Caffeine, alcohol, and 
sleep logs; breath-alcohol measurements upon arrival in the laboratory; and wrist-
actigraphy were used to verify adherence to these instructions.  
 
     All subjects completed two experimental blocks, referred to as sleep control and 
sleep deprivation conditions. The two conditions occurred in randomized, cross-over 
fashion, typically 1 week apart, and included polysomnographically recorded 
adaptation, baseline, and experimental nights (time in bed: 11:30 PM–07:30 AM). In 
the sleep deprivation condition, the baseline night was followed by 40 hours 
continuous wakefulness, during which the participants were under constant 
supervision of the research team. All subjects underwent two positron emission 
tomography (PET) examinations with 11C-ABP688 to quantify mGluR5 availability in 
the brain (Division of Nuclear Medicine, University Hospital Zürich). These 
assessments occurred in random order, either ~9 or ~33 hours after awakening from 
the baseline night. The time of day of the PET examinations in sleep control (4:36 PM 
± 9 minutes) and sleep deprivation (4:34 PM ± 8 minutes) conditions did not differ (p > 
.4).  
 
Magnetic resonance and PET image acquisition 
     A T1-weighted, whole-brain, three-dimensional magnetic resonance (MR) image 
(resolution: 1 x 1 x 1 mm) was obtained for each subject (Philips Achieva 3T whole-
body MR unit equipped with transmit/receive head coil; Philips Healthcare, Best, The 
Netherlands), to exclude morphological abnormalities and as anatomical standard for 
the quantification of the PET images.  
 
     Tracer synthesis and PET brain imaging with 11C-ABP688 using a bolus/infusion 
protocol were performed as previously described (Ametamey et al., 2006; 2007; 
Burger et al., 2010; Deschwanden et al., 2011). Catheters were placed into the 
antecubital veins of each participant’s arms, one for tracer injection and one for blood 
sampling. Venous blood was collected at 42 and 58 minutes after the start of the 
bolus infusion.  
 
     All PET examinations were performed in three-dimensional mode on a DVCT 
PET/computed tomography scanner (GE Medical Systems, Glattbrugg, Switzerland) 
or a DSTx PET/computed tomography scanner (B. Braun Medical, Sempach, 
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Switzerland). A low-dose computed tomography scan was performed before the PET 
examination for photon attenuation correction. The emission scans were initiated 
simultaneously with the start of the injection of radioligand using an infusion pump 
(Perfusor FM, Braun Medical). Injected activity (sleep control: 582.9 ± 23.7 MBq; 
sleep deprivation: 543.5 ± 19.5 MBq) and mass of cold compound (sleep control: 6.2 
± .7 nmol; sleep deprivation: 6.9 ± .7 nmol) did not differ between the conditions (pall 
> .39; two-tailed, paired t tests). Of the total activity, 47.6% (sleep control: 294.8 ± 9.9 
MBq; sleep deprivation: 288.9 ± 9.8 MBq) was injected as a bolus over 2 minutes 
(Kbol = 53 min) and the rest was continuously infused over 58 minutes (sleep control: 
283.7 ± 9.6 MBq; sleep deprivation: 278.0 ± 9.5 MBq). Specific activity of 11C-
ABP688 at the end of syntheses was also very similar in sleep control (132.6 ± 15.4 
GBq/mol; range: 71–289 GBq/mol) and sleep deprivation conditions (109.0 ± 13.1 
GBq/mol; range: 61–243 GBq/mol). Twenty frames were collected during the 60-
minute protocol (10 x 60 sec and 10 x 300 sec). The images were reconstructed 
using filtered back projection and displayed over 47 transaxial slices. Using a 128 x 
128 matrix, the resulting voxel size was 2.3 x 2.3 x 3.2 mm.  
 
     Subjects were instructed to not fall asleep during image acquisition and the EEG 
was simultaneously recorded, according to established procedures (Bodenmann et 
al., 2009a; Bachmann et al., 2012a), to verify wakefulness during the PET 
examinations. As soon as sleep-like EEG activity was noted, subjects were alerted 
via an intercom. Direct contact with them was avoided, to minimize movement 
artifacts. 
 
Image processing and quantification 
     Image processing consisted of within-subject motion correction by realigning the 
average of frames 17 to 19 to the average of frames 2 to 10 (rigid matching) and 
spatial normalization of averaged frames 17 to 19 to the Montreal Neurological 
Institute template brain for definition of volumes of interest (VOI). The averaged 
frames 17 to 19 of the PET images were then co-registered to the corresponding MR 
image to delineate the cerebellum (Burger et al., 2010). These steps were performed 
with the PMOD software package, version 3.1 (PMOD Technologies, Zürich, 
Switzerland). Standard VOIs for the Montreal Neurological Institute template brain 
available in PMOD were used to measure radioactivity concentration in the 
normalized PET images (Tzourio-Mazoyer et al., 2002). Because PMOD provides no 
single VOI for cerebellum, this region was defined manually in each subject on the 
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MR image and subsequently transferred to the corresponding PET images to 
measure radioactivity concentration in this region. Tissue time activity curves (TAC) 
were generated for cerebellum, anterior cingulate cortex, superior frontal cortex, 
putamen, and thalamus in both hemispheres to confirm that steady state of receptor 
binding was reached in frames 17 to 19 (45–55 min) of image acquisition. The TAC 
for cerebellum and anterior cingulate cortex in two representative individuals in sleep 
control and sleep deprivation conditions are illustrated in the supplements (see 
Appendix 2).  
 
     The average radioactivity concentration between 45 and 55 minutes was 
calculated in each VOI (Ct[VOI]). Because some venous blood metabolite analyses 
were unreliable due to technical difficulties, regional Vt values could not be obtained 
in all subjects. Instead, quantification of the PET images was done by dividing the 
regional radioactivity concentration values with the corresponding value in the 
cerebellum (Ct[Cb]) to obtain Vnorm (Vnorm = Ct[VOI] / Ct[Cb]). This method was successfully 
used in previous studies to quantify mGluR5 availability in the brain (Burger et al., 
2010; Deschwanden et al., 2011). Furthermore, a preclinical study showed that 11C-
ABP688 binding in the cerebellum is negligible and that this region can thus be used 
as a reference region (Elmenhorst et al., 2010). To address the question whether 
sleep deprivation changed 11C-ABP688 binding in the cerebellum, we calculated the 
nondisplaceable volume of distribution (VND) in sleep control and sleep deprivation 
conditions in those nine study participants in whom reliable plasma radioactivity 
concentration and metabolite concentrations were available. These analyses 
confirmed that 11C-ABP688 binding in the cerebellum was not changed after sleep 
deprivation when compared with the control condition (control: VND = 1.98 ± .14; 
sleep deprivation: VND = 2.18 ± .16; p = .19, two-tailed paired t test).  
 
Behavioral and cognitive effects of sleep deprivation 
     To document that sleep deprivation was successful, validated questionnaires 
were employed before each PET scan to assess subjective sleepiness (Karolinska 
Sleepiness Scale) (Åkerstedt and Gillberg, 1990), state anxiety (State Trait Anxiety 
Inventory) (Spielberger et al., 1970), and affective state (Profile of Mood States) 
(McNair et al., 1971). Approximately 3 hours before each scan, the subjects also 
completed a cognitive test session consisting of the psychomotor vigilance task 
(PVT) (Dinges and Powell, 1985) and the Deese-Roediger-McDermott false memory 
paradigm (Deese, 1959; Roediger and McDermott, 1995). To approach a normal 
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distribution, mean reaction time (RT) on the PVT was expressed as speed (1/RT) 
and the number of lapses (RT > 500 ms) was transformed by (√x + √[x + 1]).  
 
Cortisol concentration in saliva 
     Immediately before each PET examination, all study participants provided a saliva 
sample to determine the cortisol concentration as a measure of acute stress. 
Unstimulated saliva was collected by placing a salivette (Sarstedt, Sevelen, 
Switzerland) under the tongue and keeping the head slightly inclined for 1 to 2 
minutes. The samples were stored at -20 oC until the biochemical analysis took 
place. The saliva was centrifuged at 3000 rpm for 5 minutes before free cortisol was 
analyzed using an immunoassay with time-resolved fluorescence detection 
(Dressendörfer et al., 1992).  
 
Statistical analyses 
     All statistical analyses were performed with SAS 9.1 software (SAS Institute, 
Cary, North Carolina). Mixed-effect analysis of variance models included the factors 
condition (sleep control, sleep deprivation), region (13 VOIs), and hemisphere (left, 
right), as well as their interactions. Two-tailed, paired t tests were conducted to 
localize significant differences. To limit the number of comparisons and to control for 
type I errors, analyses of PET data were restricted to the predefined VOIs and the 
significance level was set at α < .0038 (Bonferroni correction: α = .05/13). To 
estimate the possible associations between the effects of sleep deprivation on 
mGluR5 availability and changes in behavioral and cognitive variables, regression 
analyses were performed and Spearman rank correlation coefficients were 
calculated. If not stated otherwise, only significant results are reported.  
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Regional uptake of 11C-ABP688 in human brain 
     Axial, sagittal, and coronal views of 11C-ABP688 binding in the brain of one single 
individual in sleep control and sleep deprivation conditions are presented in Figure 1. 
Consistent with previous studies (Ametamey et al., 2007; DeLorenzo et al., 2011), 
regional uptake of 11C-ABP688 reflected the known distribution of mGluR5 with most 
pronounced binding in anterior cingulate, insula, medial temporal lobe, medial 
prefrontal cortex, striatum, and amygdala. Lower radioligand binding was present in 
thalamus and substantially lower radioligand binding was present in cerebellum, 
which was used to calculate the normalized volumes of distribution (Vnorm). Visual 
inspection of TAC in distinct brain regions confirmed that a steady state of 11C-
ABP688 uptake was reached 45 minutes after tracer injection in all participants and 
scans.  
 
Figure 1. Axial, sagittal and coronal views of 11C-ABP688 binding in a representative 
individual. 
 
(A) Magnetic resonance image (MRI) template for anatomical reference. (B) Color-coded 
normalized volumes of distribution (Vnorm) of 11C-ABP688 after ~ 9 hours of wakefulness 
(sleep control condition). (C) Color-coded Vnorm of 11C-ABP688 after ~ 33 hours of 
wakefulness (sleep deprivation condition). The crosshair was placed in the right caudate 
nucleus (coordinates according to the Montreal Neurological Institute brain atlas: -14, 14, 2).  
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Figure 2. Regional differences in 
mGluR5 density and effect of sleep 
deprivation. (A) Normalized volumes 
of distribution (Vnorm) of 11C-ABP688 
uptake in 13 regions of interest after 
~ 9 hours of wakefulness (sleep 
control). (B) Vnorm after ~ 33 hours of 
wakefulness (sleep deprivation). (C) 
Percent difference in Vnorm between 
sleep deprivation and sleep control 
conditions. The two measurements 
occurred in random order and were 
separated by one week. Data 
represent means + 1 SEM (n = 21). 
Asterisks indicate significant 
differences between sleep 
deprivation and sleep control 
conditions (‘condition’: p < .0038). 
Med. Sup. Front. Cortex = medial 
superior frontal cortex; 
PFC = prefrontal cortex. 
 
 
 
 
 
 
 
 
 
 
Sleep deprivation increases functional mGluR5 availability in human brain 
     Regional Vnorm values of 11C-ABP688 in sleep control and sleep deprivation 
conditions are shown in Figure 2. Prolonged wakefulness increased global Vnorm by 
3.5 ± 1.1% when compared with control (1.50 ± .02 vs. 1.55 ± .02, p < .006). Mixed-
model analysis of variance with the factors condition, region (VOIs), and hemisphere 
revealed highly significant main effects of condition [F(1,20) = 184.5, p < .0001] and 
region [F(25,500) = 257.6, p < .0001], yet no significant effect of hemisphere [F(1,20) 
= .1, p > .7]. Thus, the data of left and right hemispheres were averaged. The 
increase in mGluR5 binding was significant in anterior cingulate cortex (3.9 ± 1.3%, p 
< .0006), insula (4.5 ± 1.3%, p < .0001), medial temporal lobe (4.2 ± 1.0%, p < 
.0005), parahippocampal gyrus (4.6 ± 1.1%, p < .0002), striatum (4.8 ± 1.4%, p < 
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.0003), and amygdala (4.3 ± 1.2%, p < .002). No VOI showed a reduction in 11C-
ABP688 binding after sleep deprivation when compared with control.  
 
Increase in 11C-ABP688 binding correlates with increase in subjective 
sleepiness 
     Sleep deprivation impaired subjective state and cognitive performance. 
Sleepiness, state anxiety, fatigue, lapses on the PVT, and false alarms on the 
Deese-Roediger-McDermott false memory paradigm were increased after prolonged 
wakefulness when compared with control (Table 2). By contrast, vigor was reduced 
and PVT reaction times were prolonged.  
 
Table 2. Behavioral and cognitive effects of sleep deprivation. 
 Sleep control Sleep deprivation p < 
Karolinska Sleepiness Scale 3.13 ± 0.28 5.04 ± 0.43 0.001 
State Anxiety Inventory 36.45 ± 2.07 40.73 ± 2.47 0.001 
Profile of Mood States (POMS) 
 Fatigue 
 Vigor 
 Depression/Anxiety 
 Irritability 
5.77 ± 1.49 
18.54 ± 1.35 
3.32 ± 1.42  
0.91 ± 0.53 
13.86 ± 2.22 
10.54 ± 1.38  
4.14 ± 2.08 
1.68 ± 0.72 
0.001 
0.001  
0.506 
0.284 
Psychomotor vigilance task 
 Mean reaction speed (s-1) 
 Lapses (transformed) 
3.79 ± 0.07 
2.29 ± 0.25 
3.50 ± 0.07 
4.71 ± 0.62 
0.001 
0.001 
Deese-Roediger-McDermott Paradigm 
 False alarms 
 False memory 
 Hit rate 
5.25 ± 0.99 
12.25 ± 0.55 
40.35 ± 1.51 
8.40 ± 0.86 
13.80 ± 0.68 
41.15 ± 1.80 
0.001 
0.067 
0.638 
Values represent means ± SEM (n = 22). p values refer to 2-tailed, paired t tests. Significant 
differences between sleep control and sleep deprivation conditions are highlighted in bold. 
 
     Correlation analyses between the sleep deprivation-induced change in subjective 
sleepiness and the percent change in mGluR5 availability revealed consistent 
associations in all brain regions showing a significant increase in 11C-ABP688 
binding. In other words, those subjects who were most affected by sleep deprivation 
exhibited the largest increase in mGluR5 binding in anterior cingulate cortex, insula, 
medial temporal lobe, parahippocampal gyrus, striatum, and amygdala (Figure 3). A 
similar association was also found for fatigue on the Profile of Mood States 
questionnaire and mGluR5 availability in medial temporal lobe (rp = .43, p = .053; rs = 
.45, p < .04; n = 21). The other behavioral and cognitive effects of sleep deprivation 
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revealed no consistent correlation with the changes in mGluR5 binding in the 
significant VOIs.  
 
Figure 3. Relationship between the individual subjects’ difference in subjective 
sleepiness and the difference in mGluR5 availability between sleep deprivation and 
sleep control conditions.  
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Individual percent changes in normalized volumes of distribution (Vnorm) of 11C-ABP688 in 
those brain regions that showed a significant increase after sleep deprivation are illustrated. A 
linear regression line was fitted through the 21 individual data points. KSS = Karolinska 
Sleepiness Scale; rp = Pearson’s product-moment correlation coefficient; rs = Spearman rank 
correlation coefficient.  
 
Cortisol concentration in saliva 
     Prolonged wakefulness tended to slightly increase salivary cortisol concentration 
when compared with the sleep control condition (9.4 ± .6 vs. 7.0 ± .6 mmol/L, p < 
.08). The individual changes in salivary cortisol were not associated with individual 
changes in mGluR5 binding. 
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Discussion 
     This in vivo molecular imaging study in humans reveals the first evidence for 
increased functional cerebral mGluR5 availability after prolonged wakefulness. After 
a single night without sleep, binding of 11C-ABP688 was significantly increased on a 
global level and in distinct brain regions that were previously shown to reflect 
physiological changes after sleep deprivation (for recent review, see (Dang-Vu et al., 
2010)). These effects of short-term sleep loss are intriguing. The expression of G-
protein coupled receptors on the cell surface is tightly regulated and provides a 
powerful mechanism of signal amplification (Nelson and Cox, 2008). A recent study 
demonstrated that regional 11C-ABP688 binding may reflect mGluR5 protein 
expression (Deschwanden et al., 2011). Because mGluR5 density is reduced in 
major depression (Deschwanden et al., 2011), our findings suggest that changes in 
functional mGluR5 availability may be involved in the rapid antidepressant effect of 
sleep deprivation in MDD patients.  
 
     The mGluR5 are mostly expressed on postsynaptic membranes of neurons and 
astrocytes in corticolimbic areas of the brain, including medial-prefrontal and 
orbitofrontal cortex, cingulate, striatum, amygdala, and hippocampus (Gasparini et 
al., 2008). They may be very well positioned to integrate and modulate the 
expression of established molecular markers of wakefulness and sleep. Indeed, 
mGluR5 interact either directly or indirectly with Homer1a, FMRP, BDNF, adenosine 
deaminase, and A2A receptors. Convergent evidence obtained from studies in 
invertebrates, rodent models, and humans strongly indicate that all these molecules 
play a causal role in sleep-wake regulation (Urade et al., 2003; Maret et al., 2007; 
Faraguna et al., 2008; Bushey et al., 2009; 2011; Bodenmann et al., 2012; 
Bachmann et al., 2012a; 2012b).  
 
     It was previously suggested that sleep is crucial for protecting and recovering the 
brain from increased intracellular calcium concentrations imposed by prolonged 
wakefulness (Maret et al., 2007). The immediate early gene Homer1a is a proposed 
core molecular marker of sleep homeostasis, i.e., the sleep-wake dependent facet of 
sleep regulation (Maret et al., 2007). Homer1a selectively uncouples mGluR5 from 
effector targets in the membrane of the postsynaptic density and attenuates the 
mGluR5-mediated rise in intracellular calcium levels (Kammermeier and Worley, 
2007). The interaction between Homer1a and mGluR5 is necessary for mGluR5-
dependent synaptic LTD (Ronesi and Huber, 2008) and may promote synaptic 
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changes during sleep (Maret et al., 2007). Interestingly, Homer1a was shown to alter 
mGluR5 signaling without inducing large-scale changes in mGluR5 distribution 
(Kammermeier and Worley, 2007).  
 
     Not only Homer1a, but also FMRP, interacts with mGluR5. A genetic defect in the 
X chromosome-linked human FMR1 (fragile X mental retardation 1) gene encoding 
FMRP gives rise to increased mGluR5 signaling and Fragile X syndrome (FXS), the 
most common form of inherited mental retardation and a leading cause of autism. 
Brain slices of FMR1 knockout mice, an established model of FXS, show enhanced 
mGluR5-mediated synaptic LTD (Huber et al., 2002). In vitro as well as in vivo, these 
mice show prolonged spontaneous UP-states, which predominantly occur in slow 
wave sleep. This altered neocortical rhythmic activity is due to enhanced mGluR5 
signaling (Hays et al., 2011). Sleep-wake regulation was studied in Drosophila 
mutants carrying dFmr1 loss-of-function (amorphs) and gain-of-function 
(hypermorphs) mutations (Bushey et al., 2009). The dFmr1 amorphs were long 
sleepers, whereas dFmr1 hypermorphs were short sleepers. A recent study further 
demonstrated that dFmr1 is important for sleep-dependent synaptic normalization 
(Bushey et al., 2011).  
 
     Also, interactions of mGluR5 with BDNF and adenosinergic neurotransmission 
may be important for sleep-wake regulation. Expression of BDNF in cerebral cortex 
is high during wakefulness, low during sleep, and increased after sleep deprivation 
(Cirelli and Tononi, 2000). Cortical injection of BDNF to awake animals promotes 
synaptic strength and enhances SWA in subsequent NREM sleep. This effect is 
reversible and opposite to the changes in local SWA after pharmacologic inhibition of 
BDNF-tyrosine-kinase-b-receptor stimulation (Faraguna et al., 2008). Pharmacologic 
activation of mGluR5 induces BDNF expression in rat cortical neurons and glia cells 
(Legutko et al., 2006; Viwatpinyo and Chongthammakun, 2009). It may, thus, be 
speculated that enhanced mGluR5-induced BDNF secretion after prolonged 
wakefulness contributes to the antidepressant response to sleep deprivation. Indeed, 
patients suffering from MDD typically exhibit reduced serum BDNF levels, which may 
normalize after antidepressant therapies (Nagahara and Tuszynski, 2011).  
 
     The facilitatory action of BDNF on hippocampal long-term potentiation requires 
adenosine A2A receptor activation by endogenous adenosine (Fontinha et al., 2008). 
A primary role for adenosine and adenosine receptors in sleep regulation is well 
established in animals and humans (Basheer et al., 2004; Landolt, 2008). In an 
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approach similar to the present study, it was recently shown that sleep deprivation 
increases A1 receptor binding in human brain (Elmenhorst et al., 2007). 
Nevertheless, accumulating evidence indicates that also A2A receptors contribute to 
sleep-wake regulation (Gallopin et al., 2005; Bodenmann et al., 2012). These 
receptors are co-localized with mGluR5, dopamine D2, and N-methyl-D-aspartate 
receptors and functionally interact in vitro and in vivo (Ferré et al., 2002; Tebano et 
al., 2005; D'Ascenzo et al., 2007; Rebola et al., 2008). Importantly, a recent PET 
study showed that one night without sleep reduced dopamine D2/3 receptor 
availability in the ventral striatum by roughly 5% (nondisplaceable binding potential of 
11C-raclopride: 2.80 ± .37 vs. 2.95 ± .37) (Volkow et al., 2012). After the same 
experimental procedure, we found an increase in mGluR5 availability in the striatum 
by 4.8 ± 1.4% (p < .0003). Given these results, it is intriguing to note that mGluR5 
and D2 receptor signaling in the striatum functionally counteract each other by means 
of intramembrane interactions (Ferré et al., 2007). The almost identical magnitude of 
sleep-deprivation induced changes in mGluR5 and D2/3 receptor availability and the 
significant correlation in both studies with increased sleepiness after the night without 
sleep strongly support the notion that the reported changes are real and have more 
than mere statistical significance.  
 
     Because plasma samples were not available for calculating regional Vt in all 
subjects, the cerebellum was used to calculate Vnorm. The density of mGluR5 in this 
region is unlikely to produce a specific binding signal with PET. Preclinical and 
clinical studies demonstrated that the cerebellum is suitable to quantify 11C-ABP688 
binding in the brain (Burger et al., 2010; Elmenhorst et al., 2010; Deschwanden et 
al., 2011). Another possible limitation of our study may be due to the fact that two 
different PET scanners were employed for examining the subjects. Because each 
volunteer was examined on the same scanner in sleep control and sleep deprivation 
conditions and a within-subject design was used, it is improbable that differences 
between PET scanners have biased the findings.  
 
     In conclusion, the current observations indicate that mGluR5 may be involved in 
the effects of sleep deprivation. To corroborate this notion and to address the 
question whether changes in glutamate concentration could underlie the current 
observations, multimodal imaging studies combining PET and magnetic resonance 
spectroscopy are warranted to simultaneously measure functional mGluR5 
availability and glutamine/ glutamate levels in the brain. The mGluR5 has been 
implicated in various central nervous system pathologies, and pharmacologic agents 
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targeting this receptor currently provide promising future treatments for psychiatric 
and neurological disorders, including schizophrenia, anxiety, FXS, substance abuse, 
and drug withdrawal (Gasparini et al., 2008; undefined author and Conn, 2010). 
Studies also suggest that mGluR5 agonists have antidepressant-like properties 
(Sanacora et al., 2008). Blockade of glutamatergic neurotransmission with the N-
methyl-D-aspartate receptor antagonist ketamine and sleep deprivation therapy both 
rapidly reverse depression in a large subgroup of patients (Bunney and Bunney, 
2012). Given the reduced mGluR5 density in depressed patients (Deschwanden et 
al., 2011) and the enhanced functional mGluR5 availability after prolonged 
wakefulness, it is tempting to hypothesize that mGluR5 are involved in the rapid 
mood-enhancing effects of sleep deprivation. Because the neurobiology of 
depressed patients is likely to differ from healthy volunteers, future research is 
needed to confirm this possible mechanism in patients with depression. Such an 
approach may lead to novel treatments of depression and other mental disorders, 
which, according to the World Health Organization, will become the biggest health 
burden on society within the next 20 years.  
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Abstract 
     Although sleep is hypothesized to play an important role for maintaining neuronal 
homeostasis, in vivo molecular mechanisms of sleep remain only poorly understood. 
In Drosophila models of Fragile X mental retardation (FXS), the expression of fragile 
X mental retardation protein (FMRP) is reduced, whereas sleep need is strongly 
enhanced. On the other hand selective inhibitors of metabotropic glutamate 
receptors of subtype 5 (mGluR5) rescue the FXS phenotype in mice. Therefore 
FMRP and mGluR5 can be considered opposing regulators of neuronal plasticity and 
used to investigate molecular mechanism of sleep in humans. Here we combine 
genetic analysis of the FMR1 gene with nocturnal EEG recordings and positron 
emission tomography scans of mGluR5 availability during a randomized cross over 
sleep deprivation study, to further elaborate on the relationship between FMRP, 
mGluR5 and EEG markers of sleep need. 26 healthy men underwent the two 
experimental blocks were mGluR5 was quantified using the highly selective 
radioligand 11C-ABP688, following 9 and 33 hours of wakefulness.  
 
     Our data reveal a strong association between global mGluR5 availability and EEG 
markers of sleep need. Especially EEG slow oscillations (<1 Hz) were found to be 
highly correlated with mGluR5 availability in both baseline and sleep deprived 
conditions. Genetic analysis revealed that healthy FMR1 odd CGG carriers have 
increased FMRP expression, associated with a damped response to sleep 
deprivation observed by a stagnant global mGluR5 availability, EEG slow oscillations 
and slow wave activity. Our data propose the mGluR5 to be a molecular marker for 
sleep need in humans and to play an important role for especially the generation of 
EEG slow oscillations. Furthermore, our data suggest that the FMR1 genotype 
modulate mGluR5 availability and affect EEG makers of sleep need in healthy adult 
men. 
 
 
 
 
Keywords:  
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Introduction 
     Synaptic plasticity underlying memory and learning, is modulated by the 
availability and activation of ionotropic glutamate receptors such as a-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs) and n-methyl-d-
aspartate receptors (NMDARs) (Malenka and Bear, 2004; Kauer and Malenka, 
2007). Metabotropic glutamate receptors of subtype 5 (mGluR5) activate 
phosporlipase C which catalyzes the second messenger’s inositol triphosphate (IP3) 
and diacyl glycerol (DAG) enhancing downstream signal amplification and protein 
synthesis (Nelson and Cox, 2008). mGluR5 thereby indirectly control NMDAR and 
AMPAR expression (Oliet et al., 1997; Collingridge et al., 2004). The mGluR5 are 
mainly post- and extra-synaptic receptors involved in long-term depression (LTD) 
and to some extent long-term potentiation (LTP) (Ayala et al., 2009; Izumi and 
Zorumski, 2012). Furthermore, the mGluR5 have been linked to the generation of 
slow-oscillation during NREM sleep (Blethyn et al., 2006), sleep specific brain-
oscillations which have been suggested to synchronize cortical synaptic processes 
(Buzsáki and Draguhn, 2004) and as such have been associated with memory 
enhancements (Marshall et al., 2006).  
 
     Stimulation of mGluR5 results in the synthesis of Fragile X mental retardation 
protein (FMRP), a RNA binding protein, suggested to regulate neuronal mRNA 
trafficking and translation at synapses (Bagni and Greenough, 2005; Ben A Oostra 
and Willemsen, 2009). Evidence suggests that FMRP and mGluR5 are functionally 
opponent; activation of mGluR5 initiates protein synthesis whereas FMRP suppress 
it (Dölen et al., 2007; Dölen and Bear, 2008). Indeed, the loss of FMRP strongly 
inhibits normal brain functions and leads to abnormal spine formation, as observed in 
Fragile X syndrome (FXS) (Irwin et al., 2001). FXS and derivative changes in FMRP 
have been extensively studied in animal models. Brain FMRP levels in drosophila 
has been shown to increase with time awake, and to be inversely linked to sleep 
duration (Bushey et al., 2009). Overexpression of FMRP in the fly model revealed 
reduced neuronal plasticity in response to sleep deprivation and an overall reduced 
sleep duration (Bushey et al., 2011). FMR1 knock-out mice also show signs of 
increased synaptic activity and spine formation (Nimchinsky et al., 2001), which can 
also be observed by an increased associations between mGluR5 and the immediate 
early gene Homer1a (Ronesi et al., 2012), a pronounced marker of sleep need 
(Franken et al., 2001; Maret et al., 2007). Treatment of FMR1 knock.-out mice with 
selective mGluR5 inhibitors rescues the FXS phenotype and reduces hyperactivity 
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(Michalon et al., 2012). Selective mGluR5 positive allosteric modulators on the other 
hand, increase locomotors activity and reduce delta sleep, a marker of sleep need in 
mice (Parmentier-Batteur et al., 2013). Moreover mGluR5 have been shown to 
interact with brain-derived neurotropic factor (BDNF) (Faraguna et al., 2008; 
Bachmann et al., 2012b), adenosine deaminase (Okada et al., 2003; Bachmann et 
al., 2012a) and adenosine A2A receptors (Gallopin et al., 2005; Bodenmann et al., 
2012) all of which are believed to be importantly involved in sleep wake regulation.  
 
     Taken together, evidence suggests a strong interaction between mGluR5, FMRP 
and sleep need, at least in the animal models. In humans, FXS is the most common 
form of inherited mental retardation, which is caused by a 5’ (CGG)n repeat 
expansion in the Fragile X mental retardation 1 (FMR1) gene. Repeat expansions 
above 200 CCG repeats result in DNA hyper methylation and complete gene 
silencing (Cummings and Zoghbi, 2000). As defined by The American College of 
Medical Genetics (Maddalena et al., 2001), premutation (CGG)n expansions of 54-
199 repeat, have been linked to milder inherited disorders such as fragile X tremor 
ataxia syndrome (FXTAS) and premature ovarian failure. Indeed, the premutation 
range is associated with increased mRNA levels (Allen et al., 2004), yet decreased 
FMRP expression  (Tassone et al., 2000; Peprah et al., 2009). Furthermore specific 
AGG interruptions in the (CGG)n sequence increase repeat stability and reduce the 
risk of maternal premutation carriers transmitting a full mutation to their offspring 
(Yrigollen et al., 2012). Nevertheless, the AGG interruptions do not appear to affect 
FMRP expression levels in premutation carriers (Yrigollen et al., 2011).  
 
     Among healthy individuals (5-45 CGG repeats), little is known about how FMR1 
expression is regulated or whether the number of CGG repeats play any significant 
role. Indeed, studies examining both premutation and healthy carriers have shown a 
linear increase in FMR1 transcription levels with increased CGG repeat number, 
however, within the healthy CGG repeat range alone, no association was found 
(Allen et al., 2004). One important factor for protein expression namely stemloop 
formation or more generally RNA folding patterns (Malys and McCarthy, 2011), have 
not systematically been investigated. Previously, FMR1 gene expression was linked 
to the formation and stability of RNA hairpins, which are known to form complex 3-
dimensional structures (Darlow and Leach, 1995; 1998a; Mirkin, 2007; Zumwalt et 
al., 2007). Nevertheless, Darlow and Leach could show in vitro, that odd number 
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CGG repeats are associated with the formation of more stable hairpins, when 
compared to even (Darlow and Leach, 1995; 1998b; 1998a).  
 
     Among healthy male subjects, we could recently show that prolonged 
wakefulness increase brain mGluR5 availability and how increased mGluR5 
availability positively correlates with increased sleepiness (Hefti et al., 2013) 
(Chapter 4). To investigate the association between mGluR5 and sleep-wake 
regulation further, we here examine how the increase in mGluR5 availability following 
sleep deprivation correlates with nocturnal and waking EEG markers of sleep need. 
Furthermore, we investigate potential roles for the FMR1 (CGG)n expansion in 
healthy men, and thereby how sleep wake regulation is modulated by FMRP 
expression and interacts with global mGluR5 availability.  
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Methods 
Study participants and pre-experimental procedure 
     In total Twenty-six healthy young men, three more than previously published, 
completed this 2-week study after giving their written informed consent and a blood 
sample for genetic analysis. As describe previously, all subjects fulfilled strict 
inclusion and exclusion criteria related to sleep quality, psychological wellbeing, 
medication and drug intake (Hefti et al., 2013). Furthermore, three days before 
experimental blocks, participants did not consume caffeine or alcohol and had to 
stringently adhere to 8 h sleep and 16 h wake periods, monitored by wrist-actigraphy 
and breath-alcohol measurements.  
 
Genotyping 
     Genotypes were determined using the MJ Research PTC-225 thermal PCR cycler 
(MJ Research/Bio-Rad, Reno, NV) at an annealing temperature of 67 °C with the 
FMR1 E1-forward primer 5’-ctccgtttcggtttcacttc-3’ and FMR1 E1-reverse primer 5’-
atcttctcttcagccctgct-3’, by HOT FIREPol DNA Polymerase. Sequencing was 
performed using the Sanger chain-termination method (Sanger et al., 1977) with an 
ABI PRISM 3100 (16 capillaries) genetic analyzer (Applied Biosystems Inc., Foster 
City, CA). Genomic DNA was extracted from 3 ml fresh EDTA-blood (Wizard 
Genomic DNA Purification Kit, Promega, Madison, WI). Based on the number of 
CGG repeats in the FMR1 gene, participants were grouped as either “odd” (n = 12) 
or “even” (n = 14) carriers.  
 
Experimental protocol and image processing 
     All experimental procedures were conducted in accordance with the declaration of 
Helsinki (1964) and approved by the cantonal and federal authorities for research on 
human subjects in Zurich, Switzerland.  
 
     The experimental protocol was explained in detail previously (Hefti et al., 2013). In 
short, subjects underwent two experimental conditions of sleep control (sc) and sleep 
deprivation (sd) in a randomized cross-over fashion. Eight hour sleep episodes were 
recorded with polysmonography. After ~9 (16:39 PM ± 8.23 min) and ~33 (16:30 PM 
± 7.40 min) hours of wakefulness, a 60 minute positron emission tomography (PET) 
scan were carried out at the Division of Nuclear Medicine, University Hospital Zürich, 
with the highly selective mGluR5 radioligand 11C-ABP688. Due to technical problems, 
three subjects had to be excluded from PET analyses. Tracer synthesis and three-
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dimensional PET brain imaging was carried out using the previously validated 
bolus/infusion protocol (Ametamey et al., 2006; 2007; Burger et al., 2010; 
Deschwanden et al., 2011), on two intra-individually assigned GE Healthcare PET 
scanners (DVCT PET/CT or DSTx PET/CT scanner) with 2.3 x 2.3 x 3.2 mm voxel 
resolution (Hefti et al., 2013). Image processing consisted of within-subject rigid 
matching motion correction as well as spatial normalization of averaged frames 17 to 
19 (45-55 min) to the Montreal Neurological Institute (MNI) template brain in PMOD 
software package, version 3.1 (PMOD Technologies, Zürich, Switzerland). 
Furthermore whole-brain T1-weighted 3D-MR images (Philips Achieva 3T whole-
body MR unit equipped with transmit/receive head coil; Philips Healthcare, Best, The 
Netherlands) were obtained to exclude subjects with morphological abnormalities 
and in order to co-register MR and PET images, allowing for accurate cerebellum 
delineation. Quantification of the PET images was done by dividing regional 
radioactivity concentration values with the corresponding value in the cerebellum 
(Ct[Cb]) to obtain Vnorm (Vnorm = Ct[VOI] / Ct[Cb]). Here we investigate not only changes in 
global mGluR5 availability but also regional specific changes for 13 regions with high 
mGluR5 expression and presumed involvement in sleep-wake regulation (Hefti et al., 
2013). 
 
     Comparison of injected radioactivity dose (sc: 582 ± 18.2, sd: 568 ± 18.5 MBq/ml), 
end of synthesis specific activity (sc: 127 ± 14.5, sd: 107 ± 11.4 GBq/mol), mass of 
cold compound (sc: 6.39 ± 0.65, sd: 6.92 ± 0.59 nmol) and cerebellar standard 
uptake values (sc: 826 ± 29.7, sd: 788 ± 24.9 g/ml) revealed no difference between 
the conditions (pall>0.1, paired t tests) nor between FMR1 odd even genotypes as 
measured by two-way repeated measure ANOVA’s (“condition”: Fall < 2.73, pall > 
0.11; “genotype”: Fall < 1.13, pall > 0.29; “genotype x condition”: Fall < 1.93, pall > 
0.17).  
 
EEG and polysomnographic recordings 
     Continuous polysomnographic EEG were recorded during PET scans and all 
experimental nights. EEG, electrooculogram (EOG), submental electromyogram 
(EMG), and electrocardiogram (ECG) were recorded with Rembrandt Datalab 
(Version 8; Embla Systems, Planegg, Germany) using an Artisan polygraphic 
amplifier (Micromed, Mogliano Veneto, Italy). During PET image acquisition, subjects 
were instructed not to fall asleep and in case of sleep-like EEG activity, were alerted 
via an intercom.  
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     The Analog EEG signals were sampled at 256 Hz and conditioned by high-pass (-
3 dB at 0.15-0.16 Hz) and low pass filtering (-3 dB at 67.2 Hz). The EEG was 
recorded from 1 referential (C3A2) and 8 bipolar derivations (only data from the 
C3A2 derivation is reported here). Sleep stages were visually scored according to 
standard criteria (Rechtschaffen and Kales 1968) in 20 s epochs. Four-second EEG 
spectra (fast Fourier transform [FFT] routine, Hanning window, 0.25 Hz resolution; 0-
20 Hz) were calculated with MATLAB (MathWorks Inc., Natick, MA) and averaged 
over 5 consecutive epochs matched with scored sleep stages. Arousal and 
movement artifacts were visually identified and eliminated. Nocturnal and PET scan 
power spectra recordings were analyzed in 0.25 Hz resolution for both NREM 
(stages 1 to 4) and REM sleep as the average of all artifact-free 20 s values. 
Classical EEG spectral power bands for SWA (0.5-4.5 Hz), Theta (4-8 Hz), Alpha (8-
12 Hz), Spindle (12-15 Hz) and Beta (15-20 Hz) activity, but also discrete 2 Hz bands 
between 0-20 Hz were calculated.  
 
Cognitive tests for assessing sleep loss  
     To evaluate the effects of sleep loss and how it may influence mGluR5 
availability, subjects completed cognitive tests and validated questionnaires to 
examine subjective sleepiness (Karolinska Sleepiness Scale) (Åkerstedt and 
Gillberg, 1990), symptoms of tiredness (tiredness symptoms scale) (Bes et al., 
1992), state and trait anxiety (State-Trait Anxiety Inventory) (Spielberger et al., 
1970), affective state (Profile of Mood States) (McNair et al., 1971), and psychomotor 
performance (psychomotor vigilance test) (Durmer and Dinges, 2005).  
 
     PVT performance and the remaining questionnaires were assessed in 3-hour 
intervals throughout prolonged wakefulness, although two PVT sessions had to be 
abandoned due to PET image acquisition. To approach a normal distribution, mean 
reaction time (RT) on the PVT was expressed as speed (1/RT) and the number of 
lapses (RT > 500 ms) was transformed by (√x+√[x+1]). 
 
Statistical analyses 
     All statistical analyses were performed with SAS® 9.1.3 software (SAS Institute, 
Cary, NC). To examine associations between mGluR5 availability and EEG markers 
of sleep need, Spearman rank correlation coefficients were calculated. To correct for 
multiple comparison when examining regional specific changes, we applied 
Bonferroni correction where the significance level was set to α < 0.0038 (Bonferroni 
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correction: α = 0.05/13). Furthermore we only considered effects significant when the 
alpha level for both baseline and sleep deprived conditions were achieved.  
 
     To assess effects of sleep deprivation related to the FMR1 odd vs even genotype, 
mixed-effect models for analysis of variance (ANOVA) were calculated, including the 
factors ‘genotype’ (odd, even), ‘condition’ (sleep control, sleep deprivation) and 
‘session’ (12-14 time points during prolonged wakefulness), as well as their 
interactions. Two-tailed, paired t-tests were conducted to localize significant 
differences. Significance level was set at p < 0.05.  
 
     To assess regional specific differences for the FMR1 odd vs even genotype, the 
number of effective comparisons was reduced to the six regions previously shown to 
have increased mGluR5 availability following sleep deprivation (Hefti et al., 2013), As 
a result the significance level of the two-way ANOVAs were set to α < 0.00833 
(Bonferroni correction: α = 0.05/6). 
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EEG markers of sleep need is associated with mGluR5 availability 
     The strongest homeostatic markers for sleep need is EEG SWA (0.5 - 4.5 Hz), 
which is increased, especially in the first NREM sleep episode following sleep 
deprivation (Achermann and Borbély, 2011). On the other hand, slow-oscillations are 
a strong hallmark of NREM sleep and have been associated with the mGLuR5 
(Blethyn et al., 2006) as well as learning and memory (Marshall et al., 2006). We 
previously showed how sleep deprivation leads to an increase in global mGluR5 
availability, which positively correlates to increased subjective sleepiness (Hefti et al., 
2013). Therefore, to further test the association between sleep need and global 
mGluR5 availability, we examined how EEG markers of sleep need in the first NREM 
sleep episode, is associated with global mGluR5 availability. EEG slow oscillations 
and SWA was calculated for baseline and recovery sleep and correlated with global 
mGluR5 availability after 9 or 33 hours of wakefulness respectively. A positive 
association was found for global mGluR5 availability with slow oscillations and SWA 
under baseline and sleep deprived conditions (Figure 1A – 1D). Also the spindle 
range (12 - 15 Hz) showed a trend-wise negative correlation with mGluR5 availability 
under baseline conditions (r = -0.39, p < 0.07) yet no other significant associations 
were found under neither condition. To examine the actual response to sleep 
deprivation, relative changes in global mGluR5 availability and EEG power was 
calculated. The increase in high SWA (2 - 4Hz) was significantly correlated with the 
increase in mGluR5 availability with sleep deprivation (Figure 1C), whereas no other 
frequency band revealed a significant association.  
 
     Finally we examined EEG markers of sleep and waking during the one hour PET 
scan. Although subjects were instructed to stay awake and were alerted via intercom 
if signs of sleep were detected, sleep deprivation reduced wakefulness (control: 62.2 
± 1.91 min; sleep deprived: 53.7 ± 2.97 min, t = -3.74, p < 0.002) and increased 
stage 1 (control: 2.07 ± 0.50 min; sleep deprived: 3.64 ± 0.77 min, t = 1.87, p < 0.08) 
and stage 2 (control: 2.90 ± 1.26 min; sleep deprived: 8.81 ± 1.94 min, t = 4.15, p < 
0.001) sleep. The increase in intermittent stage 1 sleep significantly correlated with 
the increase in global mGluR5 availability after sleep deprivation (r = 0.43, p < 0.04) 
(Figure 1D).  
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Figure 1. Association between mGluR5 availability, EEG oscillations and markers of 
sleep need 
 
To examine the association between mGluR5 and sleep need, objective markers of sleep 
loss was correlated with global mGluR5 availability in 26 healthy men. (A – D): First NREM 
sleep episode for slow oscillations (<1 Hz) and SWA (0.5 - 4.5 Hz) for baseline and recovery 
conditions was positively correlated with global mGluR5 availability after 9 and 33 hours of 
wakefulness respectively. (E): Relative change in first NREM sleep episode for high SWA (2-
4 Hz) revealed a positive correlation with the relative change in global mGluR5 availability 
caused by sleep deprivation. (F): Sleep deprivation induced changes in intermittent stage 1 
sleep during the ~60 min PET-scan was positively correlated with changes in mGluR5 
availability. Statistics calculated by Spearman's rank correlation coefficient.  
 
     To examine regional specific associations between mGluR5 availability and EEG 
markers of sleep need, we investigated 13 regions of interest. To correct for multiple 
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comparisons, regional correlations for baseline and the sleep deprived conditions 
were required to simultaneously survive Bonferroni correction with a significance 
level of α < 0.0038. Out of the 13 regions investigated, slow oscillations were found 
to be positively correlated with regional mGluR5 availability in the parietal cortex, 
precuneus, striatum, anterior cingulate cortex, medial temporal lobe, frontal superior 
medial, orbitofrontal cortex and the dorsolateral prefrontal cortex (supplementary 
Figure 1, Appendix 3). On the other hand, SWA was found to be significantly 
correlated with mGluR5 availability in the parietal cortex (supplementary Figure 2, 
Appendix 3). None of the other 12 regions investigated remained significant following 
Bonferroni correction. 
  
Odd vs. even numbers of CGG repeats modulate human FMRP expression 
     FMRP, which is transcribed by the FMR1 gene, has been shown to play an 
important role in regulating neuronal plasticity. Although FMRP expression is 
reduced among FXS full mutation carriers (>200 CGG repeats) and negatively 
correlated with the number of CGG repeats among premutation (55-199 CGG 
repeats) carriers, this correlation does not persist in among healthy subjects (5-45 
CGG repeats) (Peprah et al., 2009). Given how in vitro experiments have linked odd 
numbers of CGG repeats to more stable hairpins when compared to even (Darlow 
and Leach, 1998a), we hypothesized that FMR1 CGG odd vs even repeats would 
affect RNA hairpin stability and thereby FMRP translation, although it might not 
directly modulate FMR1 transcription levels. To examine this association we 
reanalyzed data from Allen et. al. 2004 and Peprah et al. 2009, who examined FMR1 
transcription and FMRP translation. Here we reanalyzed the expression levels 
measured in fresh human blood among healthy and FXS premutation carriers.  
 
     As previously described, CGG repeats in the healthy carrier range of 20-45, did 
not correlate with either FMR1 levels (rp = 0.02, p > 0.94; rs = -0.07, p > 0.78; n = 16) 
or FMRP expression (rp = 0.01, p>0.96; rs = 0.11, p > 0.65; n = 18). Nevertheless, 
when comparing odd with even numbers of CGG repeats in the same range, FMR1 
mRNA levels were 32.2% increased (yet not significant) among FMR1 odd, 
compared to even carriers (even: 1.04 ± 0.12, n = 8; odd: 1.38 ± 0.22, n = 8; two-
tailed t-test: p > 0.19). FMRP expression on the other hand was significantly higher 
and revealed a 90.2% increase among FMR1 odd carriers compared to even (Figure 
2A). Analysis of both premutation and healthy carriers revealed similar FMR1 levels 
(even: 1.72 ± 0.34, n = 16; odd: 1.63 ± 0.10, n = 14; two-tailed t-test: p > 0.81), but a 
significant increase in FMRP expression among odd compared to even carriers 
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(Figure 2B) corresponding to 28.4% increased FMRP expression for odd numbered 
CGG repeats. 
 
Figure 2. FMRP expression levels among healthy and premutation FXS patients 
 
Reanalysis of Peprah et. al. 2009 for comparison of odd vs. even number of FMR1 CGG 
repeats among healthy (A) and premutation carriers (B). (A): FMRP expression was 
increased by 90.2% among odd CGG carriers (n = 8) when compared to even (n = 10). (B): 
For the entire sample of healthy and premutation carriers, FMRP expression was increased 
by 28.4 % when comparing odd (n = 36) to even (n = 41) CGG repeat carriers. Statistics are 
calculated by two-tailed student’s t-tests and presented as means + SEM.  
 
Odd vs. even number of FMR1 CGG repeats modulate global mGluR5 
availability 
     To further examine the FMRP/mGluR5 association model that suggest an inverse 
relationship between mGLuR5 and FMRP (Dölen et al., 2007; Dölen and Bear, 
2008), we set out to examine the relationship between mGluR5 and FMRP under 
sleep control and sleep deprived conditions. All 26 subjects who underwent the study 
were genotyped for the number of CGG repeats in the FMR1 gene. The number of 
CGG repeats was between 17 - 44, all in the healthy range (Maddalena et al., 2001). 
Subjects were grouped either as odd or even carriers, depending on their number of 
FMR1 CGG repeats. The two groups were highly homogenous and did not differ with 
respect to age, body mass index, habitual sleep duration, habitual caffeine or alcohol 
consumption, anxiety, generalized sleepiness, sleep quality, Chronotype or verbal 
intelligence (table 1). Only habitual sleep duration revealed trend-wise sleep more 
among FMR1 even carriers when compared to odd (table 1).  
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Table 1 Demographics among FMR1 odd vs even CGG repeat carriers  
variable FMR1 odd FMR1 even p 
Group size (n) 12 14 - 
Age (years) 23.8 ± 0.58 23.5 ± 0.58 0.752 
Body mass index (kg/m2) 22.8 ± 0.53 21.8 ± 0.51 0.211 
Habitual sleep duration (hours) 7.19 ± 0.23 7.75 ± 0.17 0.055 
Daily caffeine consumption (mg/day) 167 ± 39.2 138 ± 45.1 0.645 
Alcohol consumption (drinks/week) 2.63 ± 0.46 4.21 ± 1.05 0.202 
Trait Anxiety Inventory 36.4 ± 1.56 33.9 ± 2.30 0.397 
Epworth sleepiness scale 6.50 ± 0.90 7.57 ± 0.92 0.418 
Pittsburg sleep quality index score 4.25 ± 0.45 3.36 ± 0.49 0.195 
MCTQ chronotype 4.30 ± 0.25 4.27 ± 0.21 0.856 
MWT-B verbal IQ score 108 ± 3.42 104 ± 2.60 0.296 
The demographic distribution of FMR1 odd and even CGG repeat carriers were compared by 
validated questionnaires in German (Beck et al., 1961; Weyers et al., 1995; Francis et al., 
2006; Viwatpinyo and Chongthammakun, 2009). With respect to age, BMI, habitual caffeine 
and alcohol consumption, trait anxiety, Epworth sleepiness scale, Pittsburg sleep quality 
score, chronotype and verbal IQ (Mehrfachwahl wortschatz intelligenz Test - B), the groups 
were undistinguishable. Only self-reported habitual sleep duration suggested an increased 
sleep need among FMR1 even carriers compared to odd. 
 
     Effects of sleep deprivation on 11C-ABP688 availability and EEG NREM sleep 
(exactly 30 min after sleep onset) for the odd and even FMR1 group are illustrated in 
two representative individuals (Figure 3). The axial slice show parts of the anterior 
cingulate, insula, medial temporal lobe, medial superior frontal cortex, dorsolateral 
prefrontal cortex, striatum, precuneus, hippocampus and thalamus. Indeed, both 
sleep deprivation and FMR1 odd vs. even genotype modulated global mGluR5 
availability (‘condition’: F1,21 = 10.79, p < 0.004; ‘genotype’: F1,21 = 1.93, p > 0.179; 
‘condition x genotype’ F1,21 = 7.74, p < 0.02). Post-hoc testing revealed higher levels 
of mGluR5 among FMR1 odd carriers compared to even; under sleep control 
conditions (Figure 4A) whereas the availability under sleep deprived conditions were 
similar between the groups (even: 1.55 ± 0.03, odd: 1.57 ± 0.03, two-tailed t-test: p > 
0.60). Despite FMR1 odd and even carriers both displayed a positive mean increase 
in global mGluR5 availability after sleep deprivation, the increase was only significant 
among FMR1 even carriers (FMR1 even: t = 4.14, p < 0.002; FMR1 odd: t = 0.37, p = 
0.718; two-tailed paired t-tests) who also displayed a markedly greater rebound 
(Figure 4E).  
 
     Finally we investigated regional specific associations between mGluR5 availability 
and FMR1 CGG odd vs. even genotype following sleep deprivation. Following 
Bonferroni correction, the main effect of sleep deprivation remained significant for the 
parrahippocampal gyrus, anterior cingulate, amygdala, medial temporal lobe and 
insula (‘conditon’: F1,21 ≥ 9.05, p < 0.007). Although no main effect of genotype was 
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observed, the rebound following sleep deprivation was found to be significant for the 
medial temporal lobe and Amygdala (‘condition x genotype’ F1,21 = 8.54, p < 0.0082). 
Similar as for the reported global changes in mGluR5 availability, the two significant 
regions revealed a highly elevated rebound among even FMR1 CGG carriers when 
compared to odd, following sleep deprivation (data not shown). 
 
 
Figure 3. Illustration of mGluR5 availability and NREM EEG oscillations in one 
representative FMR1 odd and one FMR1 even subject. 
 
Top: Axial slice in two representative FMR1 odd and even individuals, illustrating the binding 
of the non-competitive and highly selective mGluR5 antagonist 11C-ABP688 in sleep control 
(~ 9 hours of wakefulness) and sleep deprived (~ 33 hours of wakefulness) conditions. As 
illustrated, both sleep deprivation and FMR1 odd vs. even genotype (‘condition’: F1,21=10.79, 
p<0.004; ‘genotype’: F1,21=1.93, p=0.179; ‘condition x genotype’ F1,21=7.74, p<0.02) 
modulated global mGluR5 availability. The axial slice show parts of the anterior cingulate, 
insula, medial temporal lobe, medial superior frontal cortex, dorsolateral prefrontal cortex, 
striatum, precuneus, hippocampus and thalamus (z = 2 mm according to the Montreal 
Neurological Institute brain atlas). Bottom: 20 s EEG traces in the same two individuals 
exactly 30 min after sleep onset in baseline and recovery sleep. The EEG traces illustrates 
the proposed link between slow waves and mGluR5 availability (see Figure 1 for 
quantification). Furthermore, it illustrates the increased SWS among FMR1 odd carriers in 
baseline, as well as the enhanced rebound among even FMR1 carriers for EEG slow-
oscillations and SWS following sleep deprivation (see Figure 4 for quantification).  
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Figure 4. Comparisons of mGluR5 availability, NREM EEG oscillations, and their 
relation to the FMR1 odd vs even genotype. 
 
Comparison of odd (white bars) vs. even (black bars) FMR1 CGG repeat carriers, with 
respect to global mGluR5 availability (A & E), EEG sleep slow oscillations (B & F), EEG SWA 
(C & G) and relative SWS (D & H) in the first NREM sleep episode for sleep control (upper 
panel) and the rebound following sleep deprivation (lower panel). (A): Global mGluR5 was 
significantly higher under control conditions for FMR1 odd carriers compared to even. (B – D): 
The three sleep parameters showed a similar increased among odd FMR1 CGG carriers 
under baseline condition, however only for relative SWS was the association significant. (E): 
The rebound in mGluR5 availability following sleep deprivation on the other hand, was 
significantly stronger among FMR1 CGG even carriers. (F – H): The rebound for all three 
sleep parameters revealed a similar increase among even FMR1 CGG carriers compared to 
odd in response to sleep deprivation. Figure is presented as mean ± SEM. Comparisons are 
calculated with students two-tailed t-tests following a significant ‘condition x genotype’ 
interaction in the two-way ANOVAs (see text). Relative values are used for post-hoc testing 
the sleep deprivation induced changes.  
 
Objective markers of sleep need is regulated by FMR1 CGG odd vs. even 
genotype 
     The homeostatic regulation of slow oscillations (<1 Hz) and SWA (0.5 - 4.5 Hz) 
reflects rhythmic global oscillations in neuronal activity, although the exact underlying 
mechanisms remain unknown. Since overexpression of FMRP in drosophila 
melanogaster was shown to reduce neuronal plasticity and affect overall sleep 
duration, we wanted to examine how the odd vs. even number of CGG repeats in the 
FMR1 gene might affect EEG markers of sleep need in the first non-REM sleep 
episode. Analysis of EEG spectral power revealed a genotype independent increase 
in delta, theta and alpha activity (0.5 - 11.5 Hz: ‘deprivation’: F1,24 ≥ 4.78, p < 0.04) as 
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well as a significant reduction in low spindle activity (12.5 - 13.25 Hz: ‘deprivation’ 
F1,24 ≥ 9.90, p < 0.005). A general increase among FMR1 even carriers compared to 
odd was observed in theta and low alpha activity (7 - 10 Hz: ‘genotype’ F1,24 ≥ 4.54, p 
< 0.05). Finally we observed a significant increase in delta and low theta activity 
(0.25 - 5.25 Hz: ‘condition x genotype’ F1,24 ≥ 4.68, p < 0.05) as well as a reduction in 
spindle activity (13.5 - 13.75 Hz: ‘condition x genotype’ F1,24 ≥ 4.46, p < 0.05) among 
FMR1 even carriers when compared to odd, in response to sleep deprivation. To 
further examine the genotype dependent modulation in the slow wave range, we 
calculated total EEG power for slow oscillations and SWA as well as the relative 
amount of slow wave sleep (SWS) for the first NREM episode (Figure 4). ANOVA 
revealed significant modulations of condition and the genotype interaction, for all 
three sleep parameters (‘condition’: F1,24 ≥ 6.04, p < 0.03; ‘condition x genotype’ F1,24 
≥ 5.87, p < 0.03). A significant main effect of genotype was only found for relative 
SWS (‘genotype’ F1,24 ≥ 5.88, p < 0.03). Comparison of the baseline condition 
revealed a nominal increase for all three-sleep parameters among the FMR1 CGG 
odd compared to even carriers, however the difference was only significant for 
relative SWS (Figure 4B - 4D). No differences were observed for any parameter 
under sleep deprived conditions (data not shown). Finally, when analyzing the 
rebound for slow oscillations, SWA and SWS, all three parameters were significantly 
reduced among FMR1 CGG odd carriers when compared to even (Figure 4F – 4H).  
 
Objective and subjective measures of sleep need is higher among FMR1 odd 
carriers compared to even 
     To quantify how sleep deprivation affects FMR1 odd and even carriers throughout 
prolonged wakefulness, performance measures and ratings of sleepiness were 
examined in 3-hour intervals throughout sustained waking. Interpercentile 
performance (10-90th percentile) on the psychomotor vigilance task (PVT) a measure 
of consistent performance, is highly sensitive in detecting early sings of increased 
sleep pressure (Graw et al., 2004). Subjective signs of sleep need, can be examined 
by the tiredness symptoms scale (TSS) and the Karolinska sleepiness scale (KSS). 
Where the TSS is a 14-items checklist with physical and mental symptoms of 
tiredness (Bes et al., 1992), the KSS is a more subjective 9-point scale assessing 
increasing sleepiness. The interpercentile PVT performance revealed both a 
circadian and homeostatic component, with a strong main effect of time awake 
(‘session’ F11,206 = 7.39, p < 0.0001, Figure 5A). Independent of time awake, FMR1 
odd carriers demonstrated an overall reduced performance when compared to even 
(‘genotype’ F1,40 = 4.87, p < 0.04).  Also KSS and TSS ratings revealed a strong 
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homeostatic and circadian modulation (KSS: ‘session’ F13,192 = 17.2, p < 0.001; TSS: 
‘session’ F13,219 = 10.4, p < 0.0001). However like for interpercentile PVT 
performance, FMR1 odd carriers demonstrated an overall increase in symptoms of 
tiredness when compared to even (‘genotype’ F1,46.5 = 4.51, p<0.04, ‘genotype x 
session’ F13,219 = 1.01, p > 0.44) (Figure 5B), although no association between KSS 
score and genotype was found (‘genotype’ F1,55.1=1.10, p=0.30; ‘genotype x session’ 
F13,192=1.21, p=0.27);  (data not shown).  
 
Figure 5. Psychomotor performance and signs of sleepiness during prolonged 
wakefulness, depends on the FMR1 odd vs even genotype.  
 
To quantify the effects of sleep deprivation, interpercentile PVT performance (10-90th 
percentile) a sensitive method for detecting sings of increased sleep pressure (Graw et al., 
2004), and symptoms of tiredness (TSS) were assessed in 3-hour intervals throughout 
prolonged wakefulness. FMR1 odd CGG repeat carriers showed reduced PVT performance 
(‘genotype’ F1,40=4.87, p<0.04) (A) and increased symptoms of tiredness (‘genotype’ 
F1,46.5=4.51, p<0.04) (B) throughout prolonged wakefulness when compared to even.  
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Discussion 
     This multimodal PET imaging study reveals for the first time a molecular marker 
for EEG slow oscillations (<1 Hz) and SWA (0.5 - 4.5 Hz) in humans in vivo, visible 
under both control and sleep deprived conditions. Slow oscillations during sleep are 
characterized by sequences of membrane depolarization and frequent neuronal firing 
(UP states) followed by membrane hyperpolarization and neuronal silence (DOWN 
states), typically at frequencies around 0.2 – 0.9 Hz (Steriade et al., 1993a; 
Achermann and Borbély, 1997). The slow oscillations are believed to primarily be 
cortically generated since they persists following thalamectomy (Steriade et al., 
1993b) and are strongly reduced when cortical inputs are removed (Timofeev and 
Steriade, 1996). Nevertheless spike burst of thalamocortical neurons often proceeds 
cortical UP states in vivo suggesting that they might be importantly involved in the 
synchronization of slow oscillations, similarly as for spindles and slow waves 
(Steriade et al., 1993b; Contreras and Steriade, 1995). The slow oscillations are 
enhanced following NMDAR blockage, observed following ketamine administration 
(Feinberg and Campbell, 1993), but also following mGluR type 1 agonists in vitro 
(Hughes et al., 2002). Given how mGluR type 1 receptors are known to regulate 
NMDAR (Oliet et al., 1997; Collingridge et al., 2004), it is likely that mGluR5 play an 
important role for sleep slow oscillations and that increased availability of mGluR5 is 
associated with enhanced slow oscillations. Indeed, we here show a strong and 
highly significant positive association between global mGluR5 availability and slow 
oscillations under both baseline and sleep deprived conditions suggesting that 
mGluR5 may play an essential role in maintaining slow oscillations especially during 
the first NREM sleep episode. Indeed, enhancing slow oscillations in the early (but 
not late) part of NREM sleep has previously been shown to improve hippocampal 
dependent declarative memory retention in humans (Marshall et al., 2006), an effect 
which therefore could be linked to increased mGluR5 activation. Slow oscillations 
have previously been associated with specific increases in cerebral blood flow in the 
precuneus, posterior cingulate, medial frontal, parietal, and central gyrus (Dang-Vu et 
al., 2008), brain regions which are remarkably similar to where we find the strongest 
association between mGluR5 availability and slow oscillation power. Indeed the 
mGluR5 availability in the parietal cortex and the precuneus explain between 64% 
and 70% of the variance in slow oscillation power under both sleep control and sleep 
deprived conditions. Also SWA, a strong marker of homeostatic sleep need was 
found to be significantly associated with global availability of mGluR5 under both 
sleep control and sleep deprived conditions. Also the relative increase in high SWA 
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(2 – 4 Hz) was positively associated with the increase in global mGluR5. This shows 
that mGluR5 does not only play a role for EEG slow oscillations but is also involved 
in the regulation of homeostatic sleep need. Homer 1a was previously shown to be a 
core molecular marker of sleep need in the mouse (Maret et al., 2007) but in 
humans, no such molecular marker has previously been described. Homer1a is 
known to selectively uncouple mGluR5 from effector targets in the membrane of the 
postsynaptic density and attenuates the mGluR5-mediated rise in intracellular 
calcium levels (Kammermeier and Worley, 2007). This interaction between Homer1a 
and mGluR5 is necessary for mGluR5-dependent synaptic LTD (Ronesi and Huber, 
2008). 
 
     In the second part we analyzed genetic influences of the trinucleotide CGG repeat 
in the FMR1 gene to investigate the role of FMRP on mGluR5 availability and sleep 
need. Although the expansion of the trinucleotide CGG is known to cause FXS and 
the complete loss of FMRP (Cummings and Zoghbi, 2000), CGG’s in the healthy 
range (< 45) had newer previously been shown to modulate FMRP expression, 
although RNA stemloops had been suggested to affect expression in vitro (Darlow 
and Leach, 1995; 1998a; 1998b).  By reanalyzing previously published data on 
FMR1 and FMRP expression levels (Allen et al., 2004; Peprah et al., 2009), we here 
show how stemloops may influence FMRP expression by revealing an almost two-
fold increase in FRMP among healthy carriers of odd number FMR1 CGG’s when 
compared to healthy even carriers. This higher FMRP expression associated with 
odd numbered CGG’s persisted even when examining the entire sample of healthy 
and premutation carriers where an increase in FMRP expression of almost 30% was 
found to be associated with the odd number of CGG’s compared to even.  
 
     Finally, based on the odd or even number of FMR1 CGG repeats, we examined 
how FMRP expression may influence mGluR5 availability and sleep need. The 
mGluR5 and FMRP have been shown to have opposing roles, were activation of 
mGluR5 was associated with increased mRNA translation, FMRP would suppress it 
(Dölen et al., 2007; Dölen and Bear, 2008). Inspection of Drosophila melanogaster 
mutants revealed that FMRP expression is inversely linked to sleep duration (Bushey 
et al., 2009), and that overexpression of FMRP leads to reduced neuronal plasticity 
in response to sleep deprivation (Bushey et al., 2011). Indeed, we here show how 
the allegedly overexpressing odd CGG carriers report to sleep 30 min less every 
night when compared to even CGG carriers. Although this effect was only trend-wise 
significant, it further supports the functional significance of the odd/even FMR1 CGG 
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repeat polymorphism. Fascinatingly, odd FMR1 CGG repeat carriers were found to 
have increased global mGluR5 availability under control conditions when compared 
to even, a difference corresponding to 6.5% or almost twice the difference as 
observed overall following sleep deprivation. When analyzing differences in baseline 
sleep parameters in the first NREM episode, odd FMR1 CGG carriers had a larger 
percentage of SWS when compared to even, corresponding to more than 15 
minutes. Nevertheless, the overall length of the NREM episode was not different 
between the two genotypes. This increase in EEG markers of sleep need among 
FMR1 CGG odd carriers was also observed for EEG slow oscillations and SWA 
although the difference did not reach significance. This difference in global mGluR5 
availability at control conditions and the increased SWS in baseline were 
unexpected, especially since the odd FMR1 CGG carriers reported reduced habitual 
sleep. Therefore, these findings may suggest a faster dissipation of sleep pressure 
among the odd CGG FMR1 carriers, or it may suggest a compensatory mechanism 
due to chronically increased FMRP expression. An answer may come from the rating 
of sleepiness and PVT performance during prolonged wakefulness, where odd CGG 
FMR1 carriers were found to have a chronically poorer PVT performance and 
increased signs of sleepiness. Taken together, this would suggest that the baseline 
differences in mGluR5 availability and SWS are related to compensatory mechanism 
due to chronically increased FMRP.  
 
     Finally we observed a highly blunted response to sleep deprivation among the 
odd FMR1 CGG repeat carriers compared to even, observed for global mGluR5 
availability, EEG slow oscillations, SWA and SWS. These findings appear to confirm 
what has been observed among FMRP overexpressing flies, which show signs of 
reduced neuronal plasticity following sleep deprivation (Bushey et al., 2011) 
suggesting that odd CGG FMR1 carriers are especially vulnerable to sleep 
deprivation.  
 
     Taken together, our data reveal an important role for the mGluR5 in regulating 
EEG markers of sleep need and especially for the <1 Hz slow oscillations. 
Furthermore, mGluR5 may be considered a molecular marker of sleep need in 
humans in vivo. On the other hand, odd or even numbers of CGG’s in the FMR1 
gene may affect FMRP expression even among healthy individuals. Odd CGG 
carriers with increased FMRP expression reveal increased mGluR5 availability and 
SWS under normal conditions, yet a strongly reduced response in mGluR5 
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availability and markers of sleep need following sleep deprivation, effects that further 
corroborates findings in FMRP overexpression flies.  
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Concluding remarks 
     By using an integrative approach, this thesis investigated molecular aspects of 
sleep-wake regulation in humans. Roles for the dopaminergic and glutamatergic 
systems were examined, by studying genetic variants, molecular brain imaging, 
pharmacological interventions, polygraphic EEG recordings, actigraphy and cognitive 
performance in healthy human volunteers.  
 
     In the first two studies, genetic polymorphisms of the genes coding for the 
dopamine metabolizing enzyme catechol-O-methyl transferase (COMT) and for the 
dopamine transporter (DAT), were determined in 129 healthy adult subjects who 
underwent continuous rest-activity monitoring for roughly 4 weeks. Following the 
actigraphy study, effects related to the DAT polymorphism on sleep-wake regulation 
were investigated in 57 volunteers in a controlled sleep deprivation study. The 
protocol consisted of a baseline sleep opportunity and 40 hours of sustained 
wakefulness, followed by a recovery sleep episode. Furthermore, subgroups of these 
participants completed the study protocol twice, where 2 x 200 mg caffeine (n=16) or 
2 x 100 mg modafinil (n=22) were administered in double-blind, placebo-controlled 
manner, during prolonged waking. The response to sleep deprivation and to the two 
treatments, were assessed by analyses of EEG spectra, individual slow wave 
characteristics and questionnaires. 
 
     In the second two studies, positron emission tomography (PET) imaging was 
used to investigate the availability of metabotropic glutamate receptors of subtype 5 
(mGluR5) in the human brain. The highly selective, non-competitive radioligand 11C-
ABP688 was used for mGluR5 quantification. In total, 26 healthy men underwent a 
two-week, randomized, crossover study protocol where the PET scans were 
scheduled after either 9 or 33 hour of sustained wakefulness.  
 
     An overview of the results in this thesis is summarized in Table 1. In the following 
sections, the most important results are presented in a broader context and related to 
current research. 
 
DAT dependent dopaminergic neurotransmission modulates sleep-wake regulation 
110 
DAT dependent dopaminergic neurotransmission modulates 
sleep-wake regulation  
     As described in the introduction (Chapter 1), the role for dopamine (DA) in 
modulating sleep and wakefulness was long thought to be of minor importance 
because of inconsistent alterations of DA across the sleep-wake cycle in cats (Miller 
et al., 1983; Steinfels et al., 1983; Trulson and Preussler, 1984). However, the 
prevailing opinion changed, when it could be shown that: enhanced dopaminergic 
transmission induced wakefulness in mice and Drosophila (Wisor et al., 2001; Kume 
et al., 2005); that the genetic ablation of DA D2 receptors in mice was associated with 
prolonged sleep time (Qu et al., 2010); and that the firing rate of dopaminergic 
neurons changed across the sleep wake cycle in rats (Léna et al., 2005; Dahan et 
al., 2007). Altered dopaminergic neurotransmission also interferes with sleep and 
wakefulness in humans. The loss of dopaminergic cells in the substantia nigra (SN) 
observed in Parkinson’s patients, not only causes motor symptoms, but is also 
associated with disturbed sleep (Lees et al., 1988) and increased nocturnal activity 
as demonstrated by continuous activity monitoring (van Hilten et al., 1994). Similarly, 
patients diagnosed with attention deficit hyperactive disorder (ADHD) show reduced 
nocturnal sleep efficiency, which can be improved by methylphenidate (Sobanski et 
al., 2008), a treatment which, at least in part, inhibits DAT and thereby increases 
dopaminergic neurotransmission (Volkow et al., 1998).  
 
     In Chapters 2 and 3, it was investigated whether the dopaminergic system affects 
long-term habitual sleep-wake patterns, effects of acute sleep loss on markers of 
sleep homeostasis, and interactions of homeostatic sleep regulation with caffeine 
and modafinil. To address these questions, distinct polymorphisms that have been 
reported to affect dopaminergic neurotransmission were investigated. Specifically, 
the COMT Val158Met polymorphism (SNP-ID: rs4680) and the 3’-untranslated region 
(UTR) variable-number-tandem-repeat (VNTR) polymorphism of DAT1 (SNP-ID: 
rs28363170) were investigated. The polymorphism of COMT is associated with a 
Val-to-Met amino acid substitution in the COMT protein, which decreases enzymatic 
activity in Met-allele carriers (Akil et al., 2003; Chen et al., 2004). Furthermore, the 
DAT1 polymorphism has been associated with increased striatal DAT availability in 
9-repeat allele carriers (9R) compared to 10-repeat allele homozygotes (10R/10R) 
(van de Giessen et al., 2009; Costa et al., 2011; Spencer et al., 2013).  
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     Interestingly, the DAT and COMT proteins show different regional distributions in 
human brain. The DAT is primarily expressed in the striatum and thought to be the 
rate limiting protein, responsible for striatal dopaminergic neurotransmission (Ciliax et 
al., 1995; 1999; Lewis et al., 2001). On the other hand, COMT is mainly expressed in 
the prefrontal cortex and only to a lesser extent in the striatum (Meyer-Lindenberg et 
al., 2005; Tunbridge et al., 2006). Such expression patterns cannot completely be 
separated, given how altered striatal dopaminergic neurotransmission have been 
reported to modulate prefrontal dopamine transmission (Kandel et al., 2000). 
Nevertheless, the simultaneous examination of these two individual polymorphisms, 
not only enabled an investigation of the impacts of the dopaminergic system on 
sleep-wake regulation, but also to some extent, to discriminate between effects of 
prefrontal and striatal DA neurotransmission. Investigation of long-term habitual 
sleep-wake regulation (Chapter 2) was performed by a wrist-actimetry device as 
previously validated for sleep-wake estimates (Sadeh, 2011). Subjective 
questionnaires, as well as activity over roughly 4-weeks, with no behavioral 
restrictions, were analyzed for variables including total daily activity, as well as the 
most active 10-hours and least active 5-hours (L5). The polymorphism of COMT was 
found to modulate BMI and the change in sleep duration from weekdays to rest days. 
On the other hand, the DAT1 polymorphism was associated with differences in 
subjective sleepiness and daily rest-activity patterns in men. Here, the DAT1 9R 
carriers revealed increased prevalence of elevated daytime sleepiness, increased 
overall motor activity and an augmented activity during L5 when compared to 
10R/10R. The data suggest that mainly the polymorphism of DAT1, but to some 
extent also the COMT polymorphism, may modulate sleep-wake regulation.  
 
     Given the limitations of actigraphy to unambiguously quantify wakefulness and 
sleep (Sadeh, 2011) and the lack of a challenge to the sleep-wake regulatory 
systems, caution should be taken in interpreting these findings. Therefore, to 
investigate associations of the DAT1 polymorphism and sleep-wake regulation, the 
effects of sleep deprivation were examined in 57 genotyped individuals of previous 
laboratory studies. For COMT, such studies have been performed previously, and 
revealed no impact of the COMT polymorphism on homeostatically regulated 
markers of sleep need (Bodenmann et al., 2009a; 2009b; Bodenmann and Landolt, 2010). 
However, it should be noted that previous studies by Bodenmann and colleagues, 
focused solely on homozygote carriers of COMT Val158Met genotypes. The effects 
of the COMT polymorphism reported in Chapter 2, highlight a difference between 
homozygote and heterozygote Val158Met carriers. The findings are consistent with 
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the proposed inverted-U-shape relationship relating prefrontal cortical functions with 
dopaminergic neurotransmission (Figure 1) (Tunbridge et al., 2006). Consequently, 
future studies, including interventions, are warranted to examine the effects of COMT 
in relation to sleep homeostasis, not only to investigate the difference between 
homo- and heterozygotes, but also to investigate causality. 
 
Figure 1: Modulations of frontal cortex functions by catechol-O-methyl transferase 
 
 
Frontal cortex function is hypothesized to be modulated by dopamine in an inverted-U-shaped 
manner, which depends on the activity of COMT At baseline, high COMT activity in Val/Val 
homozygous subjects may be associated with suboptimal pre-frontal cortex (PFC) dopamine 
levels/function, whereas homozygous Met/Met allele carriers may have near-optimal PFC 
dopamine levels/function. By increasing cortical dopamine, for instance by amphetamine 
(AMPH) administration, Val/Val homozygous subjects can be pushed nearer to the peak of 
the inverted-U-shaped curve and improved frontal functioning. On the other hand, increasing 
dopaminergic tone by AMPH may not change or even decrease PFC functioning in COMT 
Met/Met homozygotes. Adapted from Tunbridge et al., 2006. 
 
     One way to address causality is to pharmacologically inhibit COMT, which can be 
achieved by administration of Tolcapone, a COMT inhibitor used for secondary 
treatment of Parkinson’s disease (Dingemanse et al., 1995). Similarly, to study the 
role of DAT, blockers such as cocaine (Kilty et al., 1991) or modafinil (Volkow et al., 
2009a) may be used. Indeed, modafinil has been suggested to work, at least in part, 
by binding to and inhibiting DAT (Mignot et al., 1994; Madras et al., 2006; 
Minzenberg and Carter, 2008; Volkow et al., 2009a). Thus, administration of 
modafinil during sleep-deprivation may provide valuable insights into the involvement 
of DAT on sleep homeostasis. 
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     In Chapter 3, we examined effects related to the DAT1 polymorphism on 
homeostatic EEG markers of sleep need during a strictly controlled sleep deprivation 
study. Both, 9R-carriers and 10R/10R genotypes of DAT1 revealed a normal 
response to sleep deprivation (i.e. enhanced slow wave sleep (SWS), slow wave 
activity (SWA), and number of slow waves). Nevertheless, the rebound was 
modulated by DAT1 and attenuated among 10R/10R carriers when compared to 9R. 
The effects of DAT1 on SWS corresponded roughly to a 15 min larger rebound 
following sleep deprivation in 10R/10R compared to 9R-carriers. The 10R/10R 
genotypes exhibited on average an increase in SWS of ~64 minutes after sleep 
deprivation (Appendix 1). Accordingly, the effect of the DAT1 polymorphism may 
account for ~23% of the difference in SWS rebound after sleep deprivation. As 
reported elsewhere, the polymorphism of DAT1 has been linked to an approximately 
15-20 % reduced striatal DAT availability in 10R/10R compared to 9R-carriers 
(Jacobsen et al., 2000; van Dyck et al., 2005; Youdim et al., 2006; van de Giessen et 
al., 2009; Costa et al., 2011; Spencer et al., 2013), which appears to correspond well 
to the findings reported in Chapter 3. However, DA modulates G-protein coupled 
receptors, which are known to provide a powerful mechanism of signal amplification 
(Nelson and Cox, 2008) and it therefore may not be meaningful to directly compare 
effect sizes of SWS and DAT expression. Nevertheless, the data support preclinical 
evidence for a role of DAT in modulating sleep and waking (Greenspan et al., 2001; 
Wisor et al., 2001; Kume et al., 2005) and the notion that the striatum and nucleus 
accumbens (NAc) may play an important role in maintaining wakefulness (Lazarus et 
al., 2012; 2013).  
 
     In the striatum, stimulatory (Gs-coupled) A2A receptors are preferentially found 
post-synaptically on dendritic spines of GABAergic medium spiny neurons, where 
they form heteromers with inhibitory dopamine (Gi-coupled) D2 receptors and (Gq-
coupled) mGluR5 (Ferré et al., 2002; Ciruela et al., 2006; Ferré et al., 2007). Under 
normal conditions (Figure 2A) the concentrations of glutamate and adenosine are 
low, which favors activation of DA D2 receptors. Lazarus and colleagues suggested 
that activation of DA D2 receptors in the striatum leads to activation of the ascending 
reticular arousal system (ARAS), which promotes wakefulness (Chapter 1, Figure 6) 
(Lazarus et al., 2012). On the other hand, stimulation of mGluR5 in mGluR5-A2A-D2 
heteromers, causes reduced affinity of DA for D2 receptors, whereas co-stimulation 
of both A2A and mGluR5 reduces the affinity of DA for D2 receptors even further 
(Popoli et al., 2001). This in turn reduces ARAS activation and favors sleep (Figure 
2B). Additionally, A2A receptor antagonists such as caffeine will enhance 
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wakefulness. Furthermore, also modafinil, by enhancing dopamine 
neurotransmission, will promote wakefulness by increasing the activation of DA D2 
receptors (Figure 2). 
 
     It is well established that caffeine attenuates EEG SWA (Landolt et al., 2004), and 
that the interference is modulated by the adenosine A2A receptor ADORA2A 
polymorphisms (Rétey et al., 2007; Bodenmann et al., 2012). In Chapter 3, the 
stimulating effects of caffeine and modafinil were investigated with respect to the 
DAT1 polymorphism. The results revealed that the response and sensitivity is 
modulated by the DAT1 polymorphisms, suggesting a striatial dopaminergic 
modulation of the stimulant effects of modafinil and caffeine. The findings are 
consistent with the notion that DAT knock-out mice are hypersensitive to caffeine, yet 
unresponsive to modafinil (Wisor et al., 2001).  
 
Figure 2. Striatal receptor heteromers interconnects metabotropic glutamate receptors 
of subtype 5 (mGluR5), adenosine A2A receptors and dopamine D2 receptors. 
 
Illustration of mGluR5-A2A-D2 striatal receptor heteromers, which are mainly expressed 
postsynaptically on the dendritic spines of GABAergic medium spiny neurons. A: Under basal 
conditions, striatal glutamate and adenosine concentrations can be considered low. This 
favors D2 receptor signaling which in turn leads to the activation of the ARAS and thereby 
enhanced wakefulness. B: Following prolonged wakefulness, glutamate and adenosine 
concentrations are hypothesized to increase and bind to their respective receptors in 
mGluR5-A2A-D2 receptor heteromers. This results in a decreased affinity of D2 receptors for 
dopamine. This in turn enhances NAc inhibition on the ARAS and thereby promotes sleep.  
mGluR5: metabotropic glutamate receptor of subtype 5, A2A: adenosine A2A receptor, D2: 
dopamine D2 receptor, G: glutamate, A: adenosine, D: dopamine, GP: G-protein. Adapted 
from Ferré et al., 2007; Bodenmann, 2009. 
 
Glutamatergic mGluR5 dependent neurotransmission modu-
lates sleep wake regulation 
     Through the heteromeric interaction with dopamine D2 and adenosine A2A 
receptors in the striatum described above, activation of mGluR5 may promote sleep. 
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The mGluR5 are mainly expressed on postsynaptic membranes of neurons and 
astrocytes in corticolimbic areas of the brain. These include the medial-prefrontal and 
orbitofrontal cortex, cingulate, striatum, amygdala, and hippocampus (Ametamey et 
al., 2007; Gasparini et al., 2008). Given the central role of glutamate in the human 
brain, it may not be surprising that the mGluR5 have been proposed to modulate a 
number of brain processes, including anxiety, memory, autism, learning, pain 
perception, depression and addiction (Swanson et al., 2005; Barker et al., 2006; 
Dölen et al., 2007; Nelson and Cox, 2008; Xu et al., 2009; Deschwanden et al., 2011; 
Jung et al., 2011; Hulka et al., 2013). Indeed, mGluR5 are known to modulate 
synaptic plasticity, long-term depression (LTD) and long-term potentiation (LTP) (Lu 
et al., 1997; Anwyl, 2009; Ayala et al., 2009; Izumi and Zorumski, 2012), which may 
explain why mGluR5 play a role in such a wide range of brain processes. However, 
the hypothesis that mGluR5 play a specific role in sleep-wake regulation is not only 
based on the striatal heteromeric interaction between mGluR5, DA D2 and 
adensosine A2A receptors. The mGluR5 also interact with the immediate early gene 
Homer1a, a proposed molecular marker of sleep homeostasis (Maret et al., 2007), 
which attenuates the mGluR5-mediated rise in intracellular calcium (Kammermeier 
and Worley, 2007). Homer1a-mGluR5 interaction is required for mGluR5-dependent 
synaptic LTD (Ronesi and Huber, 2008). Another important possible link between 
sleep-wake regulation and mGluR5, is its interaction with brain-derived neurotrophic 
factor (BDNF). The pharmacological activation of mGluR5, induce BDNF expression 
in cortical neurons and glia cells in rats (Legutko et al., 2006; Viwatpinyo and 
Chongthammakun, 2009). The BDNF expression in the cerebral cortex is high during 
wakefulness, low during sleep, and increased after sleep deprivation (Cirelli and 
Tononi, 2000). Furthermore, cortical injection of BDNF to awake animals promotes 
synaptic strength and enhances SWA in subsequent NREM sleep (Faraguna et al., 
2008). Finally, mGluR5 has been proposed to be tightly linked with the Fragile X 
mental retardation protein (FMRP) (Dölen et al., 2007). Although the roles for FMRP 
in human sleep have previously not been explored, FMRP levels in Drosophila are 
inversely linked to sleep duration (Bushey et al., 2009) (Figure 3), and 
overexpression of FMRP in the fly model results in reduced neuronal plasticity in 
response to sleep deprivation (Bushey et al., 2011).  
 
     In human volunteers, sleep deprivation increased cerebral mGluR5 availability by 
roughly 3.5%, whereas the increase in anterior cingulate cortex, insula, medial 
temporal lobe, parahippocampal gyrus, striatum, and amygdala withstood statistical 
correction for multiple comparisons (Chapter 4). Furthermore, the increase in global 
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and regional mGluR5 availability was correlated with the change in subjective 
sleepiness at the time of PET imaging. 
 
Figure 3. The dFmr1 gene in drosophila mutants modulates sleep time. 
 
Comparison of amorph, hypermorph, and wild type flies, showing reduced, enhanced, or 
normal FMRP expression, respectively. Sleep across 24 hours was tracked, first under light-
dark (LD) and later dark-dark (DD) conditions. The figure illustrates that FMRP is inversely 
linked to sleep time, such that FMRP over-expression is associated with reduced sleep time 
and reduced FMRP expression associated with increased time asleep. Upper panel gray 
squares: significant differences between wild-type and amorph flies, upper panel black dots: 
significant difference between hypermorph and wild-type files. Figure from Bushey et al., 
2009 
 
     In Chapter 5, it was further examined whether sleep deprivation-induced changes 
in mGluR5 are related to EEG oscillations in baseline and recovery sleep. Indeed, 
mGluR5 availability in sleep control and sleep deprivation conditions was correlated 
with EEG SWA (0.5 – 4.5 Hz) and EEG slow oscillations (< 1 Hz) in baseline and 
recovery sleep. Furthermore, the increase in mGluR5 was specifically correlated with 
the increase in high SWA (2 - 4 Hz). Together, these findings suggest a tight 
relationship between mGluR5 availability and sleep-wake regulation. To further 
examine if the link between mGluR5 and sleep need is really causal, 
pharmacological intervention would be required to either block or activate mGluR5. 
Such an intervention would make it possible to document causal impacts on sleep 
and wakefulness. Interestingly, selective mGluR5 positive allosteric modulators were 
shown to increase locomotor activity and indirectly reduce delta sleep (Parmentier-
Batteur et al., 2013). Intriguingly, preliminary observations in rats suggest that 
mGluR5 receptor antagonists consolidate deep sleep and enhance sleep efficiency, 
whereas allosteric activation of mGluR5 increase waking and decrease deep sleep 
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(Ahnaou et al., 2012; Huysmans et al., 2012). These observations provide a causal 
link between mGluR5 and sleep wake regulation, but in an inverse way as 
hypothesized by the mGluR5-D2-A2A receptor heteromer theory (Lazarus et al., 2012; 
2013). Although preclinical result from animals cannot always be directly compared to 
human data, this emphasises the complex nature of neurotransmitter interactions in 
modulating sleep and waking. Interpretation of the preliminary data reported by 
Ahnaou and Huysmans in combination with the results reported in chapter 4 and 5, 
may suggest that the build-up of mGluR5 observed following sleep deprivation, 
depicts a compensatory mechanisms, promoting wakefulness and allowing the 
subjects to stay awake. However, this interpretation assumes that glutamatergic 
neurotransmission is unaltered following sleep deprivation, and that the preliminary 
data from Ahnaou and Huysmans will endure peer-reviewing. Nevertheless, it further 
highlights the importance of establishing how endogenous glutamate concentration 
are affected by sleep deprivation, for instance by the use of magnetic resonance 
spectroscopy.  
 
     If the enhanced mGluR5 availability following sleep deprivation is really a 
compensatory mechanism to promote wakefulness, rather than an actual marker of 
sleep need, this may explain why the correlation between EEG SWA and global 
mGluR5 availability under baseline and sleep deprived conditions, although 
significant, explains “only” about 19-23% of total SWA variance. On the other hand, 
the correlation between global mGluR5 availability and EEG slow oscillations in 
baseline and recovery, explain almost 55% of the variance in EEG power in this 
frequency band, supporting the role for mGluR5 receptors in modulating these slow 
brain oscillations (Cobb et al., 2000; Hughes et al., 2002; Blethyn et al., 2006). 
Indeed, slow oscillations have been linked to neuronal plasticity and memory 
processing (Steriade and Timofeev, 2003; Marshall et al., 2006), processes 
hypothesized to benefit from sleep (Tononi and Cirelli, 2003; 2006; Diekelmann and 
Born, 2010; Rasch and Born, 2013).  
 
     Finally, the link between sleep-wake regulation, mGluR5 and FMRP was analyzed 
by examining effects of the FMR1 CGG repeat polymorphism among the 26 healthy 
men who had mGluR5 availability quantified after 9 and 33 hour of wakefulness. As 
already mentioned, the role of FMRP in sleep-wake regulation was studied in amorph 
(reduced FMRP expression) and hypermorph (enhanced FMRP expression) dFmr1 
Drosophila mutants (Bushey et al., 2009) (Figure 3). Whereas the dFmr1 amorphs 
were long sleepers, dFmr1 hypermorphs were short sleepers and the wild-type fly 
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revealed a intermediate sleep phenotype, suggesting a dose-dependent relationship 
between FMRP expression and sleep time (Bushey et al., 2009). In humans, the 
FMR1 CCG repeat polymorphism is known to be the cause of Fragile X syndrome 
(FXS), where a repeat expansion of >200 CGGs leads to DNA hypermethylation, 
gene silencing, and complete loss of FMRP (Cummings and Zoghbi, 2000; Barker, 
2002). In healthy CGG repeat carriers (5 - 45 CGG repeats) no association between 
FMRP expression and number of CGG repeats has previously been described 
(Peprah et al., 2009). Nevertheless, in vitro experiments have linked odd numbers of 
CGG repeats to more stable RNA hairpins when compared to even repeat numbers 
(Darlow and Leach, 1998a). This observation lead to the hypothesis that FMR1 CGG 
odd vs. even repeats, would affect RNA hairpin stability and thereby FMRP 
translation. By reanalysing data from Peprah et al. (2009), we found that odd FMR1 
CGG repeat carriers have a roughly 90% higher FMRP expression when compared 
to even number repeat carriers. By investigating this odd vs. even FMR1 CGG repeat 
polymorphism we observed that this genetic variant modulates not only mGluR5 
availability and percentage of SWS under baseline conditions, but also the rebound 
caused by sleep deprivation for mGluR5 availability, EEG slow oscillations, EEG 
SWA and the percentage of SWS. Similarly to FMRP over-expressing Drosophila 
mutants (Bushey et al., 2011), the rebound in the neurophysiological markers of 
sleep homeostasis was blunted in the high FMRP expressing odd FMR1 CGG repeat 
carriers (Chapter 5).  
 
Perspectives  
     In conclusion, the results of this thesis enhance our understanding of the 
molecular bases of sleep-wake regulation in healthy humans. Thus, both the 
dopaminergic and glutamatergic neurotransmitter systems play important roles in 
sleep homeostasis. Furthermore, the integrative approach applied here, combining 
molecular imaging, electroencephalographic recordings, human genetics, and 
subjective questionnaires; is a powerful tool to investigate complex human traits such 
as homeostatic sleep-wake regulation. Specifically, this thesis shows that DAT and 
mGluR5 play a role in human sleep-wake regulation. This basic knowledge may be 
crucial for the development of future pharmacological treatments of disturbed 
wakefulness and sleep, as it unravels new aspects of pharmacogenetics, the 
response to stimulants, and previously unknown aspects of the mGluR5-FMRP 
interaction.  
 
  
Table 1: Synopsis of the results in the current thesis 
Topic Subjective effects Behavioural and electroencephalographic effects Neuroimaging 
 
Motor-activity behaviour 
modulated by COMT 
(Val158Met) and DAT1 (9R-
10R) polymorphisms 
 
Chapter 2 
 
Effects of DAT1 (9R vs. 10R/10R) 
polymorphism: 
 Increased likelihood of elevated daytime 
sleepiness among 9R carriers. 
 
DAT & COMT combined: 
 Similar chronotypes.  
 
Motor activity for DAT1 polymorphism: 
 Motor activity modulated by gender and 
DAT1 genotype. Genotype dependent 
effects only observed among males.  
 Overall increased motor activity among 
male 9R carriers. 
 L5 activity increased among male 9R 
carriers. 
 
Motor activity for COMT (Val158Met) 
polymorphism: 
 The increase in rest-activity from weekdays 
to weekends is attenuated among Val/Met 
heterozygotes 
 BMI is reduced among Val/Met 
heterozygotes 
 
DAT & COMT combined: 
 Similar activity patterns, no epistatic 
interactions 
 
n/a 
 
Acute sleep loss and the 
response to the stimulants 
caffeine and modafinil is 
modulated by the DAT1 (9R-
10R) polymorphism 
 
Chapter 3 
 
Effects of DAT1 (9R vs. 10R/10R) 
polymorphism: 
 Reduced caffeine sensitivity associated with 
the 9-allele. 
 
EEG markers associated with DAT1 (9R vs. 
10R/10R) polymorphism: 
 Caffeine modulates beta activity during 
waking in DAT1 genotype dependent 
manner. 
 Enhanced caffeine sensitivity among 
10R/10R carriers for the number, amplitude, 
and slope of slow waves (< 2 Hz). 
 Enhanced response to modafinil among 9R-
carriers for sigma activity during sleep. 
 “Normal” response to sleep deprivation for 
both DAT1 genotypes.  
 
n/a 
  
Topic Subjective effects Behavioural and electroencephalographic effects Neuroimaging 
 
 
  
 Sleep deprivation enhanced SWS, SWA 
and number of slow waves (< 2 Hz) more 
among 10R/10R carriers. 
 
 
Sleep loss is associated with 
increased availability of 
mGluR5 in human brain 
 
Chapter 4 
 
The mGluR5 availability was correlated to the 
subjective sleepiness following sleep 
deprivation:  
 Globally 
 Anterior cingulate cortex 
 Insula 
 Medial temporal lobe 
 Parahippocampal gyrus 
 Striatum 
  Amygdala 
 
n/a The availability of mGluR5 was increased 
following sleep deprivation: 
 Globally 
 Anterior cingulate cortex 
 Insula 
 Medial temporal lobe 
 Parahippocampal gyrus 
 Striatum 
  Amygdala 
 
 
Availability of mGluR5 is 
linked to EEG oscillations 
and to a distinct 
polymorphism of the fragile X 
gene 
 
Chapter 5 
 
FMR1 odd vs even genotype: 
 Reduced habitual sleep duration among 
FMR1 odd compared to even carriers. 
 Increased sleepiness symptoms throughout 
prolonged wakefulness among FMR1 odd 
compared to even carriers  
 Reduced psychomotor performance (PVT 
percentile range) among FMR1 odd 
compared to even carriers. 
 
 
EEG oscillations correlated with the availability 
of mGluR5 
 EEG slow-oscillations (< 1 Hz) in baseline 
and recovery. 
 EEG SWA (0.5 – 4.5 Hz) in baseline and 
recovery. 
 EEG high SWA (2-4 Hz) is correlated to 
mGluR5 availability following sleep 
deprivation.
 light sleep (stage 1) in PET scanner is 
correlated to mGluR5 availability following 
sleep deprivation.
 EEG slow oscillations and SWA correlated 
with regional mGluR5 availability (see 
Appendix 3).
 
 
FMR1 genotype modulated mGluR5 availability: 
 FMR1 odd had increased mGluR5 
availability under baseline conditions when 
compared to even.  
 mGluR5 with sleep deprivation was 
enhanced among FMR1 even carriers when 
compared to odd. 
  
Topic Subjective effects Behavioural and 
electroencephalographic effects 
Neuroimaging 
   
FMR1 odd vs even genotype 
 Healthy FMR1 odd carriers show a 1.9x 
increase in FMRP expression when 
compared to even. 
 FMR1 odd carriers have increase SWS% 
under baseline conditions when compared 
to even.  
 FMR1 even carriers show an increased 
slow-oscillations compared to odd 
following sleep deprivation 
 FMR1 even carriers show an increased 
SWA compared to odd following sleep 
deprivation 
 FMR1 even carriers show an increased 
SWS% compared to odd following sleep 
deprivation 
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Supplementary information to Chapter 3 
 
 
Dopaminergic role in regulating neurophysiological markers of sleep 
homeostasis in humans 
 
  
Supplementary Table 1: Visually scored sleep variables in 10R/10R (n = 30) and 9R allele carriers (n = 27) of DAT1. 
  10R/10R  9R allele carriers  ‘genotype’ F1,55, p 
‘condition’ 
F1,55, p 
‘genotype’ x ‘condition’ 
F1,55, p Baseline  Recovery  Baseline  Recovery 
Sleep efficiency (%)  93.4 ± 0.7  97.2 ± 0.2  93.1 ± 0.7  97.1 ± 0.2  0.2, 0.67  61.8, <0.0001  0.1, 0.76 
Stage 1 (min)  37.0 ± 2.5  18.9 ± 2.3  33.0 ± 2.4  16.6 ± 1.9  1.1, 0.30  163.0, <0.0001  0.4, 0.55 
Stage 2 (min)  221.0 ± 6.4  200.0 ± 7.0  213.0 ± 5.3  203.0 ± 7.7  0.1, 0.77  21.3, <0.0001  3.0, 0.09 
SWS (min)  93.6 ± 6.5  158.0 ± 7.1  100.0 ± 5.4  149.0 ± 6.8  0.0, 0.91  639.9, <0.0001  11.0, 0.002 
NREM sleep (min)  315.0 ± 4.0  357.0 ± 4.6  313.0 ± 4.0  352.0 ± 5.7  0.4, 0.53  150.1, <0.0001  0.2, 0.64 
REM sleep (min)  96.4 ± 3.3  90.2 ± 4.5  101.0 ± 3.3  97.3 ± 5.3  1.2, 0.27  2.5, 0.12  0.2, 0.63 
MT (min)  9.4 ± 0.8  9.7 ± 0.8  10.7 ± 0.8  9.3 ± 0.6  0.2, 0.65  1.6, 0.21  3.2, 0.08 
WASO (min)  9.0 ± 2.6  0.8 ± 0.4  5.3 ± 1.3  0.9 ± 0.3  1.4, 0.25  17.3, 0.0001  1.6, 0.22 
Sleep latency (min)  13.1 ± 2.1  3.1 ± 0.4  17.2 ± 3.1  3.8 ± 0.5  1.6, 0.22  42.6, <0.0001  0.9, 0.34 
REM latency (min)  70.1 ± 4.1  83.2 ± 7.8  64.6 ± 3.0  70.9 ± 3.5  0.2, 0.67  61.8, <0.0001  0.1, 0.76 
Values represent means ± SEM in baseline and recovery nights. Analyses of the recovery nights were restricted to 480 minutes. Sleep efficiency: percentage 
of total sleep time per 480 minutes. Stages 1, stage 2 and SWS: non-rapid-eye-movement (NREM) sleep stages. REM sleep: rapid-eye-movement sleep. MT: 
movement time. WASO: wakefulness after sleep onset. Sleep latency: time from lights-out to the first occurrence of stage 2 sleep. REM latency: time from 
sleep onset to the first occurrence of REM sleep. 
F- and p-values: Two-way mixed-model ANOVA with factors ‘genotype’ (10R/10R, 9R) and ‘condition’ (baseline, recovery). 
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Supplementary Figure 1. Prolonged wakefulness increases number, amplitude, and 
slope of EEG slow waves in NREM sleep 
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Effect of sleep deprivation on amplitude (A & B), slope (C & D) and number (E & F) of 
positive (left) and negative (right) slow (0.5-2.0 Hz) half-waves in NREM sleep in baseline 
(continuous lines) and recovery nights (dotted lines) in 10R/10R (gray, n = 30) and 9R (black, 
n = 27) genotypes of DAT1. Except for negative half-waves between 0.8-1.1 Hz, sleep 
deprivation increased amplitude, slope and number of half-waves (three-way mixed model 
ANOVA ‘condition’: F1,55 > 93.7, pall < 0.0001). The sleep deprivation-induced increase in the 
number of negative and positive slow half was significantly larger in 10R/10R carriers than in 
9R carriers of DAT1. Three-way mixed model ANOVA: ‘condition’: F1,55 ≥ 3977.0, p ≤ 0.0001; 
‘genotype’: ns; ‘frequency bin’: F15,825 ≥ 55.3, p ≤ 0.0001; ‘genotype’ × ‘deprivation’: F1,55 ≥ 
40.6, p ≤ 0.0001; ‘condition’ × ‘frequency bins’: F15,840 ≥ 35.9, p ≤ 0.0001; ‘genotype’ × 
‘frequency bins’: ns. Triangles on top of the panels indicate frequency bins that were 
significantly affected by sleep deprivation (p < 0.05, 2-tailed paired t-tests). 
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Supplementary Figure S2. Exponential decay of homeostatically regulated EEG slow 
wave activity across consecutive NREM sleep episodes in 10R/10R and 9R allele 
carriers of DAT1 
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Exponential decay of EEG slow-wave activity (SWA, 0.5-4.5 Hz) in baseline (left) and 
recovery (right) nights. Individual SWA values per NREM sleep episode, expressed as a 
percentage of the corresponding all-night value in baseline (horizontal dashed line at 100 %), 
were plotted at episode midpoint relative to sleep onset. The lines represent exponential 
decay fits of the homeostatic process S, in 10R/10R (black dots, black line) and 9R (grey 
dots, grey line) carriers. Insets: Time constants (d ± 95% confidence interval) represent the 
best exponential decay fits. Overlapping confidence intervals suggest that τd did not differ 
between 10R/10R and 9R genotypes. 
Modeling of the homeostatic Process S was performed as described by (Rusterholz et al., 
2010). To summarize, individual SWA (0.5-4.5 Hz) in NREM sleep was normalized to whole-
night baseline levels and plotted against individual NREM sleep episode midpoints. 
Decreasing exponential functions were fitted to mean episodic SWA values using the 
function: 
ܵሺݐሻ ൌ ሺܵ଴ െ ܮܣሻ ∙ exp ൬െ ݐ߬ௗ൰ ൅ ܮܣ 
Where S(t) is the time dependent homeostatic process, S0 is the level of S at sleep onset, LA 
is the lower asymptote required to be positive whereas the time constant, τd, reflects the 
dissipation of sleep pressure during sleep. To investigate effects of the DAT1 polymorphism, 
the fit was done separately in 10R/10R and 9R allele carriers in baseline and recovery nights. 
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Increased metabotropic glutamate receptor subtype 5 availability in 
human brain after one night without sleep 
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Figure S1. Tissue time-activity-curves (TAC) 
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Tissue time-activity-curves (TAC) of cerebellum (grey symbols) and anterior cingulate cortex 
(ACC; black symbols) of representative subjects # 05 and 21 show that in sleep control (open 
symbols) and sleep deprivation (filled symbols) conditions a steady state of receptor binding 
was reached after 45-55 min of image acquisition. The AAC was chosen because this region 
showed the highest 11C-ABP688 binding in both conditions. 
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Sleep deprivation induced no change in cerebellar VND 
To address the question whether sleep deprivation changed 11C-ABP688 binding in 
the cerebellum, which could have driven the results in the other regions, we 
calculated the non-displaceable volume of distribution (VND) in sleep control and 
sleep deprivation conditions in those 9 study participants in whom reliable blood 
metabolite concentrations were available. These analyses confirmed that 11C-
ABP688 binding in the cerebellum was not changed after sleep deprivation when 
compared to the control condition. 
VND = CCb/Cplasma , where Cplasma is the 11C-ABP688 concentration (kBq/mL) in 
plasma.  
Sleep control:  VND = 1.98 ± 0.14 
Sleep deprivation:     VND = 2.18 ± 0.16        p = 0.19 (2-tailed, paired t-test, n = 
9) 
 
 
  
Table S1: Individual normalized volumes of distribution (Vnorm) in sleep control and sleep deprivation conditions. 
Values represent cerebellum-normalized volumes of distribution (Vnorm) of 11C-ABP688 uptake in 13 volumes-of-interest (VOI) after 9 (control, Ctrl.) and 32 
hours (sleep deprivation, SD) of wakefulness. Mean values + SEM are also presented in Fig. 2. Asterisks indicate those six VOI that showed a significant 
increase in Vnorm after sleep deprivation (Bonferroni-corrected p-value of factor ‘condition’: p < 0.0038). Ant. cingulate cortex = anterior cingulate cortex; Med. 
sup. frontal cortex = medial superior frontal cortex; Dorssolat. prefrontal cortex = dorsolateral prefrontal cortex; STD= standard deviation. 
 
# 
Ant. cingulate 
cortex Insula 
Medial 
temporal lobe 
Orbitofrontal 
cortex 
Parahippo-
campal gyrus 
Med. sup. 
frontal gyrus 
Dorsolat.  pre-
frontal cortex Striatum Precuneus Parietal cortex Amygdala Hippocampus Thalamus 
Ctrl. SD Ctrl. SD Ctrl. SD Ctrl. SD Ctrl. SD Ctrl. SD Ctrl. SD Ctrl. SD Ctrl. SD Ctrl. SD Ctrl. SD Ctrl. SD Ctrl. SD 
2 2.044 1.995 1.882 1.880 1.769 1.781 1.728 1.754 1.777 1.814 1.759 1.793 1.598 1.643 1.561 1.655 1.556 1.542 1.537 1.524 1.656 1.640 1.319 1.369 1.248 1.305 
3 1.778 1.861 1.710 1.785 1.620 1.698 1.605 1.655 1.550 1.639 1.605 1.639 1.503 1.557 1.460 1.495 1.477 1.506 1.447 1.519 1.420 1.454 1.218 1.243 1.186 1.177 
4 1.692 1.854 1.593 1.747 1.581 1.731 1.531 1.651 1.488 1.654 1.427 1.546 1.374 1.500 1.404 1.520 1.329 1.429 1.319 1.446 1.425 1.597 1.228 1.347 1.201 1.280 
5 1.648 1.726 1.526 1.640 1.523 1.667 1.528 1.617 1.482 1.604 1.455 1.516 1.365 1.427 1.314 1.380 1.338 1.417 1.342 1.433 1.398 1.478 1.203 1.253 1.173 1.224 
6 1.790 1.816 1.760 1.794 1.627 1.657 1.622 1.650 1.672 1.692 1.574 1.585 1.485 1.510 1.514 1.542 1.484 1.467 1.448 1.436 1.530 1.487 1.368 1.331 1.255 1.281 
7 1.542 1.731 1.460 1.608 1.405 1.502 1.382 1.529 1.460 1.525 1.370 1.503 1.274 1.381 1.291 1.418 1.268 1.327 1.248 1.327 1.276 1.340 1.129 1.141 1.175 1.218 
8 1.618 1.831 1.491 1.652 1.475 1.633 1.447 1.581 1.378 1.571 1.453 1.582 1.372 1.488 1.314 1.447 1.308 1.383 1.306 1.412 1.276 1.362 1.072 1.161 1.170 1.217 
10 1.813 1.787 1.750 1.745 1.615 1.635 1.624 1.617 1.530 1.576 1.579 1.589 1.494 1.487 1.404 1.389 1.451 1.438 1.479 1.456 1.398 1.440 1.144 1.138 1.127 1.092 
11 1.786 1.698 1.635 1.598 1.651 1.591 1.628 1.546 1.555 1.508 1.525 1.508 1.420 1.400 1.312 1.340 1.477 1.440 1.515 1.487 1.428 1.415 1.212 1.217 1.187 1.169 
12 1.799 1.914 1.798 1.892 1.686 1.753 1.649 1.701 1.606 1.676 1.602 1.679 1.554 1.631 1.624 1.685 1.532 1.573 1.494 1.489 1.385 1.496 1.324 1.362 1.270 1.292 
13 1.647 1.705 1.582 1.635 1.517 1.545 1.485 1.530 1.376 1.429 1.432 1.481 1.395 1.432 1.362 1.404 1.350 1.378 1.390 1.425 1.287 1.362 1.081 1.119 1.009 1.049 
14 1.666 1.500 1.559 1.455 1.470 1.413 1.462 1.357 1.490 1.402 1.419 1.320 1.358 1.246 1.372 1.270 1.286 1.237 1.285 1.249 1.321 1.263 1.164 1.104 1.134 1.053 
15 1.915 2.118 1.731 1.939 1.678 1.820 1.657 1.773 1.622 1.805 1.603 1.821 1.531 1.701 1.579 1.855 1.440 1.576 1.453 1.520 1.475 1.701 1.270 1.574 1.319 1.444 
16 1.586 1.739 1.486 1.636 1.494 1.617 1.453 1.561 1.387 1.523 1.340 1.436 1.316 1.403 1.264 1.403 1.324 1.417 1.354 1.441 1.343 1.434 1.110 1.205 1.095 1.201 
17 1.926 1.893 1.872 1.849 1.762 1.739 1.769 1.741 1.636 1.664 1.701 1.602 1.681 1.532 1.637 1.617 1.568 1.437 1.489 1.413 1.491 1.490 1.354 1.325 1.336 1.282 
18 1.969 1.976 1.946 1.969 1.838 1.858 1.780 1.798 1.687 1.719 1.757 1.776 1.659 1.675 1.660 1.686 1.642 1.673 1.577 1.579 1.559 1.593 1.339 1.348 1.289 1.285 
19 2.014 1.972 1.850 1.751 1.786 1.794 1.754 1.697 1.760 1.700 1.772 1.653 1.660 1.558 1.737 1.605 1.608 1.568 1.605 1.568 1.605 1.559 1.386 1.294 1.370 1.305 
20 1.730 1.906 1.568 1.786 1.540 1.707 1.542 1.687 1.491 1.665 1.546 1.695 1.461 1.603 1.438 1.650 1.465 1.596 1.526 1.637 1.422 1.596 1.211 1.363 1.265 1.400 
21 1.771 1.894 1.604 1.770 1.594 1.690 1.592 1.686 1.617 1.726 1.484 1.645 1.411 1.535 1.398 1.569 1.316 1.404 1.358 1.451 1.399 1.530 1.215 1.369 1.217 1.287 
22 1.728 1.832 1.668 1.722 1.617 1.680 1.612 1.669 1.517 1.567 1.614 1.670 1.516 1.576 1.443 1.479 1.517 1.532 1.467 1.535 1.460 1.502 1.220 1.266 1.224 1.217 
23 1.593 1.664 1.634 1.751 1.573 1.680 1.514 1.626 1.523 1.593 1.408 1.484 1.370 1.455 1.376 1.470 1.339 1.404 1.374 1.432 1.374 1.444 1.191 1.284 1.181 1.249 
mean 1.765 1.829 1.672 1.743 1.611 1.676 1.589 1.639 1.553 1.621 1.544 1.596 1.467 1.511 1.451 1.518 1.432 1.464 1.429 1.466 1.425 1.485 1.227 1.277 1.211 1.239 
STD 0.144 0.137 0.142 0.125 0.114 0.106 0.112 0.101 0.114 0.109 0.130 0.124 0.117 0.110 0.135 0.142 0.114 0.102 0.100 0.085 0.102 0.107 0.094 0.112 0.084 0.098 
	            
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Supplementary information to chapter 5 
 
 
Human electroencephalographic markers of sleep need is associated 
with cerebral mGluR5 availability and modulated by the fragile X gene 
 
  
Additional Table 1: Effects of sleep deprivation on sleep stages in relation to the FMR1 odd vs even genotype 
FMR1 odd (n=12) FMR1 even (n=14) Two-way ANOVA (p-values)
 Baseline Recovery Baseline Recovery ‘condition’ ‘genotype’ ‘condition × genotype’ 
Sleep efficiency (%) 93.7 ± 0.96 97.6 ± 0.41 95.4 ± 0.48 98.3 ± 0.25 <0.0001 <0.05 0.32 
Stage 1 (min) 24.2 ± 3.60 13.2 ± 2.62 18.4 ± 2.92 7.19 ± 1.00 <0.0004 <0.04 0.97 
Stage 2 (min) 218 ± 7.19 203 ± 8.94 229 ± 4.82 212 ± 7.31 <0.05 0.17 0.86 
SWS (min) 97.4 ± 6.52 140 ± 6.71 89.7 ± 6.32 143 ± 8.44 <0.0001 0.73 0.48 
NREM sleep (min) 315 ± 5.86 343 ± 5.78 319 ± 6.44 355 ± 5.97 <0.0001 0.22 0.52 
REM sleep (min) 110 ± 5.66 112 ± 3.88 120 ± 4.47 109 ± 5.74 0.37 0.46 0.23 
MT (min) 6.31 ± 0.94 6.53 ± 1.46 5.83 ± 0.66 4.79 ± 0.63 0.67 0.25 0.51 
WASO (min) 5.89 ± 2.46 1.47 ± 0.53 3.90 ± 1.26 0.74 ± 0.42 <0.02 0.33 0.65 
Sleep latency (min) 16.1 ± 3.22 3.36 ± 0.73 12.2 ± 1.43 2.79 ± 0.73 <0.0001 0.21 0.35 
REM latency (min) 60.7 ± 2.97 58.4 ± 3.65 65.3 ± 3.79 64.6 ± 3.90 0.69 0.15 0.84 
Values represent means ± SEM in baseline and recovery nights. Analyses of the recovery nights were restricted to 480 minutes. Sleep efficiency: percentage 
of total sleep time per 480 minutes. Stages 1, stage 2 and SWS: non-rapid-eye-movement (NREM) sleep stages. REM sleep: rapid-eye-movement sleep. MT: 
movement time. WASO: wakefulness after sleep onset. Sleep latency: time from lights-out to the first occurrence of stage 2 sleep. REM latency: time from 
sleep onset to the first occurrence of REM sleep. 
p-values: Two-way mixed-model ANOVA with factors ‘genotype’ (odd, even) and ‘condition’ (baseline, recovery). 
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Supplementary figure 1. Regional specific correlations between mGluR5 availability 
and EEG slow oscillations 
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recoverybaseline
 Medial temporal lobe
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Insula
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Hippocampus
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Regional specific correlations between mGluR5 availability and EEG slow oscillations ( < 
1Hz) in baseline (left) and recovery nights (right).  The parietal cortex, precuneus, striatum, 
anterior cingulate cortex, medial temporal lobe, frontal superior medial, orbitofrontal cortex 
and the dorsolateral prefrontal cortex all survived 13 region Bonferroni corrections ( < 
0.0038) in baseline and recovery nights simultaneously.  
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Supplementary figure 2. Regional specific correlations between mGluR5 availability 
and EEG SWA. 
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Regional specific correlations between mGluR5 availability and EEG slow wave activity 
(SWA, 0.5 – 4.5 Hz) in baseline (left) and recovery nights (right).  Only the parietal cortex 
survived 13 region Bonferroni corrections ( < 0.0038) in baseline and recovery nights 
simultaneously. 
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